[
  {
    "PMID": 19293728,
    "id": 7,
    "text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with fenoldopam, a D1-like receptor agonist, inhibited the stimulatory effect of insulin.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [96, 106],
        "name": "fenoldopam",
        "tok_span": [21, 26],
        "new_tok_span": [22, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [13, 29],
        "name": "D1-like receptor",
        "tok_span": [2, 7],
        "new_tok_span": [2, 7]
      },
      {
        "ent_type": "GENE",
        "char_span": [110, 126],
        "name": "D1-like receptor",
        "tok_span": [28, 33],
        "new_tok_span": [30, 35]
      },
      {
        "ent_type": "GENE",
        "char_span": [172, 179],
        "name": "insulin",
        "tok_span": [41, 42],
        "new_tok_span": [43, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "fenoldopam",
        "sbj_char_span": [96, 106],
        "object": "D1-like receptor",
        "obj_char_span": [110, 126],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [21, 26],
        "obj_tok_span": [28, 33],
        "new_sbj_tok_span": [22, 27],
        "new_obj_tok_span": [30, 35]
      },
      {
        "subject": "fenoldopam",
        "sbj_char_span": [96, 106],
        "object": "insulin",
        "obj_char_span": [172, 179],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 26],
        "obj_tok_span": [41, 42],
        "new_sbj_tok_span": [22, 27],
        "new_obj_tok_span": [43, 44]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "fenoldopam",
        "char_span": [96, 106],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [21, 26],
        "new_tok_span": [22, 27]
      }
    ],
    "new_text": "Although the D1 - like receptor, by itself, had no effect on VSMC proliferation, stimulation with <START=Pharmacologic Substance> fenoldopam <END=Pharmacologic Substance>, a D1 - like receptor agonist, inhibited the stimulatory effect of insulin."
  },
  {
    "PMID": 21712771,
    "id": 5,
    "text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 129],
        "name": "reserpine",
        "tok_span": [23, 26],
        "new_tok_span": [24, 27]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [165, 178],
        "name": "tetrabenazine",
        "tok_span": [35, 38],
        "new_tok_span": [40, 43]
      },
      {
        "ent_type": "GENE",
        "char_span": [105, 109],
        "name": "VMAT",
        "tok_span": [20, 22],
        "new_tok_span": [20, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [210, 216],
        "name": "VMAT-2",
        "tok_span": [45, 49],
        "new_tok_span": [51, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "reserpine",
        "sbj_char_span": [120, 129],
        "object": "VMAT",
        "obj_char_span": [105, 109],
        "rel_type": "inhibitor",
        "sbj_tok_span": [23, 26],
        "obj_tok_span": [20, 22],
        "new_sbj_tok_span": [24, 27],
        "new_obj_tok_span": [20, 22]
      },
      {
        "subject": "tetrabenazine",
        "sbj_char_span": [165, 178],
        "object": "VMAT-2",
        "obj_char_span": [210, 216],
        "rel_type": "regulator",
        "sbj_tok_span": [35, 38],
        "obj_tok_span": [45, 49],
        "new_sbj_tok_span": [40, 43],
        "new_obj_tok_span": [51, 55]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "reserpine",
        "char_span": [120, 129],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [23, 26],
        "new_tok_span": [24, 27]
      },
      {
        "mention": "proton",
        "char_span": [136, 142],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [28, 29],
        "new_tok_span": [31, 32]
      },
      {
        "mention": "tetrabenazine",
        "char_span": [165, 178],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [35, 38],
        "new_tok_span": [40, 43]
      }
    ],
    "new_text": "Transfection of the brain cDNA into COS - 1 cells resulted in transporter activity that was blocked by the VMAT inhibitor <START=Pharmacologic Substance> reserpine <END=Pharmacologic Substance> and a <START=Pharmacologic Substance> proton <END=Pharmacologic Substance> ionophore, but not by <START=Pharmacologic Substance> tetrabenazine <END=Pharmacologic Substance>, which has a high affinity for VMAT - 2."
  },
  {
    "PMID": 9015795,
    "id": 12,
    "text": "The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and melperone had low affinity for the dopamine D2 receptor (radioligand-independent dissociation constants of 30 to 90 nM). Such low affinity makes these latter five drugs readily displaceable by high levels of endogenous dopamine in the caudate or putamen.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [26, 37],
        "name": "remoxipride",
        "tok_span": [6, 11],
        "new_tok_span": [9, 14]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [39, 48],
        "name": "clozapine",
        "tok_span": [12, 15],
        "new_tok_span": [16, 19]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [50, 59],
        "name": "perlapine",
        "tok_span": [16, 19],
        "new_tok_span": [21, 24]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [61, 69],
        "name": "seroquel",
        "tok_span": [20, 23],
        "new_tok_span": [27, 30]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [75, 84],
        "name": "melperone",
        "tok_span": [25, 28],
        "new_tok_span": [33, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [110, 118],
        "name": "dopamine",
        "tok_span": [33, 34],
        "new_tok_span": [41, 42]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [294, 302],
        "name": "dopamine",
        "tok_span": [69, 70],
        "new_tok_span": [77, 78]
      },
      {
        "ent_type": "GENE",
        "char_span": [119, 130],
        "name": "D2 receptor",
        "tok_span": [34, 37],
        "new_tok_span": [42, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "remoxipride",
        "sbj_char_span": [26, 37],
        "object": "D2 receptor",
        "obj_char_span": [119, 130],
        "rel_type": "regulator",
        "sbj_tok_span": [6, 11],
        "obj_tok_span": [34, 37],
        "new_sbj_tok_span": [9, 14],
        "new_obj_tok_span": [42, 45]
      },
      {
        "subject": "clozapine",
        "sbj_char_span": [39, 48],
        "object": "D2 receptor",
        "obj_char_span": [119, 130],
        "rel_type": "regulator",
        "sbj_tok_span": [12, 15],
        "obj_tok_span": [34, 37],
        "new_sbj_tok_span": [16, 19],
        "new_obj_tok_span": [42, 45]
      },
      {
        "subject": "perlapine",
        "sbj_char_span": [50, 59],
        "object": "D2 receptor",
        "obj_char_span": [119, 130],
        "rel_type": "regulator",
        "sbj_tok_span": [16, 19],
        "obj_tok_span": [34, 37],
        "new_sbj_tok_span": [21, 24],
        "new_obj_tok_span": [42, 45]
      },
      {
        "subject": "seroquel",
        "sbj_char_span": [61, 69],
        "object": "D2 receptor",
        "obj_char_span": [119, 130],
        "rel_type": "regulator",
        "sbj_tok_span": [20, 23],
        "obj_tok_span": [34, 37],
        "new_sbj_tok_span": [27, 30],
        "new_obj_tok_span": [42, 45]
      },
      {
        "subject": "melperone",
        "sbj_char_span": [75, 84],
        "object": "D2 receptor",
        "obj_char_span": [119, 130],
        "rel_type": "regulator",
        "sbj_tok_span": [25, 28],
        "obj_tok_span": [34, 37],
        "new_sbj_tok_span": [33, 36],
        "new_obj_tok_span": [42, 45]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "neuroleptics",
        "char_span": [13, 25],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [2, 6],
        "new_tok_span": [3, 7]
      },
      {
        "mention": "remoxipride",
        "char_span": [26, 37],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [6, 11],
        "new_tok_span": [9, 14]
      },
      {
        "mention": "perlapine",
        "char_span": [50, 59],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [16, 19],
        "new_tok_span": [21, 24]
      },
      {
        "mention": "seroquel",
        "char_span": [61, 69],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [20, 23],
        "new_tok_span": [27, 30]
      }
    ],
    "new_text": "The atypical <START=Pharmacologic Substance> neuroleptics <END=Pharmacologic Substance> <START=Pharmacologic Substance> remoxipride <END=Pharmacologic Substance>, clozapine, <START=Pharmacologic Substance> perlapine <END=Pharmacologic Substance>, <START=Pharmacologic Substance> seroquel <END=Pharmacologic Substance>, and melperone had low affinity for the dopamine D2 receptor ( radioligand - independent dissociation constants of 30 to 90 nM ). Such low affinity makes these latter five drugs readily displaceable by high levels of endogenous dopamine in the caudate or putamen."
  },
  {
    "PMID": 23574017,
    "id": 8,
    "text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic CYP3A subfamily-mediated metabolism (21.9% decrease) of doxorubicin.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [153, 164],
        "name": "doxorubicin",
        "tok_span": [36, 37],
        "new_tok_span": [40, 41]
      },
      {
        "ent_type": "GENE",
        "char_span": [97, 102],
        "name": "CYP3A",
        "tok_span": [21, 24],
        "new_tok_span": [24, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "doxorubicin",
        "sbj_char_span": [153, 164],
        "object": "CYP3A",
        "obj_char_span": [97, 102],
        "rel_type": "product or substrate",
        "sbj_tok_span": [36, 37],
        "obj_tok_span": [21, 24],
        "new_sbj_tok_span": [40, 41],
        "new_obj_tok_span": [24, 27]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "was",
        "char_span": [14, 17],
        "sem_type": "Gene or Genome",
        "tok_span": [3, 4],
        "new_tok_span": [4, 5]
      },
      {
        "mention": "CYP3A",
        "char_span": [97, 102],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 24],
        "new_tok_span": [24, 27]
      }
    ],
    "new_text": "The slower CL <START=Gene or Genome> was <END=Gene or Genome> due to the reduction of hepatic biliary excretion ( 67. 0 % decrease ) and hepatic <START=Gene or Genome> CYP3A <END=Gene or Genome> subfamily - mediated metabolism ( 21. 9 % decrease ) of doxorubicin."
  },
  {
    "PMID": 17380207,
    "id": 1,
    "text": "Because of their low asparagine synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [160, 170],
        "name": "asparagine",
        "tok_span": [37, 41],
        "new_tok_span": [46, 50]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [21, 31],
        "name": "asparagine",
        "tok_span": [4, 8],
        "new_tok_span": [7, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [65, 75],
        "name": "asparagine",
        "tok_span": [16, 20],
        "new_tok_span": [23, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [21, 42],
        "name": "asparagine synthetase",
        "tok_span": [4, 10],
        "new_tok_span": [7, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [44, 48],
        "name": "ASNS",
        "tok_span": [11, 13],
        "new_tok_span": [17, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "asparagine",
        "sbj_char_span": [65, 75],
        "object": "asparagine synthetase",
        "obj_char_span": [21, 42],
        "rel_type": "product or substrate",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [4, 10],
        "new_sbj_tok_span": [23, 27],
        "new_obj_tok_span": [7, 13]
      },
      {
        "subject": "asparagine",
        "sbj_char_span": [65, 75],
        "object": "ASNS",
        "obj_char_span": [44, 48],
        "rel_type": "product or substrate",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [11, 13],
        "new_sbj_tok_span": [23, 27],
        "new_obj_tok_span": [17, 19]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "asparagine synthetase",
        "char_span": [21, 42],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [4, 10],
        "new_tok_span": [7, 13]
      },
      {
        "mention": "asparagine synthetase",
        "char_span": [21, 42],
        "sem_type": "Gene or Genome",
        "tok_span": [4, 10],
        "new_tok_span": [7, 13]
      },
      {
        "mention": "asparagine",
        "char_span": [21, 31],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [4, 8],
        "new_tok_span": [7, 11]
      },
      {
        "mention": "asparagine",
        "char_span": [65, 75],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [16, 20],
        "new_tok_span": [23, 27]
      },
      {
        "mention": "asparagine",
        "char_span": [160, 170],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 41],
        "new_tok_span": [46, 50]
      }
    ],
    "new_text": "Because of their low <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> asparagine <END=Amino Acid, Peptide, or Protein> synthetase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( ASNS ) expression and <START=Amino Acid, Peptide, or Protein> asparagine <END=Amino Acid, Peptide, or Protein> biosynthesis, acute lymphoblastic leukemia ( ALL ) cells are exquisitely sensitive to <START=Amino Acid, Peptide, or Protein> asparagine <END=Amino Acid, Peptide, or Protein> depletion."
  },
  {
    "PMID": 12560076,
    "id": 1,
    "text": "D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 8],
        "name": "D-Serine",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [116, 136],
        "name": "N-methyl-D-aspartate",
        "tok_span": [27, 35],
        "new_tok_span": [27, 35]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [138, 142],
        "name": "NMDA",
        "tok_span": [36, 37],
        "new_tok_span": [36, 37]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [95, 102],
        "name": "glycine",
        "tok_span": [22, 23],
        "new_tok_span": [22, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [116, 158],
        "name": "N-methyl-D-aspartate (NMDA)-type receptors",
        "tok_span": [27, 41],
        "new_tok_span": [27, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "glycine",
        "sbj_char_span": [95, 102],
        "object": "N-methyl-D-aspartate (NMDA)-type receptors",
        "obj_char_span": [116, 158],
        "rel_type": "part of",
        "sbj_tok_span": [22, 23],
        "obj_tok_span": [27, 41],
        "new_sbj_tok_span": [22, 23],
        "new_obj_tok_span": [27, 41]
      },
      {
        "subject": "D-Serine",
        "sbj_char_span": [0, 8],
        "object": "N-methyl-D-aspartate (NMDA)-type receptors",
        "obj_char_span": [116, 158],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [27, 41],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [27, 41]
      }
    ],
    "umls_entity_list": [],
    "new_text": "D - Serine was previously identified in mammalian brain and was shown to be a co - agonist at the'glycine'site of the N - methyl - D - aspartate ( NMDA ) - type receptors."
  },
  {
    "PMID": 23455597,
    "id": 11,
    "text": "CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that ABT-288 is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [114, 121],
        "name": "ABT-288",
        "tok_span": [22, 26],
        "new_tok_span": [22, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [83, 85],
        "name": "H3",
        "tok_span": [16, 18],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [214, 216],
        "name": "H3",
        "tok_span": [42, 44],
        "new_tok_span": [42, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "ABT-288",
        "sbj_char_span": [114, 121],
        "object": "H3",
        "obj_char_span": [214, 216],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [22, 26],
        "obj_tok_span": [42, 44],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [42, 44]
      }
    ],
    "umls_entity_list": [],
    "new_text": "CONCLUSIONS : The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that ABT - 288 is unlikely to possess a high potential for abuse in the human population and suggests that H3 antagonists, as a class, are similar in this regard."
  },
  {
    "PMID": 14984733,
    "id": 8,
    "text": "Moreover, a normal level of expression of PSS1 and/or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [102, 108],
        "name": "PtdSer",
        "tok_span": [25, 28],
        "new_tok_span": [27, 30]
      },
      {
        "ent_type": "GENE",
        "char_span": [42, 46],
        "name": "PSS1",
        "tok_span": [8, 11],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [54, 58],
        "name": "PSS2",
        "tok_span": [14, 17],
        "new_tok_span": [16, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "PtdSer",
        "sbj_char_span": [102, 108],
        "object": "PSS1",
        "obj_char_span": [42, 46],
        "rel_type": "product or substrate",
        "sbj_tok_span": [25, 28],
        "obj_tok_span": [8, 11],
        "new_sbj_tok_span": [27, 30],
        "new_obj_tok_span": [9, 12]
      },
      {
        "subject": "PtdSer",
        "sbj_char_span": [102, 108],
        "object": "PSS2",
        "obj_char_span": [54, 58],
        "rel_type": "product or substrate",
        "sbj_tok_span": [25, 28],
        "obj_tok_span": [14, 17],
        "new_sbj_tok_span": [27, 30],
        "new_obj_tok_span": [16, 19]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PSS1",
        "char_span": [42, 46],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 11],
        "new_tok_span": [9, 12]
      }
    ],
    "new_text": "Moreover, a normal level of expression of <START=Gene or Genome> PSS1 <END=Gene or Genome> and / or PSS2 is not required for generating the pool of PtdSer externalized during apoptosis."
  },
  {
    "PMID": 20135071,
    "id": 4,
    "text": "Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [33, 43],
        "name": "dabigatran",
        "tok_span": [6, 9],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [68, 79],
        "name": "rivaroxaban",
        "tok_span": [14, 18],
        "new_tok_span": [21, 25]
      },
      {
        "ent_type": "GENE",
        "char_span": [14, 22],
        "name": "thrombin",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [48, 57],
        "name": "factor Xa",
        "tok_span": [10, 13],
        "new_tok_span": [15, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "dabigatran",
        "sbj_char_span": [33, 43],
        "object": "thrombin",
        "obj_char_span": [14, 22],
        "rel_type": "inhibitor",
        "sbj_tok_span": [6, 9],
        "obj_tok_span": [4, 5],
        "new_sbj_tok_span": [9, 12],
        "new_obj_tok_span": [5, 6]
      },
      {
        "subject": "rivaroxaban",
        "sbj_char_span": [68, 79],
        "object": "factor Xa",
        "obj_char_span": [48, 57],
        "rel_type": "inhibitor",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [10, 13],
        "new_sbj_tok_span": [21, 25],
        "new_obj_tok_span": [15, 18]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "dabigatran",
        "char_span": [33, 43],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [6, 9],
        "new_tok_span": [9, 12]
      },
      {
        "mention": "thrombin",
        "char_span": [14, 22],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      },
      {
        "mention": "factor Xa inhibitor",
        "char_span": [48, 67],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [10, 14],
        "new_tok_span": [15, 19]
      },
      {
        "mention": "rivaroxaban",
        "char_span": [68, 79],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [14, 18],
        "new_tok_span": [21, 25]
      }
    ],
    "new_text": "Of these, the <START=Pharmacologic Substance> thrombin <END=Pharmacologic Substance> inhibitor <START=Pharmacologic Substance> dabigatran <END=Pharmacologic Substance> and <START=Pharmacologic Substance> factor Xa inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> rivaroxaban <END=Pharmacologic Substance> have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe."
  },
  {
    "PMID": 18081314,
    "id": 6,
    "text": "The bound conformation of U46619 fits the crystal structure of the PGIS substrate binding pocket considerably better than that of the unbound U46619.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [142, 148],
        "name": "U46619",
        "tok_span": [27, 31],
        "new_tok_span": [32, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [26, 32],
        "name": "U46619",
        "tok_span": [4, 8],
        "new_tok_span": [5, 9]
      },
      {
        "ent_type": "GENE",
        "char_span": [67, 71],
        "name": "PGIS",
        "tok_span": [14, 16],
        "new_tok_span": [17, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "U46619",
        "sbj_char_span": [26, 32],
        "object": "PGIS",
        "obj_char_span": [67, 71],
        "rel_type": "regulator",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [14, 16],
        "new_sbj_tok_span": [5, 9],
        "new_obj_tok_span": [17, 19]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "U46619",
        "char_span": [26, 32],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 8],
        "new_tok_span": [5, 9]
      },
      {
        "mention": "U46619",
        "char_span": [142, 148],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [27, 31],
        "new_tok_span": [32, 36]
      },
      {
        "mention": "PGIS",
        "char_span": [67, 71],
        "sem_type": "Gene or Genome",
        "tok_span": [14, 16],
        "new_tok_span": [17, 19]
      }
    ],
    "new_text": "The bound conformation of <START=Pharmacologic Substance> U46619 <END=Pharmacologic Substance> fits the crystal structure of the <START=Gene or Genome> PGIS <END=Gene or Genome> substrate binding pocket considerably better than that of the unbound <START=Pharmacologic Substance> U46619 <END=Pharmacologic Substance>."
  },
  {
    "PMID": 16344985,
    "id": 0,
    "text": "Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 13],
        "name": "Valproic acid",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [106, 131],
        "name": "long-chain fatty acyl-CoA",
        "tok_span": [24, 32],
        "new_tok_span": [26, 34]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [49, 65],
        "name": "arachidonic acid",
        "tok_span": [8, 12],
        "new_tok_span": [8, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [69, 85],
        "name": "arachidonoyl-CoA",
        "tok_span": [13, 20],
        "new_tok_span": [14, 21]
      },
      {
        "ent_type": "GENE",
        "char_span": [89, 143],
        "name": "brain microsomal long-chain fatty acyl-CoA synthetases",
        "tok_span": [21, 35],
        "new_tok_span": [23, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "arachidonic acid",
        "sbj_char_span": [49, 65],
        "object": "brain microsomal long-chain fatty acyl-CoA synthetases",
        "obj_char_span": [89, 143],
        "rel_type": "product or substrate",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [21, 35],
        "new_sbj_tok_span": [8, 12],
        "new_obj_tok_span": [23, 37]
      },
      {
        "subject": "arachidonoyl-CoA",
        "sbj_char_span": [69, 85],
        "object": "brain microsomal long-chain fatty acyl-CoA synthetases",
        "obj_char_span": [89, 143],
        "rel_type": "product or substrate",
        "sbj_tok_span": [13, 20],
        "obj_tok_span": [21, 35],
        "new_sbj_tok_span": [14, 21],
        "new_obj_tok_span": [23, 37]
      },
      {
        "subject": "Valproic acid",
        "sbj_char_span": [0, 13],
        "object": "brain microsomal long-chain fatty acyl-CoA synthetases",
        "obj_char_span": [89, 143],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [21, 35],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [23, 37]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "arachidonoyl-CoA",
        "char_span": [69, 85],
        "sem_type": "Organic Chemical",
        "tok_span": [13, 20],
        "new_tok_span": [14, 21]
      }
    ],
    "new_text": "Valproic acid selectively inhibits conversion of arachidonic acid to <START=Organic Chemical> arachidonoyl - CoA <END=Organic Chemical> by brain microsomal long - chain fatty acyl - CoA synthetases : relevance to bipolar disorder."
  },
  {
    "PMID": 11585753,
    "id": 0,
    "text": "The tyrosine kinase inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [30, 36],
        "name": "ZD1839",
        "tok_span": [4, 8],
        "new_tok_span": [7, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [39, 45],
        "name": "Iressa",
        "tok_span": [10, 13],
        "new_tok_span": [14, 17]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [4, 12],
        "name": "tyrosine",
        "tok_span": [1, 2],
        "new_tok_span": [2, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [108, 112],
        "name": "HER2",
        "tok_span": [26, 28],
        "new_tok_span": [30, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [4, 19],
        "name": "tyrosine kinase",
        "tok_span": [1, 3],
        "new_tok_span": [2, 4]
      },
      {
        "ent_type": "GENE",
        "char_span": [57, 61],
        "name": "HER2",
        "tok_span": [16, 18],
        "new_tok_span": [20, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "ZD1839",
        "sbj_char_span": [30, 36],
        "object": "tyrosine kinase",
        "obj_char_span": [4, 19],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [1, 3],
        "new_sbj_tok_span": [7, 11],
        "new_obj_tok_span": [2, 4]
      },
      {
        "subject": "ZD1839",
        "sbj_char_span": [30, 36],
        "object": "HER2",
        "obj_char_span": [57, 61],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [16, 18],
        "new_sbj_tok_span": [7, 11],
        "new_obj_tok_span": [20, 22]
      },
      {
        "subject": "Iressa",
        "sbj_char_span": [39, 45],
        "object": "HER2",
        "obj_char_span": [108, 112],
        "rel_type": "inhibitor",
        "sbj_tok_span": [10, 13],
        "obj_tok_span": [26, 28],
        "new_sbj_tok_span": [14, 17],
        "new_obj_tok_span": [30, 32]
      },
      {
        "subject": "Iressa",
        "sbj_char_span": [39, 45],
        "object": "tyrosine kinase",
        "obj_char_span": [4, 19],
        "rel_type": "inhibitor",
        "sbj_tok_span": [10, 13],
        "obj_tok_span": [1, 3],
        "new_sbj_tok_span": [14, 17],
        "new_obj_tok_span": [2, 4]
      },
      {
        "subject": "Iressa",
        "sbj_char_span": [39, 45],
        "object": "HER2",
        "obj_char_span": [57, 61],
        "rel_type": "inhibitor",
        "sbj_tok_span": [10, 13],
        "obj_tok_span": [16, 18],
        "new_sbj_tok_span": [14, 17],
        "new_obj_tok_span": [20, 22]
      },
      {
        "subject": "tyrosine",
        "sbj_char_span": [4, 12],
        "object": "tyrosine kinase",
        "obj_char_span": [4, 19],
        "rel_type": "product or substrate",
        "sbj_tok_span": [1, 2],
        "obj_tok_span": [1, 3],
        "new_sbj_tok_span": [2, 3],
        "new_obj_tok_span": [2, 4]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "tyrosine kinase inhibitor",
        "char_span": [4, 29],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [1, 4],
        "new_tok_span": [2, 5]
      },
      {
        "mention": "ZD1839",
        "char_span": [30, 36],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 8],
        "new_tok_span": [7, 11]
      }
    ],
    "new_text": "The <START=Pharmacologic Substance> tyrosine kinase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> ZD1839 <END=Pharmacologic Substance> ( \" Iressa \" ) inhibits HER2 - driven signaling and suppresses the growth of HER2 - overexpressing tumor cells."
  },
  {
    "PMID": 9876137,
    "id": 1,
    "text": "Cocaine block of human cardiac (hH1) and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 7],
        "name": "Cocaine",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [67, 73],
        "name": "sodium",
        "tok_span": [20, 21],
        "new_tok_span": [25, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [17, 36],
        "name": "human cardiac (hH1)",
        "tok_span": [5, 12],
        "new_tok_span": [5, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [41, 82],
        "name": "rat skeletal (mu1) muscle sodium channels",
        "tok_span": [13, 22],
        "new_tok_span": [17, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "Cocaine",
        "sbj_char_span": [0, 7],
        "object": "human cardiac (hH1)",
        "obj_char_span": [17, 36],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [5, 12],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [5, 12]
      },
      {
        "subject": "Cocaine",
        "sbj_char_span": [0, 7],
        "object": "rat skeletal (mu1) muscle sodium channels",
        "obj_char_span": [41, 82],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [13, 22],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [17, 26]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "hH1",
        "char_span": [32, 35],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [8, 11],
        "new_tok_span": [10, 13]
      },
      {
        "mention": "hH1",
        "char_span": [32, 35],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 11],
        "new_tok_span": [10, 13]
      },
      {
        "mention": "sodium channels",
        "char_span": [67, 82],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [20, 22],
        "new_tok_span": [25, 27]
      }
    ],
    "new_text": "Cocaine block of human cardiac ( <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> hH1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ) and rat skeletal ( mu1 ) muscle <START=Amino Acid, Peptide, or Protein> sodium channels <END=Amino Acid, Peptide, or Protein> was examined under whole - cell voltage clamp in transiently transfected HEK293t cells."
  },
  {
    "PMID": 17111172,
    "id": 7,
    "text": "CONCLUSIONS: We were able to demonstrate a moderate 5-HT(2A) and D(1) occupancy under clinically relevant doses of flupentixol, albeit lower than expected from in vitro data and clearly below saturation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [115, 126],
        "name": "flupentixol",
        "tok_span": [27, 31],
        "new_tok_span": [28, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [52, 60],
        "name": "5-HT(2A)",
        "tok_span": [9, 16],
        "new_tok_span": [9, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [65, 69],
        "name": "D(1)",
        "tok_span": [17, 21],
        "new_tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "flupentixol",
        "sbj_char_span": [115, 126],
        "object": "5-HT(2A)",
        "obj_char_span": [52, 60],
        "rel_type": "regulator",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [9, 16],
        "new_sbj_tok_span": [28, 32],
        "new_obj_tok_span": [9, 16]
      },
      {
        "subject": "flupentixol",
        "sbj_char_span": [115, 126],
        "object": "D(1)",
        "obj_char_span": [65, 69],
        "rel_type": "regulator",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [17, 21],
        "new_sbj_tok_span": [28, 32],
        "new_obj_tok_span": [17, 21]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "flupentixol",
        "char_span": [115, 126],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [27, 31],
        "new_tok_span": [28, 32]
      }
    ],
    "new_text": "CONCLUSIONS : We were able to demonstrate a moderate 5 - HT ( 2A ) and D ( 1 ) occupancy under clinically relevant doses of <START=Pharmacologic Substance> flupentixol <END=Pharmacologic Substance>, albeit lower than expected from in vitro data and clearly below saturation."
  },
  {
    "PMID": 16248990,
    "id": 6,
    "text": "In these conditions, a dose-dependent increase of [3H]-ACh release was observed in the presence of (+/-)-HX, GAL and HPA. To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [187, 195],
        "name": "[3H]-ACh",
        "tok_span": [50, 56],
        "new_tok_span": [56, 62]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [205, 217],
        "name": "mecamylamine",
        "tok_span": [58, 62],
        "new_tok_span": [65, 69]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [219, 222],
        "name": "MEC",
        "tok_span": [63, 65],
        "new_tok_span": [71, 73]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [50, 58],
        "name": "[3H]-ACh",
        "tok_span": [10, 16],
        "new_tok_span": [10, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [142, 161],
        "name": "nicotinic receptors",
        "tok_span": [41, 44],
        "new_tok_span": [46, 49]
      }
    ],
    "relation_list": [
      {
        "subject": "mecamylamine",
        "sbj_char_span": [205, 217],
        "object": "nicotinic receptors",
        "obj_char_span": [142, 161],
        "rel_type": "inhibitor",
        "sbj_tok_span": [58, 62],
        "obj_tok_span": [41, 44],
        "new_sbj_tok_span": [65, 69],
        "new_obj_tok_span": [46, 49]
      },
      {
        "subject": "MEC",
        "sbj_char_span": [219, 222],
        "object": "nicotinic receptors",
        "obj_char_span": [142, 161],
        "rel_type": "inhibitor",
        "sbj_tok_span": [63, 65],
        "obj_tok_span": [41, 44],
        "new_sbj_tok_span": [71, 73],
        "new_obj_tok_span": [46, 49]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "HX",
        "char_span": [105, 107],
        "sem_type": "Gene or Genome",
        "tok_span": [29, 31],
        "new_tok_span": [30, 32]
      },
      {
        "mention": "GAL",
        "char_span": [109, 112],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [32, 33],
        "new_tok_span": [35, 36]
      },
      {
        "mention": "nicotinic",
        "char_span": [142, 151],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [41, 43],
        "new_tok_span": [46, 48]
      },
      {
        "mention": "mecamylamine",
        "char_span": [205, 217],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [58, 62],
        "new_tok_span": [65, 69]
      }
    ],
    "new_text": "In these conditions, a dose - dependent increase of [ 3H ] - ACh release was observed in the presence of ( + / - ) - <START=Gene or Genome> HX <END=Gene or Genome>, <START=Amino Acid, Peptide, or Protein> GAL <END=Amino Acid, Peptide, or Protein> and HPA. To test the role of <START=Amino Acid, Peptide, or Protein> nicotinic <END=Amino Acid, Peptide, or Protein> receptors in the drugs'effects on [ 3H ] - ACh release, <START=Pharmacologic Substance> mecamylamine <END=Pharmacologic Substance> ( MEC ) 100 microM was used to block such receptors."
  },
  {
    "PMID": 16432501,
    "id": 1,
    "text": "Two beta(2)-agonists, formoterol and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [22, 32],
        "name": "formoterol",
        "tok_span": [8, 11],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [37, 47],
        "name": "salmeterol",
        "tok_span": [12, 16],
        "new_tok_span": [12, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [168, 188],
        "name": "beta(2)-adrenoceptor",
        "tok_span": [36, 44],
        "new_tok_span": [38, 46]
      }
    ],
    "relation_list": [
      {
        "subject": "formoterol",
        "sbj_char_span": [22, 32],
        "object": "beta(2)-adrenoceptor",
        "obj_char_span": [168, 188],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [8, 11],
        "obj_tok_span": [36, 44],
        "new_sbj_tok_span": [8, 11],
        "new_obj_tok_span": [38, 46]
      },
      {
        "subject": "salmeterol",
        "sbj_char_span": [37, 47],
        "object": "beta(2)-adrenoceptor",
        "obj_char_span": [168, 188],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [36, 44],
        "new_sbj_tok_span": [12, 16],
        "new_obj_tok_span": [38, 46]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "duration",
        "char_span": [103, 111],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [26, 27],
        "new_tok_span": [27, 28]
      }
    ],
    "new_text": "Two beta ( 2 ) - agonists, formoterol and salmeterol, are approved for treating asthma and have an extended <START=Pharmacologic Substance> duration <END=Pharmacologic Substance> of action and increased safety, associated with greater beta ( 2 ) - adrenoceptor selectivity."
  },
  {
    "PMID": 23703578,
    "id": 14,
    "text": "Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 12],
        "name": "Atorvastatin",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [23, 28],
        "name": "CYP3A",
        "tok_span": [6, 9],
        "new_tok_span": [6, 9]
      },
      {
        "ent_type": "GENE",
        "char_span": [103, 108],
        "name": "CYP3A",
        "tok_span": [22, 25],
        "new_tok_span": [22, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "Atorvastatin",
        "sbj_char_span": [0, 12],
        "object": "CYP3A",
        "obj_char_span": [23, 28],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [6, 9],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [6, 9]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Atorvastatin is also a CYP3A substrate, but less potent drug - drug interactions have been reported with CYP3A inhibitors."
  },
  {
    "PMID": 11292635,
    "id": 5,
    "text": "Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of NKCC1-mediated Cl- transport.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 10],
        "name": "Bumetanide",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [21, 24],
        "name": "Cl-",
        "tok_span": [6, 8],
        "new_tok_span": [8, 10]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [66, 69],
        "name": "Na+",
        "tok_span": [13, 15],
        "new_tok_span": [15, 17]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [81, 83],
        "name": "K+",
        "tok_span": [17, 19],
        "new_tok_span": [19, 21]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [87, 89],
        "name": "NH",
        "tok_span": [20, 21],
        "new_tok_span": [22, 23]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [144, 147],
        "name": "Cl-",
        "tok_span": [33, 35],
        "new_tok_span": [37, 39]
      },
      {
        "ent_type": "GENE",
        "char_span": [129, 134],
        "name": "NKCC1",
        "tok_span": [28, 31],
        "new_tok_span": [31, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "Cl-",
        "sbj_char_span": [144, 147],
        "object": "NKCC1",
        "obj_char_span": [129, 134],
        "rel_type": "product or substrate",
        "sbj_tok_span": [33, 35],
        "obj_tok_span": [28, 31],
        "new_sbj_tok_span": [37, 39],
        "new_obj_tok_span": [31, 34]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Bumetanide",
        "char_span": [0, 10],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "mention": "NKCC1",
        "char_span": [129, 134],
        "sem_type": "Gene or Genome",
        "tok_span": [28, 31],
        "new_tok_span": [31, 34]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> Bumetanide <END=Pharmacologic Substance> - sensitive Cl - secretion was dependent on extracellular Na + and either K + or NH, consistent with the ion dependency of <START=Gene or Genome> NKCC1 <END=Gene or Genome> - mediated Cl - transport."
  },
  {
    "PMID": 8242725,
    "id": 1,
    "text": "Two migraine patients were studied by in vivo SPECT using the dopamine D2-receptor specific radioligand 123I-3-iodo-6-methoxybenzamide (123I-IBZM) during ergotamine abuse and after withdrawal.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [104, 134],
        "name": "123I-3-iodo-6-methoxybenzamide",
        "tok_span": [20, 34],
        "new_tok_span": [22, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [136, 145],
        "name": "123I-IBZM",
        "tok_span": [35, 41],
        "new_tok_span": [40, 46]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [154, 164],
        "name": "ergotamine",
        "tok_span": [43, 47],
        "new_tok_span": [50, 54]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [62, 70],
        "name": "dopamine",
        "tok_span": [11, 12],
        "new_tok_span": [12, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [62, 82],
        "name": "dopamine D2-receptor",
        "tok_span": [11, 16],
        "new_tok_span": [12, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "123I-3-iodo-6-methoxybenzamide",
        "sbj_char_span": [104, 134],
        "object": "dopamine D2-receptor",
        "obj_char_span": [62, 82],
        "rel_type": "regulator",
        "sbj_tok_span": [20, 34],
        "obj_tok_span": [11, 16],
        "new_sbj_tok_span": [22, 36],
        "new_obj_tok_span": [12, 17]
      },
      {
        "subject": "123I-IBZM",
        "sbj_char_span": [136, 145],
        "object": "dopamine D2-receptor",
        "obj_char_span": [62, 82],
        "rel_type": "regulator",
        "sbj_tok_span": [35, 41],
        "obj_tok_span": [11, 16],
        "new_sbj_tok_span": [40, 46],
        "new_obj_tok_span": [12, 17]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "dopamine",
        "char_span": [62, 70],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [11, 12],
        "new_tok_span": [12, 13]
      },
      {
        "mention": "iodo",
        "char_span": [111, 115],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [25, 27],
        "new_tok_span": [28, 30]
      },
      {
        "mention": "123I-IBZM",
        "char_span": [136, 145],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [35, 41],
        "new_tok_span": [40, 46]
      },
      {
        "mention": "ergotamine",
        "char_span": [154, 164],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [43, 47],
        "new_tok_span": [50, 54]
      }
    ],
    "new_text": "Two migraine patients were studied by in vivo SPECT using the <START=Amino Acid, Peptide, or Protein> dopamine <END=Amino Acid, Peptide, or Protein> D2 - receptor specific radioligand 123I - 3 - <START=Pharmacologic Substance> iodo <END=Pharmacologic Substance> - 6 - methoxybenzamide ( <START=Pharmacologic Substance> 123I - IBZM <END=Pharmacologic Substance> ) during <START=Pharmacologic Substance> ergotamine <END=Pharmacologic Substance> abuse and after withdrawal."
  },
  {
    "PMID": 22989703,
    "id": 6,
    "text": "Both apo-lycopenoic acids also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and COX-2 expressions caused by CSE. However, in both the models of oxidative stress, apo-14'-lycopenoic acid was much more potent as an antioxidant than apo-10'-lycopenoic acid, showing antioxidant properties similar to lycopene.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [206, 229],
        "name": "apo-14'-lycopenoic acid",
        "tok_span": [52, 62],
        "new_tok_span": [58, 68]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [274, 297],
        "name": "apo-10'-lycopenoic acid",
        "tok_span": [70, 80],
        "new_tok_span": [77, 87]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [341, 349],
        "name": "lycopene",
        "tok_span": [86, 89],
        "new_tok_span": [95, 98]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [5, 25],
        "name": "apo-lycopenoic acids",
        "tok_span": [1, 8],
        "new_tok_span": [1, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [69, 75],
        "name": "8-OHdG",
        "tok_span": [17, 22],
        "new_tok_span": [21, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [114, 119],
        "name": "NOX-4",
        "tok_span": [28, 32],
        "new_tok_span": [32, 36]
      },
      {
        "ent_type": "GENE",
        "char_span": [124, 129],
        "name": "COX-2",
        "tok_span": [33, 36],
        "new_tok_span": [37, 40]
      }
    ],
    "relation_list": [
      {
        "subject": "apo-lycopenoic acids",
        "sbj_char_span": [5, 25],
        "object": "NOX-4",
        "obj_char_span": [114, 119],
        "rel_type": "regulator",
        "sbj_tok_span": [1, 8],
        "obj_tok_span": [28, 32],
        "new_sbj_tok_span": [1, 8],
        "new_obj_tok_span": [32, 36]
      },
      {
        "subject": "apo-lycopenoic acids",
        "sbj_char_span": [5, 25],
        "object": "COX-2",
        "obj_char_span": [124, 129],
        "rel_type": "regulator",
        "sbj_tok_span": [1, 8],
        "obj_tok_span": [33, 36],
        "new_sbj_tok_span": [1, 8],
        "new_obj_tok_span": [37, 40]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "CSE",
        "char_span": [41, 44],
        "sem_type": "Gene or Genome",
        "tok_span": [10, 12],
        "new_tok_span": [11, 13]
      },
      {
        "mention": "CSE",
        "char_span": [152, 155],
        "sem_type": "Gene or Genome",
        "tok_span": [39, 41],
        "new_tok_span": [44, 46]
      },
      {
        "mention": "ROS",
        "char_span": [53, 56],
        "sem_type": "Gene or Genome",
        "tok_span": [14, 15],
        "new_tok_span": [17, 18]
      },
      {
        "mention": "apo-10'-lycopenoic",
        "char_span": [274, 292],
        "sem_type": "Organic Chemical",
        "tok_span": [70, 79],
        "new_tok_span": [77, 86]
      },
      {
        "mention": "lycopene",
        "char_span": [341, 349],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [86, 89],
        "new_tok_span": [95, 98]
      }
    ],
    "new_text": "Both apo - lycopenoic acids also decreased <START=Gene or Genome> CSE <END=Gene or Genome> - induced <START=Gene or Genome> ROS <END=Gene or Genome> production, 8 - OHdG formation and reduced the increase in NOX - 4 and COX - 2 expressions caused by <START=Gene or Genome> CSE <END=Gene or Genome>. However, in both the models of oxidative stress, apo - 14'- lycopenoic acid was much more potent as an antioxidant than <START=Organic Chemical> apo - 10'- lycopenoic <END=Organic Chemical> acid, showing antioxidant properties similar to <START=Pharmacologic Substance> lycopene <END=Pharmacologic Substance>."
  },
  {
    "PMID": 20596674,
    "id": 5,
    "text": "MXF or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II. VP-16 induced cell cycle arrest at G2/M and the appearance of the subG1 peak which was increased by the addition of MXF. Apoptosis studies (DAPI staining and caspase 3 activity) showed a marked increase in the presence of MXF and VP-16 compared to VP-16 alone.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [324, 327],
        "name": "MXF",
        "tok_span": [68, 71],
        "new_tok_span": [72, 75]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [348, 352],
        "name": "DAPI",
        "tok_span": [75, 76],
        "new_tok_span": [80, 81]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [430, 433],
        "name": "MXF",
        "tok_span": [90, 93],
        "new_tok_span": [96, 99]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [438, 443],
        "name": "VP-16",
        "tok_span": [94, 97],
        "new_tok_span": [101, 104]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [456, 461],
        "name": "VP-16",
        "tok_span": [99, 102],
        "new_tok_span": [108, 111]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 3],
        "name": "MXF",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [7, 12],
        "name": "VP-16",
        "tok_span": [4, 7],
        "new_tok_span": [5, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [208, 213],
        "name": "VP-16",
        "tok_span": [40, 43],
        "new_tok_span": [43, 46]
      },
      {
        "ent_type": "GENE",
        "char_span": [366, 375],
        "name": "caspase 3",
        "tok_span": [78, 80],
        "new_tok_span": [84, 86]
      },
      {
        "ent_type": "GENE",
        "char_span": [40, 47],
        "name": "topo II",
        "tok_span": [10, 13],
        "new_tok_span": [12, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [199, 206],
        "name": "topo II",
        "tok_span": [36, 39],
        "new_tok_span": [38, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "MXF",
        "sbj_char_span": [0, 3],
        "object": "topo II",
        "obj_char_span": [199, 206],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [36, 39],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [38, 41]
      },
      {
        "subject": "VP-16",
        "sbj_char_span": [7, 12],
        "object": "topo II",
        "obj_char_span": [199, 206],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 7],
        "obj_tok_span": [36, 39],
        "new_sbj_tok_span": [5, 8],
        "new_obj_tok_span": [38, 41]
      },
      {
        "subject": "MXF",
        "sbj_char_span": [430, 433],
        "object": "caspase 3",
        "obj_char_span": [366, 375],
        "rel_type": "regulator",
        "sbj_tok_span": [90, 93],
        "obj_tok_span": [78, 80],
        "new_sbj_tok_span": [96, 99],
        "new_obj_tok_span": [84, 86]
      },
      {
        "subject": "VP-16",
        "sbj_char_span": [438, 443],
        "object": "caspase 3",
        "obj_char_span": [366, 375],
        "rel_type": "regulator",
        "sbj_tok_span": [94, 97],
        "obj_tok_span": [78, 80],
        "new_sbj_tok_span": [101, 104],
        "new_obj_tok_span": [84, 86]
      },
      {
        "subject": "VP-16",
        "sbj_char_span": [456, 461],
        "object": "caspase 3",
        "obj_char_span": [366, 375],
        "rel_type": "regulator",
        "sbj_tok_span": [99, 102],
        "obj_tok_span": [78, 80],
        "new_sbj_tok_span": [108, 111],
        "new_obj_tok_span": [84, 86]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "VP-16",
        "char_span": [7, 12],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 7],
        "new_tok_span": [5, 8]
      },
      {
        "mention": "VP-16",
        "char_span": [208, 213],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [40, 43],
        "new_tok_span": [43, 46]
      },
      {
        "mention": "VP-16",
        "char_span": [438, 443],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [94, 97],
        "new_tok_span": [101, 104]
      },
      {
        "mention": "VP-16",
        "char_span": [456, 461],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [99, 102],
        "new_tok_span": [108, 111]
      },
      {
        "mention": "DAPI",
        "char_span": [348, 352],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [75, 76],
        "new_tok_span": [80, 81]
      }
    ],
    "new_text": "MXF or <START=Pharmacologic Substance> VP - 16 <END=Pharmacologic Substance> slightly affected cellular topo II activity in nuclear extracts derived from drug - treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of topo II. <START=Pharmacologic Substance> VP - 16 <END=Pharmacologic Substance> induced cell cycle arrest at G2 / M and the appearance of the subG1 peak which was increased by the addition of MXF. Apoptosis studies ( <START=Pharmacologic Substance> DAPI <END=Pharmacologic Substance> staining and caspase 3 activity ) showed a marked increase in the presence of MXF and <START=Pharmacologic Substance> VP - 16 <END=Pharmacologic Substance> compared to <START=Pharmacologic Substance> VP - 16 <END=Pharmacologic Substance> alone."
  },
  {
    "PMID": 17015640,
    "id": 1,
    "text": "Licofelone, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 10],
        "name": "Licofelone",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "GENE",
        "char_span": [157, 172],
        "name": "cycloxygenase-2",
        "tok_span": [36, 42],
        "new_tok_span": [38, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [191, 206],
        "name": "cycloxygenase-1",
        "tok_span": [45, 51],
        "new_tok_span": [47, 53]
      },
      {
        "ent_type": "GENE",
        "char_span": [56, 70],
        "name": "5-lipoxygenase",
        "tok_span": [13, 17],
        "new_tok_span": [13, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [72, 75],
        "name": "LOX",
        "tok_span": [18, 20],
        "new_tok_span": [18, 20]
      },
      {
        "ent_type": "GENE",
        "char_span": [81, 95],
        "name": "cyclooxygenase",
        "tok_span": [22, 24],
        "new_tok_span": [23, 25]
      },
      {
        "ent_type": "GENE",
        "char_span": [97, 100],
        "name": "COX",
        "tok_span": [25, 26],
        "new_tok_span": [27, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "Licofelone",
        "sbj_char_span": [0, 10],
        "object": "cycloxygenase-1",
        "obj_char_span": [191, 206],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [45, 51],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [47, 53]
      },
      {
        "subject": "Licofelone",
        "sbj_char_span": [0, 10],
        "object": "5-lipoxygenase",
        "obj_char_span": [56, 70],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [13, 17],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [13, 17]
      },
      {
        "subject": "Licofelone",
        "sbj_char_span": [0, 10],
        "object": "LOX",
        "obj_char_span": [72, 75],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [18, 20],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [18, 20]
      },
      {
        "subject": "Licofelone",
        "sbj_char_span": [0, 10],
        "object": "cyclooxygenase",
        "obj_char_span": [81, 95],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [22, 24],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [23, 25]
      },
      {
        "subject": "Licofelone",
        "sbj_char_span": [0, 10],
        "object": "COX",
        "obj_char_span": [97, 100],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [25, 26],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [27, 28]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "cyclooxygenase",
        "char_span": [81, 95],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [22, 24],
        "new_tok_span": [23, 25]
      },
      {
        "mention": "blockade",
        "char_span": [207, 215],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [51, 52],
        "new_tok_span": [54, 55]
      }
    ],
    "new_text": "Licofelone, a dual anti - inflammatory drug that inhibits 5 - lipoxygenase ( LOX ) and <START=Amino Acid, Peptide, or Protein> cyclooxygenase <END=Amino Acid, Peptide, or Protein> ( COX ) enzymes, may have a better cardiovascular profile that cycloxygenase - 2 inhibitors due to cycloxygenase - 1 <START=Pharmacologic Substance> blockade <END=Pharmacologic Substance> - mediated antithrombotic effect and a better gastrointestinal tolerability."
  },
  {
    "PMID": 16893531,
    "id": 5,
    "text": "The exception was bupropion, a dual norepinephrine transporter/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [18, 27],
        "name": "bupropion",
        "tok_span": [3, 6],
        "new_tok_span": [3, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [36, 50],
        "name": "norepinephrine",
        "tok_span": [9, 10],
        "new_tok_span": [9, 10]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [63, 71],
        "name": "dopamine",
        "tok_span": [12, 13],
        "new_tok_span": [14, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [36, 62],
        "name": "norepinephrine transporter",
        "tok_span": [9, 11],
        "new_tok_span": [9, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [63, 83],
        "name": "dopamine transporter",
        "tok_span": [12, 14],
        "new_tok_span": [14, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "bupropion",
        "sbj_char_span": [18, 27],
        "object": "norepinephrine transporter",
        "obj_char_span": [36, 62],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 6],
        "obj_tok_span": [9, 11],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [9, 11]
      },
      {
        "subject": "bupropion",
        "sbj_char_span": [18, 27],
        "object": "dopamine transporter",
        "obj_char_span": [63, 83],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 6],
        "obj_tok_span": [12, 14],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [14, 16]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "dopamine transporter",
        "char_span": [63, 83],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [12, 14],
        "new_tok_span": [14, 16]
      },
      {
        "mention": "dopamine transporter",
        "char_span": [63, 83],
        "sem_type": "Gene or Genome",
        "tok_span": [12, 14],
        "new_tok_span": [14, 16]
      }
    ],
    "new_text": "The exception was bupropion, a dual norepinephrine transporter / <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dopamine transporter <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> blocker, which tended to increase spontaneous locomotor activity."
  },
  {
    "PMID": 19389876,
    "id": 1,
    "text": "Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4. The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 11],
        "name": "Ambrisentan",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [192, 204],
        "name": "ketoconazole",
        "tok_span": [43, 46],
        "new_tok_span": [47, 50]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [289, 300],
        "name": "ambrisentan",
        "tok_span": [65, 69],
        "new_tok_span": [70, 74]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [331, 358],
        "name": "4-hydroxymethyl ambrisentan",
        "tok_span": [74, 82],
        "new_tok_span": [81, 89]
      },
      {
        "ent_type": "GENE",
        "char_span": [166, 172],
        "name": "CYP3A4",
        "tok_span": [35, 39],
        "new_tok_span": [39, 43]
      },
      {
        "ent_type": "GENE",
        "char_span": [18, 62],
        "name": "endothelin type A (ET(A))-selective receptor",
        "tok_span": [6, 19],
        "new_tok_span": [9, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [241, 247],
        "name": "CYP3A4",
        "tok_span": [54, 58],
        "new_tok_span": [58, 62]
      }
    ],
    "relation_list": [
      {
        "subject": "ketoconazole",
        "sbj_char_span": [192, 204],
        "object": "CYP3A4",
        "obj_char_span": [241, 247],
        "rel_type": "inhibitor",
        "sbj_tok_span": [43, 46],
        "obj_tok_span": [54, 58],
        "new_sbj_tok_span": [47, 50],
        "new_obj_tok_span": [58, 62]
      },
      {
        "subject": "Ambrisentan",
        "sbj_char_span": [0, 11],
        "object": "endothelin type A (ET(A))-selective receptor",
        "obj_char_span": [18, 62],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [6, 19],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [9, 22]
      },
      {
        "subject": "Ambrisentan",
        "sbj_char_span": [0, 11],
        "object": "CYP3A4",
        "obj_char_span": [166, 172],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [35, 39],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [39, 43]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "endothelin",
        "char_span": [18, 28],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [6, 8],
        "new_tok_span": [9, 11]
      },
      {
        "mention": "Ambrisentan",
        "char_span": [0, 11],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "mention": "ambrisentan",
        "char_span": [289, 300],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [65, 69],
        "new_tok_span": [70, 74]
      },
      {
        "mention": "ambrisentan",
        "char_span": [347, 358],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [78, 82],
        "new_tok_span": [88, 92]
      },
      {
        "mention": "ambrisentan,",
        "char_span": [347, 359],
        "sem_type": "Organic Chemical",
        "tok_span": [78, 83],
        "new_tok_span": [88, 93]
      },
      {
        "mention": "4-hydroxymethyl",
        "char_span": [331, 346],
        "sem_type": "Organic Chemical",
        "tok_span": [74, 78],
        "new_tok_span": [81, 85]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> Ambrisentan <END=Pharmacologic Substance> is an <START=Amino Acid, Peptide, or Protein> endothelin <END=Amino Acid, Peptide, or Protein> type A ( ET ( A ) ) - selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4. The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, to alter the pharmacokinetic profile of <START=Pharmacologic Substance> ambrisentan <END=Pharmacologic Substance> and its oxidative metabolite, <START=Organic Chemical> 4 - hydroxymethyl <END=Organic Chemical> <START=Pharmacologic Substance> <START=Organic Chemical> ambrisentan <END=Pharmacologic Substance>, <END=Organic Chemical> was assessed in an open - label, nonrandomized, 2 - period, single - sequence study in 16 healthy men."
  },
  {
    "PMID": 23102509,
    "id": 5,
    "text": "The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP). Oral administration of AA (5, 10 and 20 mg/kg b.w.) and glibenclamide (600 μg/kg b.w.) to diabetic rats for 45 days prevented the above alteration and reverted to near normalcy.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [378, 385],
        "name": "alanine",
        "tok_span": [80, 81],
        "new_tok_span": [86, 87]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [493, 506],
        "name": "glibenclamide",
        "tok_span": [112, 116],
        "new_tok_span": [120, 124]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [46, 53],
        "name": "glucose",
        "tok_span": [8, 9],
        "new_tok_span": [8, 9]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [72, 80],
        "name": "fructose",
        "tok_span": [14, 15],
        "new_tok_span": [14, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [103, 115],
        "name": "carbohydrate",
        "tok_span": [24, 25],
        "new_tok_span": [24, 25]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [180, 188],
        "name": "pyruvate",
        "tok_span": [40, 41],
        "new_tok_span": [42, 43]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [197, 216],
        "name": "glucose-6-phosphate",
        "tok_span": [43, 48],
        "new_tok_span": [45, 50]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [348, 357],
        "name": "aspartate",
        "tok_span": [72, 74],
        "new_tok_span": [76, 78]
      },
      {
        "ent_type": "GENE",
        "char_span": [372, 375],
        "name": "AST",
        "tok_span": [77, 78],
        "new_tok_span": [83, 84]
      },
      {
        "ent_type": "GENE",
        "char_span": [378, 398],
        "name": "alanine transaminase",
        "tok_span": [80, 83],
        "new_tok_span": [86, 89]
      },
      {
        "ent_type": "GENE",
        "char_span": [400, 403],
        "name": "ALT",
        "tok_span": [84, 85],
        "new_tok_span": [92, 93]
      },
      {
        "ent_type": "GENE",
        "char_span": [409, 429],
        "name": "alkaline phosphatase",
        "tok_span": [87, 89],
        "new_tok_span": [95, 97]
      },
      {
        "ent_type": "GENE",
        "char_span": [431, 434],
        "name": "ALP",
        "tok_span": [90, 91],
        "new_tok_span": [98, 99]
      },
      {
        "ent_type": "GENE",
        "char_span": [46, 67],
        "name": "glucose-6-phosphatase",
        "tok_span": [8, 13],
        "new_tok_span": [8, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [72, 99],
        "name": "fructose-1,6-bisphosphatase",
        "tok_span": [14, 23],
        "new_tok_span": [14, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [168, 178],
        "name": "hexokinase",
        "tok_span": [36, 39],
        "new_tok_span": [37, 40]
      },
      {
        "ent_type": "GENE",
        "char_span": [180, 195],
        "name": "pyruvate kinase",
        "tok_span": [40, 42],
        "new_tok_span": [42, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [197, 230],
        "name": "glucose-6-phosphate dehydrogenase",
        "tok_span": [43, 49],
        "new_tok_span": [45, 51]
      },
      {
        "ent_type": "GENE",
        "char_span": [348, 370],
        "name": "aspartate transaminase",
        "tok_span": [72, 76],
        "new_tok_span": [76, 80]
      }
    ],
    "relation_list": [
      {
        "subject": "carbohydrate",
        "sbj_char_span": [103, 115],
        "object": "glucose-6-phosphatase",
        "obj_char_span": [46, 67],
        "rel_type": "product or substrate",
        "sbj_tok_span": [24, 25],
        "obj_tok_span": [8, 13],
        "new_sbj_tok_span": [24, 25],
        "new_obj_tok_span": [8, 13]
      },
      {
        "subject": "carbohydrate",
        "sbj_char_span": [103, 115],
        "object": "fructose-1,6-bisphosphatase",
        "obj_char_span": [72, 99],
        "rel_type": "product or substrate",
        "sbj_tok_span": [24, 25],
        "obj_tok_span": [14, 23],
        "new_sbj_tok_span": [24, 25],
        "new_obj_tok_span": [14, 23]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "hexokinase",
        "char_span": [168, 178],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [36, 39],
        "new_tok_span": [37, 40]
      },
      {
        "mention": "glycogen",
        "char_span": [235, 243],
        "sem_type": "Organic Chemical",
        "tok_span": [50, 51],
        "new_tok_span": [53, 54]
      },
      {
        "mention": "transaminase",
        "char_span": [358, 370],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [74, 76],
        "new_tok_span": [79, 81]
      },
      {
        "mention": "transaminase",
        "char_span": [386, 398],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [81, 83],
        "new_tok_span": [88, 90]
      }
    ],
    "new_text": "The altered activities of key enzymes such as glucose - 6 - phosphatase and fructose - 1, 6 - bisphosphatase of carbohydrate metabolism significantly ( p < 0. 05 ) increased whereas <START=Amino Acid, Peptide, or Protein> hexokinase <END=Amino Acid, Peptide, or Protein>, pyruvate kinase, glucose - 6 - phosphate dehydrogenase and <START=Organic Chemical> glycogen <END=Organic Chemical> content significantly ( p < 0. 05 ) decreased in the liver of diabetic rats and also increased activities of aspartate <START=Amino Acid, Peptide, or Protein> transaminase <END=Amino Acid, Peptide, or Protein> ( AST ), alanine <START=Amino Acid, Peptide, or Protein> transaminase <END=Amino Acid, Peptide, or Protein> ( ALT ) and alkaline phosphatase ( ALP ). Oral administration of AA ( 5, 10 and 20 mg / kg b. w. ) and glibenclamide ( 600 μg / kg b. w. ) to diabetic rats for 45 days prevented the above alteration and reverted to near normalcy."
  },
  {
    "PMID": 23172777,
    "id": 0,
    "text": "3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [57, 68],
        "name": "quinazoline",
        "tok_span": [14, 17],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [75, 88],
        "name": "Aurora kinase",
        "tok_span": [19, 22],
        "new_tok_span": [22, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "quinazoline",
        "sbj_char_span": [57, 68],
        "object": "Aurora kinase",
        "obj_char_span": [75, 88],
        "rel_type": "inhibitor",
        "sbj_tok_span": [14, 17],
        "obj_tok_span": [19, 22],
        "new_sbj_tok_span": [15, 18],
        "new_obj_tok_span": [22, 25]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "quinazoline",
        "char_span": [57, 68],
        "sem_type": "Organic Chemical",
        "tok_span": [14, 17],
        "new_tok_span": [15, 18]
      },
      {
        "mention": "Aurora",
        "char_span": [75, 81],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [19, 21],
        "new_tok_span": [22, 24]
      }
    ],
    "new_text": "3D - QSAR - assisted drug design : identification of a potent <START=Organic Chemical> quinazoline <END=Organic Chemical> - based <START=Amino Acid, Peptide, or Protein> Aurora <END=Amino Acid, Peptide, or Protein> kinase inhibitor."
  },
  {
    "PMID": 17488480,
    "id": 6,
    "text": "In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [36, 55],
        "name": "DL-propargylglycine",
        "tok_span": [8, 15],
        "new_tok_span": [9, 16]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [57, 60],
        "name": "PAG",
        "tok_span": [16, 18],
        "new_tok_span": [20, 22]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [111, 116],
        "name": "H(2)S",
        "tok_span": [32, 37],
        "new_tok_span": [38, 43]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 129],
        "name": "caerulein",
        "tok_span": [38, 42],
        "new_tok_span": [44, 48]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [200, 205],
        "name": "H(2)S",
        "tok_span": [56, 61],
        "new_tok_span": [64, 69]
      },
      {
        "ent_type": "GENE",
        "char_span": [71, 74],
        "name": "CSE",
        "tok_span": [24, 26],
        "new_tok_span": [29, 31]
      },
      {
        "ent_type": "GENE",
        "char_span": [161, 164],
        "name": "CSE",
        "tok_span": [47, 49],
        "new_tok_span": [54, 56]
      }
    ],
    "relation_list": [
      {
        "subject": "DL-propargylglycine",
        "sbj_char_span": [36, 55],
        "object": "CSE",
        "obj_char_span": [71, 74],
        "rel_type": "inhibitor",
        "sbj_tok_span": [8, 15],
        "obj_tok_span": [24, 26],
        "new_sbj_tok_span": [9, 16],
        "new_obj_tok_span": [29, 31]
      },
      {
        "subject": "PAG",
        "sbj_char_span": [57, 60],
        "object": "CSE",
        "obj_char_span": [71, 74],
        "rel_type": "inhibitor",
        "sbj_tok_span": [16, 18],
        "obj_tok_span": [24, 26],
        "new_sbj_tok_span": [20, 22],
        "new_obj_tok_span": [29, 31]
      },
      {
        "subject": "H(2)S",
        "sbj_char_span": [200, 205],
        "object": "CSE",
        "obj_char_span": [161, 164],
        "rel_type": "product or substrate",
        "sbj_tok_span": [56, 61],
        "obj_tok_span": [47, 49],
        "new_sbj_tok_span": [64, 69],
        "new_obj_tok_span": [54, 56]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "propargylglycine",
        "char_span": [39, 55],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [10, 15],
        "new_tok_span": [13, 18]
      },
      {
        "mention": "DL",
        "char_span": [36, 38],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 9],
        "new_tok_span": [9, 10]
      },
      {
        "mention": "CSE",
        "char_span": [71, 74],
        "sem_type": "Gene or Genome",
        "tok_span": [24, 26],
        "new_tok_span": [29, 31]
      },
      {
        "mention": "CSE",
        "char_span": [161, 164],
        "sem_type": "Gene or Genome",
        "tok_span": [47, 49],
        "new_tok_span": [54, 56]
      }
    ],
    "new_text": "In addition, cells pre - treated with <START=Gene or Genome> DL <END=Gene or Genome> - <START=Pharmacologic Substance> propargylglycine <END=Pharmacologic Substance> ( PAG, 3 mM ), a <START=Gene or Genome> CSE <END=Gene or Genome> inhibitor, reduced the formation of H ( 2 ) S in caerulein treated cells, suggesting that <START=Gene or Genome> CSE <END=Gene or Genome> may be the main enzyme involved in H ( 2 ) S formation in mouse acinar cells."
  },
  {
    "PMID": 17015640,
    "id": 8,
    "text": "Moreover, licofelone inhibited COX-2 and 5-LOX protein expression in vascular lesions.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [10, 20],
        "name": "licofelone",
        "tok_span": [2, 6],
        "new_tok_span": [2, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [31, 36],
        "name": "COX-2",
        "tok_span": [7, 10],
        "new_tok_span": [7, 10]
      },
      {
        "ent_type": "GENE",
        "char_span": [41, 46],
        "name": "5-LOX",
        "tok_span": [11, 15],
        "new_tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "licofelone",
        "sbj_char_span": [10, 20],
        "object": "COX-2",
        "obj_char_span": [31, 36],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [7, 10],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [7, 10]
      },
      {
        "subject": "licofelone",
        "sbj_char_span": [10, 20],
        "object": "5-LOX",
        "obj_char_span": [41, 46],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [11, 15],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Moreover, licofelone inhibited COX - 2 and 5 - LOX protein expression in vascular lesions."
  },
  {
    "PMID": 16938288,
    "id": 0,
    "text": "Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 11],
        "name": "Telmisartan",
        "tok_span": [0, 5],
        "new_tok_span": [0, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [26, 56],
        "name": "angiotensin II type 1 receptor",
        "tok_span": [8, 13],
        "new_tok_span": [8, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [79, 127],
        "name": "peroxisome proliferator-activated receptor gamma",
        "tok_span": [16, 24],
        "new_tok_span": [17, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "Telmisartan",
        "sbj_char_span": [0, 11],
        "object": "peroxisome proliferator-activated receptor gamma",
        "obj_char_span": [79, 127],
        "rel_type": "activator",
        "sbj_tok_span": [0, 5],
        "obj_tok_span": [16, 24],
        "new_sbj_tok_span": [0, 5],
        "new_obj_tok_span": [17, 25]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "peroxisome proliferator-activated receptor gamma",
        "char_span": [79, 127],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [16, 24],
        "new_tok_span": [17, 25]
      }
    ],
    "new_text": "Telmisartan downregulates angiotensin II type 1 receptor through activation of <START=Amino Acid, Peptide, or Protein> peroxisome proliferator - activated receptor gamma <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 22931533,
    "id": 2,
    "text": "The structurally diverse opioids codeine and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [33, 40],
        "name": "codeine",
        "tok_span": [5, 7],
        "new_tok_span": [8, 10]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [45, 54],
        "name": "eseroline",
        "tok_span": [8, 11],
        "new_tok_span": [13, 16]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [61, 72],
        "name": "galantamine",
        "tok_span": [13, 17],
        "new_tok_span": [19, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [83, 88],
        "name": "nAChR",
        "tok_span": [20, 23],
        "new_tok_span": [26, 29]
      },
      {
        "ent_type": "GENE",
        "char_span": [135, 139],
        "name": "AChE",
        "tok_span": [32, 34],
        "new_tok_span": [38, 40]
      },
      {
        "ent_type": "GENE",
        "char_span": [193, 198],
        "name": "nAChR",
        "tok_span": [41, 44],
        "new_tok_span": [47, 50]
      }
    ],
    "relation_list": [
      {
        "subject": "codeine",
        "sbj_char_span": [33, 40],
        "object": "nAChR",
        "obj_char_span": [83, 88],
        "rel_type": "regulator",
        "sbj_tok_span": [5, 7],
        "obj_tok_span": [20, 23],
        "new_sbj_tok_span": [8, 10],
        "new_obj_tok_span": [26, 29]
      },
      {
        "subject": "eseroline",
        "sbj_char_span": [45, 54],
        "object": "nAChR",
        "obj_char_span": [83, 88],
        "rel_type": "regulator",
        "sbj_tok_span": [8, 11],
        "obj_tok_span": [20, 23],
        "new_sbj_tok_span": [13, 16],
        "new_obj_tok_span": [26, 29]
      },
      {
        "subject": "galantamine",
        "sbj_char_span": [61, 72],
        "object": "nAChR",
        "obj_char_span": [83, 88],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [20, 23],
        "new_sbj_tok_span": [19, 23],
        "new_obj_tok_span": [26, 29]
      },
      {
        "subject": "codeine",
        "sbj_char_span": [33, 40],
        "object": "AChE",
        "obj_char_span": [135, 139],
        "rel_type": "regulator",
        "sbj_tok_span": [5, 7],
        "obj_tok_span": [32, 34],
        "new_sbj_tok_span": [8, 10],
        "new_obj_tok_span": [38, 40]
      },
      {
        "subject": "eseroline",
        "sbj_char_span": [45, 54],
        "object": "AChE",
        "obj_char_span": [135, 139],
        "rel_type": "regulator",
        "sbj_tok_span": [8, 11],
        "obj_tok_span": [32, 34],
        "new_sbj_tok_span": [13, 16],
        "new_obj_tok_span": [38, 40]
      },
      {
        "subject": "galantamine",
        "sbj_char_span": [61, 72],
        "object": "AChE",
        "obj_char_span": [135, 139],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [32, 34],
        "new_sbj_tok_span": [19, 23],
        "new_obj_tok_span": [38, 40]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "opioids",
        "char_span": [25, 32],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [3, 5],
        "new_tok_span": [4, 6]
      },
      {
        "mention": "codeine",
        "char_span": [33, 40],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [5, 7],
        "new_tok_span": [8, 10]
      },
      {
        "mention": "eseroline",
        "char_span": [45, 54],
        "sem_type": "Organic Chemical",
        "tok_span": [8, 11],
        "new_tok_span": [13, 16]
      }
    ],
    "new_text": "The structurally diverse <START=Pharmacologic Substance> opioids <END=Pharmacologic Substance> <START=Pharmacologic Substance> codeine <END=Pharmacologic Substance> and <START=Organic Chemical> eseroline <END=Organic Chemical>, like galantamine, are also nAChR - APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR - APL development."
  },
  {
    "PMID": 12719755,
    "id": 4,
    "text": "The hypothalamic defence area (HDA) is a potential source of descending fibres containing angiotensin II that innervate the NTS. We investigated the effect of AT1 receptor blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent pancuronium bromide.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [90, 104],
        "name": "angiotensin II",
        "tok_span": [16, 18],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [298, 317],
        "name": "pancuronium bromide",
        "tok_span": [58, 62],
        "new_tok_span": [69, 73]
      },
      {
        "ent_type": "GENE",
        "char_span": [90, 104],
        "name": "angiotensin II",
        "tok_span": [16, 18],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [159, 171],
        "name": "AT1 receptor",
        "tok_span": [31, 34],
        "new_tok_span": [35, 38]
      }
    ],
    "relation_list": [
      {
        "subject": "pancuronium bromide",
        "sbj_char_span": [298, 317],
        "object": "AT1 receptor",
        "obj_char_span": [159, 171],
        "rel_type": "inhibitor",
        "sbj_tok_span": [58, 62],
        "obj_tok_span": [31, 34],
        "new_sbj_tok_span": [69, 73],
        "new_obj_tok_span": [35, 38]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "NTS",
        "char_span": [124, 127],
        "sem_type": "Gene or Genome",
        "tok_span": [23, 25],
        "new_tok_span": [25, 27]
      },
      {
        "mention": "NTS",
        "char_span": [188, 191],
        "sem_type": "Gene or Genome",
        "tok_span": [37, 39],
        "new_tok_span": [43, 45]
      },
      {
        "mention": "NTS",
        "char_span": [124, 127],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [23, 25],
        "new_tok_span": [25, 27]
      },
      {
        "mention": "NTS",
        "char_span": [188, 191],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 39],
        "new_tok_span": [43, 45]
      },
      {
        "mention": "neuromuscular blocking agent",
        "char_span": [269, 297],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [55, 58],
        "new_tok_span": [64, 67]
      },
      {
        "mention": "pancuronium bromide",
        "char_span": [298, 317],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [58, 62],
        "new_tok_span": [69, 73]
      }
    ],
    "new_text": "The hypothalamic defence area ( HDA ) is a potential source of descending fibres containing angiotensin II that innervate the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NTS <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. We investigated the effect of AT1 receptor blockade in the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NTS <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> on the response to stimulation of HDA in anaesthetised rats treated with the <START=Pharmacologic Substance> neuromuscular blocking agent <END=Pharmacologic Substance> <START=Pharmacologic Substance> pancuronium bromide <END=Pharmacologic Substance>."
  },
  {
    "PMID": 8894610,
    "id": 6,
    "text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and oxymetazoline-sensitive subtype of alpha 1-adrenoceptors, is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [72, 88],
        "name": "(+/-)-tamsulosin",
        "tok_span": [12, 22],
        "new_tok_span": [14, 24]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [94, 107],
        "name": "oxymetazoline",
        "tok_span": [24, 29],
        "new_tok_span": [26, 31]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [233, 252],
        "name": "inositol phosphates",
        "tok_span": [54, 59],
        "new_tok_span": [57, 62]
      },
      {
        "ent_type": "GENE",
        "char_span": [129, 150],
        "name": "alpha 1-adrenoceptors",
        "tok_span": [33, 40],
        "new_tok_span": [35, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "oxymetazoline",
        "sbj_char_span": [94, 107],
        "object": "alpha 1-adrenoceptors",
        "obj_char_span": [129, 150],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [24, 29],
        "obj_tok_span": [33, 40],
        "new_sbj_tok_span": [26, 31],
        "new_obj_tok_span": [35, 42]
      },
      {
        "subject": "(+/-)-tamsulosin",
        "sbj_char_span": [72, 88],
        "object": "alpha 1-adrenoceptors",
        "obj_char_span": [129, 150],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [12, 22],
        "obj_tok_span": [33, 40],
        "new_sbj_tok_span": [14, 24],
        "new_obj_tok_span": [35, 42]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "mediated",
        "char_span": [59, 67],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [10, 11],
        "new_tok_span": [11, 12]
      },
      {
        "mention": "inositol",
        "char_span": [233, 241],
        "sem_type": "Organic Chemical",
        "tok_span": [54, 57],
        "new_tok_span": [57, 60]
      }
    ],
    "new_text": "These results indicate that the positive inotropic effect, <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> via ( + / - ) - tamsulosin - and oxymetazoline - sensitive subtype of alpha 1 - adrenoceptors, is exerted by a subcellular mechanism that is independent of the accumulation of <START=Organic Chemical> inositol <END=Organic Chemical> phosphates."
  },
  {
    "PMID": 7837275,
    "id": 9,
    "text": "In conclusion, these data demonstrate that: (1) the Leu144-Gly150 loop and the FRS are both involved in the conformational transition linked to the binding of p-aminobenzamidine to the thrombin active site; (2) the extent of thrombin's capacity to undergo conformational transitions in alpha-, zeta- and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the FRS.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [159, 177],
        "name": "p-aminobenzamidine",
        "tok_span": [34, 40],
        "new_tok_span": [36, 42]
      },
      {
        "ent_type": "GENE",
        "char_span": [79, 82],
        "name": "FRS",
        "tok_span": [20, 22],
        "new_tok_span": [21, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [185, 193],
        "name": "thrombin",
        "tok_span": [42, 43],
        "new_tok_span": [45, 46]
      },
      {
        "ent_type": "GENE",
        "char_span": [225, 235],
        "name": "thrombin's",
        "tok_span": [52, 55],
        "new_tok_span": [57, 60]
      },
      {
        "ent_type": "GENE",
        "char_span": [471, 474],
        "name": "FRS",
        "tok_span": [94, 96],
        "new_tok_span": [103, 105]
      }
    ],
    "relation_list": [
      {
        "subject": "p-aminobenzamidine",
        "sbj_char_span": [159, 177],
        "object": "thrombin",
        "obj_char_span": [185, 193],
        "rel_type": "regulator",
        "sbj_tok_span": [34, 40],
        "obj_tok_span": [42, 43],
        "new_sbj_tok_span": [36, 42],
        "new_obj_tok_span": [45, 46]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "FRS",
        "char_span": [79, 82],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [20, 22],
        "new_tok_span": [21, 23]
      },
      {
        "mention": "FRS",
        "char_span": [471, 474],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [94, 96],
        "new_tok_span": [103, 105]
      },
      {
        "mention": "thrombin",
        "char_span": [185, 193],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [42, 43],
        "new_tok_span": [45, 46]
      },
      {
        "mention": "thrombin",
        "char_span": [225, 233],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [52, 53],
        "new_tok_span": [57, 58]
      },
      {
        "mention": "zeta",
        "char_span": [294, 298],
        "sem_type": "Gene or Genome",
        "tok_span": [64, 66],
        "new_tok_span": [71, 73]
      }
    ],
    "new_text": "In conclusion, these data demonstrate that : ( 1 ) the Leu144 - Gly150 loop and the <START=Pharmacologic Substance> FRS <END=Pharmacologic Substance> are both involved in the conformational transition linked to the binding of p - aminobenzamidine to the <START=Amino Acid, Peptide, or Protein> thrombin <END=Amino Acid, Peptide, or Protein> active site ; ( 2 ) the extent of <START=Amino Acid, Peptide, or Protein> thrombin <END=Amino Acid, Peptide, or Protein>'s capacity to undergo conformational transitions in alpha -, <START=Gene or Genome> zeta <END=Gene or Genome> - and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the <START=Pharmacologic Substance> FRS <END=Pharmacologic Substance>."
  },
  {
    "PMID": 12181285,
    "id": 11,
    "text": "Our observations indicate an OCT-mediated transmembrane transport of [3H]-MPP+. Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [69, 78],
        "name": "[3H]-MPP+",
        "tok_span": [10, 18],
        "new_tok_span": [10, 18]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [250, 259],
        "name": "[3H]-MPP+",
        "tok_span": [54, 62],
        "new_tok_span": [60, 68]
      },
      {
        "ent_type": "GENE",
        "char_span": [29, 32],
        "name": "OCT",
        "tok_span": [4, 5],
        "new_tok_span": [4, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [98, 102],
        "name": "OCTs",
        "tok_span": [23, 25],
        "new_tok_span": [27, 29]
      },
      {
        "ent_type": "GENE",
        "char_span": [125, 129],
        "name": "OCT3",
        "tok_span": [31, 33],
        "new_tok_span": [36, 38]
      }
    ],
    "relation_list": [
      {
        "subject": "[3H]-MPP+",
        "sbj_char_span": [69, 78],
        "object": "OCT",
        "obj_char_span": [29, 32],
        "rel_type": "product or substrate",
        "sbj_tok_span": [10, 18],
        "obj_tok_span": [4, 5],
        "new_sbj_tok_span": [10, 18],
        "new_obj_tok_span": [4, 5]
      },
      {
        "subject": "[3H]-MPP+",
        "sbj_char_span": [250, 259],
        "object": "OCT3",
        "obj_char_span": [125, 129],
        "rel_type": "product or substrate",
        "sbj_tok_span": [54, 62],
        "obj_tok_span": [31, 33],
        "new_sbj_tok_span": [60, 68],
        "new_obj_tok_span": [36, 38]
      },
      {
        "subject": "[3H]-MPP+",
        "sbj_char_span": [250, 259],
        "object": "OCTs",
        "obj_char_span": [98, 102],
        "rel_type": "product or substrate",
        "sbj_tok_span": [54, 62],
        "obj_tok_span": [23, 25],
        "new_sbj_tok_span": [60, 68],
        "new_obj_tok_span": [27, 29]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "OCT3",
        "char_span": [125, 129],
        "sem_type": "Gene or Genome",
        "tok_span": [31, 33],
        "new_tok_span": [36, 38]
      },
      {
        "mention": "MPP+",
        "char_span": [74, 78],
        "sem_type": "Organic Chemical",
        "tok_span": [15, 18],
        "new_tok_span": [17, 20]
      },
      {
        "mention": "MPP+",
        "char_span": [255, 259],
        "sem_type": "Organic Chemical",
        "tok_span": [59, 62],
        "new_tok_span": [67, 70]
      },
      {
        "mention": "MPP",
        "char_span": [74, 77],
        "sem_type": "Gene or Genome",
        "tok_span": [15, 17],
        "new_tok_span": [17, 19]
      },
      {
        "mention": "MPP",
        "char_span": [255, 258],
        "sem_type": "Gene or Genome",
        "tok_span": [59, 61],
        "new_tok_span": [67, 69]
      }
    ],
    "new_text": "Our observations indicate an OCT - mediated transmembrane transport of [ 3H ] - <START=Organic Chemical> <START=Gene or Genome> MPP <END=Gene or Genome> + <END=Organic Chemical>. Amongst the three OCTs expressed in the SCG, <START=Gene or Genome> OCT3 <END=Gene or Genome> best fits the profile of substrates and antagonists that cause trans - stimulation and trans - inhibition, respectively, of [ 3H ] - <START=Organic Chemical> <START=Gene or Genome> MPP <END=Gene or Genome> + <END=Organic Chemical> release."
  },
  {
    "PMID": 22370641,
    "id": 5,
    "text": "Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of β-catenin to the proximal WNT6 promoter.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 3],
        "name": "Epi",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [34, 53],
        "name": "human WNT6 promoter",
        "tok_span": [7, 12],
        "new_tok_span": [9, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [62, 66],
        "name": "Cav1",
        "tok_span": [13, 15],
        "new_tok_span": [21, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [88, 97],
        "name": "β-catenin",
        "tok_span": [19, 24],
        "new_tok_span": [29, 34]
      },
      {
        "ent_type": "GENE",
        "char_span": [114, 127],
        "name": "WNT6 promoter",
        "tok_span": [27, 31],
        "new_tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "Epi",
        "sbj_char_span": [0, 3],
        "object": "human WNT6 promoter",
        "obj_char_span": [34, 53],
        "rel_type": "activator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [7, 12],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [9, 14]
      },
      {
        "subject": "Epi",
        "sbj_char_span": [0, 3],
        "object": "WNT6 promoter",
        "obj_char_span": [114, 127],
        "rel_type": "activator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [27, 31],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [39, 43]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Epi",
        "char_span": [0, 3],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "mention": "WNT6",
        "char_span": [40, 44],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 11],
        "new_tok_span": [12, 15]
      },
      {
        "mention": "WNT6",
        "char_span": [114, 118],
        "sem_type": "Gene or Genome",
        "tok_span": [27, 30],
        "new_tok_span": [39, 42]
      },
      {
        "mention": "WNT6",
        "char_span": [40, 44],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [8, 11],
        "new_tok_span": [12, 15]
      },
      {
        "mention": "WNT6",
        "char_span": [114, 118],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [27, 30],
        "new_tok_span": [39, 42]
      },
      {
        "mention": "Cav1",
        "char_span": [62, 66],
        "sem_type": "Gene or Genome",
        "tok_span": [13, 15],
        "new_tok_span": [21, 23]
      },
      {
        "mention": "Cav1",
        "char_span": [62, 66],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [13, 15],
        "new_tok_span": [21, 23]
      }
    ],
    "new_text": "<START=Amino Acid, Peptide, or Protein> Epi <END=Amino Acid, Peptide, or Protein> increased the activity of the human <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> WNT6 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> promoter through <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Cav1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - dependent binding of β - catenin to the proximal <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> WNT6 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> promoter."
  },
  {
    "PMID": 3994963,
    "id": 4,
    "text": "Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the phenoxybenzamine-calmodulin adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [46, 63],
        "name": "cyclic nucleotide",
        "tok_span": [9, 11],
        "new_tok_span": [10, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [121, 135],
        "name": "chlorpromazine",
        "tok_span": [23, 26],
        "new_tok_span": [26, 29]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [162, 178],
        "name": "phenoxybenzamine",
        "tok_span": [30, 34],
        "new_tok_span": [35, 39]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [231, 247],
        "name": "phenoxybenzamine",
        "tok_span": [45, 49],
        "new_tok_span": [52, 56]
      },
      {
        "ent_type": "GENE",
        "char_span": [46, 81],
        "name": "cyclic nucleotide phosphodiesterase",
        "tok_span": [9, 15],
        "new_tok_span": [10, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [86, 111],
        "name": "myosin light chain kinase",
        "tok_span": [16, 20],
        "new_tok_span": [18, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [179, 189],
        "name": "calmodulin",
        "tok_span": [35, 38],
        "new_tok_span": [41, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "phenoxybenzamine",
        "sbj_char_span": [162, 178],
        "object": "calmodulin",
        "obj_char_span": [179, 189],
        "rel_type": "regulator",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [35, 38],
        "new_sbj_tok_span": [35, 39],
        "new_obj_tok_span": [41, 44]
      },
      {
        "subject": "chlorpromazine",
        "sbj_char_span": [121, 135],
        "object": "calmodulin",
        "obj_char_span": [179, 189],
        "rel_type": "regulator",
        "sbj_tok_span": [23, 26],
        "obj_tok_span": [35, 38],
        "new_sbj_tok_span": [26, 29],
        "new_obj_tok_span": [41, 44]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "cyclic nucleotide phosphodiesterase",
        "char_span": [46, 81],
        "sem_type": "Gene or Genome",
        "tok_span": [9, 15],
        "new_tok_span": [10, 16]
      },
      {
        "mention": "chlorpromazine",
        "char_span": [121, 135],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [23, 26],
        "new_tok_span": [26, 29]
      },
      {
        "mention": "phenoxybenzamine",
        "char_span": [162, 178],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [30, 34],
        "new_tok_span": [35, 39]
      },
      {
        "mention": "phenoxybenzamine",
        "char_span": [231, 247],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [45, 49],
        "new_tok_span": [52, 56]
      }
    ],
    "new_text": "Each adduct had a reduced ability to activate <START=Gene or Genome> cyclic nucleotide phosphodiesterase <END=Gene or Genome> and myosin light chain kinase, and the <START=Pharmacologic Substance> chlorpromazine <END=Pharmacologic Substance> binding capacities of the <START=Pharmacologic Substance> phenoxybenzamine <END=Pharmacologic Substance> - calmodulin adducts were diminished to the extent of <START=Pharmacologic Substance> phenoxybenzamine <END=Pharmacologic Substance> incorporation into each adduct."
  },
  {
    "PMID": 23041257,
    "id": 7,
    "text": "DBDCT up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 5],
        "name": "DBDCT",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [123, 126],
        "name": "Bax",
        "tok_span": [27, 28],
        "new_tok_span": [27, 28]
      },
      {
        "ent_type": "GENE",
        "char_span": [127, 132],
        "name": "Bcl-2",
        "tok_span": [29, 32],
        "new_tok_span": [29, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [37, 40],
        "name": "Bax",
        "tok_span": [9, 10],
        "new_tok_span": [9, 10]
      },
      {
        "ent_type": "GENE",
        "char_span": [75, 80],
        "name": "Bcl-2",
        "tok_span": [17, 20],
        "new_tok_span": [17, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "DBDCT",
        "sbj_char_span": [0, 5],
        "object": "Bax",
        "obj_char_span": [37, 40],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [9, 10],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [9, 10]
      },
      {
        "subject": "DBDCT",
        "sbj_char_span": [0, 5],
        "object": "Bcl-2",
        "obj_char_span": [75, 80],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [17, 20],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [17, 20]
      },
      {
        "subject": "DBDCT",
        "sbj_char_span": [0, 5],
        "object": "Bax",
        "obj_char_span": [123, 126],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [27, 28],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [27, 28]
      },
      {
        "subject": "DBDCT",
        "sbj_char_span": [0, 5],
        "object": "Bcl-2",
        "obj_char_span": [127, 132],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [29, 32],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [29, 32]
      }
    ],
    "umls_entity_list": [],
    "new_text": "DBDCT up - regulated the expression of Bax, down - regulated the expression of Bcl - 2, and significantly increased the ratio of Bax / Bcl - 2."
  },
  {
    "PMID": 1730582,
    "id": 0,
    "text": "Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [52, 61],
        "name": "ornithine",
        "tok_span": [7, 11],
        "new_tok_span": [9, 13]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [79, 108],
        "name": "alpha-difluoromethylornithine",
        "tok_span": [15, 23],
        "new_tok_span": [20, 28]
      },
      {
        "ent_type": "GENE",
        "char_span": [46, 75],
        "name": "mouse ornithine decarboxylase",
        "tok_span": [6, 14],
        "new_tok_span": [6, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "alpha-difluoromethylornithine",
        "sbj_char_span": [79, 108],
        "object": "mouse ornithine decarboxylase",
        "obj_char_span": [46, 75],
        "rel_type": "inhibitor",
        "sbj_tok_span": [15, 23],
        "obj_tok_span": [6, 14],
        "new_sbj_tok_span": [20, 28],
        "new_obj_tok_span": [6, 14]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "ornithine",
        "char_span": [52, 61],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [7, 11],
        "new_tok_span": [9, 13]
      },
      {
        "mention": "ornithine",
        "char_span": [99, 108],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [20, 23],
        "new_tok_span": [26, 29]
      },
      {
        "mention": "ornithine decarboxylase",
        "char_span": [52, 75],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [7, 14],
        "new_tok_span": [9, 16]
      },
      {
        "mention": "alpha-difluoromethylornithine",
        "char_span": [79, 108],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [15, 23],
        "new_tok_span": [20, 28]
      }
    ],
    "new_text": "Mechanism of the irreversible inactivation of mouse <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> ornithine <END=Amino Acid, Peptide, or Protein> decarboxylase <END=Amino Acid, Peptide, or Protein> by <START=Amino Acid, Peptide, or Protein> alpha - difluoromethyl <START=Amino Acid, Peptide, or Protein>ornithine <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 23574017,
    "id": 3,
    "text": "Doxorubicin is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 11],
        "name": "Doxorubicin",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [49, 63],
        "name": "P-glycoprotein",
        "tok_span": [11, 14],
        "new_tok_span": [11, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [65, 69],
        "name": "P-gp",
        "tok_span": [15, 18],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [75, 116],
        "name": "multidrug resistance-associated protein 2",
        "tok_span": [20, 27],
        "new_tok_span": [20, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [118, 122],
        "name": "Mrp2",
        "tok_span": [28, 31],
        "new_tok_span": [28, 31]
      },
      {
        "ent_type": "GENE",
        "char_span": [167, 191],
        "name": "cytochrome P450 (CYP) 3A",
        "tok_span": [42, 50],
        "new_tok_span": [42, 50]
      }
    ],
    "relation_list": [
      {
        "subject": "Doxorubicin",
        "sbj_char_span": [0, 11],
        "object": "P-glycoprotein",
        "obj_char_span": [49, 63],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [11, 14],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [11, 14]
      },
      {
        "subject": "Doxorubicin",
        "sbj_char_span": [0, 11],
        "object": "P-gp",
        "obj_char_span": [65, 69],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [15, 18],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [15, 18]
      },
      {
        "subject": "Doxorubicin",
        "sbj_char_span": [0, 11],
        "object": "multidrug resistance-associated protein 2",
        "obj_char_span": [75, 116],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [20, 27],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [20, 27]
      },
      {
        "subject": "Doxorubicin",
        "sbj_char_span": [0, 11],
        "object": "Mrp2",
        "obj_char_span": [118, 122],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [28, 31],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [28, 31]
      },
      {
        "subject": "Doxorubicin",
        "sbj_char_span": [0, 11],
        "object": "cytochrome P450 (CYP) 3A",
        "obj_char_span": [167, 191],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [42, 50],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [42, 50]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Doxorubicin is mainly excreted into the bile via P - glycoprotein ( P - gp ) and multidrug resistance - associated protein 2 ( Mrp2 ) in hepatobiliary route and metabolized via cytochrome P450 ( CYP ) 3A subfamily."
  },
  {
    "PMID": 18068977,
    "id": 1,
    "text": "Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In this report, we show that the hypolipidemic agent atorvastatin is a competitive inhibitor of porcine DPP-IV in vitro, with K(i)=57.8+/-2.3 microM.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [261, 273],
        "name": "atorvastatin",
        "tok_span": [63, 66],
        "new_tok_span": [72, 75]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 23],
        "name": "Dipeptidyl peptidase-IV",
        "tok_span": [0, 8],
        "new_tok_span": [1, 9]
      },
      {
        "ent_type": "GENE",
        "char_span": [102, 119],
        "name": "incretin hormones",
        "tok_span": [25, 28],
        "new_tok_span": [28, 31]
      },
      {
        "ent_type": "GENE",
        "char_span": [120, 143],
        "name": "glucagon-like peptide-1",
        "tok_span": [28, 34],
        "new_tok_span": [33, 39]
      },
      {
        "ent_type": "GENE",
        "char_span": [145, 150],
        "name": "GLP-1",
        "tok_span": [35, 38],
        "new_tok_span": [41, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [156, 200],
        "name": "glucose-dependent insulinotropic polypeptide",
        "tok_span": [40, 46],
        "new_tok_span": [46, 52]
      },
      {
        "ent_type": "GENE",
        "char_span": [202, 205],
        "name": "GIP",
        "tok_span": [47, 49],
        "new_tok_span": [53, 55]
      },
      {
        "ent_type": "GENE",
        "char_span": [25, 31],
        "name": "DPP-IV",
        "tok_span": [9, 12],
        "new_tok_span": [11, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [304, 318],
        "name": "porcine DPP-IV",
        "tok_span": [71, 75],
        "new_tok_span": [81, 85]
      }
    ],
    "relation_list": [
      {
        "subject": "atorvastatin",
        "sbj_char_span": [261, 273],
        "object": "porcine DPP-IV",
        "obj_char_span": [304, 318],
        "rel_type": "inhibitor",
        "sbj_tok_span": [63, 66],
        "obj_tok_span": [71, 75],
        "new_sbj_tok_span": [72, 75],
        "new_obj_tok_span": [81, 85]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "incretin hormone",
        "char_span": [102, 118],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [25, 28],
        "new_tok_span": [28, 31]
      },
      {
        "mention": "glucagon-like",
        "char_span": [120, 133],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [28, 31],
        "new_tok_span": [33, 36]
      },
      {
        "mention": "hypolipidemic agent",
        "char_span": [241, 260],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [59, 63],
        "new_tok_span": [66, 70]
      },
      {
        "mention": "atorvastatin",
        "char_span": [261, 273],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [63, 66],
        "new_tok_span": [72, 75]
      },
      {
        "mention": "Dipeptidyl",
        "char_span": [0, 10],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> Dipeptidyl <END=Pharmacologic Substance> peptidase - IV ( DPP - IV ) is an enzyme responsible for the inactivation of the glucoregulatory <START=Amino Acid, Peptide, or Protein> incretin hormones <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> glucagon - like <END=Amino Acid, Peptide, or Protein> peptide - 1 ( GLP - 1 ) and glucose - dependent insulinotropic polypeptide ( GIP ). In this report, we show that the <START=Pharmacologic Substance> hypolipidemic agent <END=Pharmacologic Substance> <START=Pharmacologic Substance> atorvastatin <END=Pharmacologic Substance> is a competitive inhibitor of porcine DPP - IV in vitro, with K ( i ) = 57. 8 + / - 2. 3 microM."
  },
  {
    "PMID": 23506741,
    "id": 4,
    "text": "Treatment with Fc11a-2 dose-dependently attenuated the loss of body weight and shortening of colon length induced by DSS. In addition, the disease activity index, histopathologic scores and myeloperoxidase activity were also significantly reduced by Fc11a-2 treatment.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [250, 257],
        "name": "Fc11a-2",
        "tok_span": [47, 52],
        "new_tok_span": [49, 54]
      },
      {
        "ent_type": "GENE",
        "char_span": [190, 205],
        "name": "myeloperoxidase",
        "tok_span": [38, 41],
        "new_tok_span": [40, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "Fc11a-2",
        "sbj_char_span": [250, 257],
        "object": "myeloperoxidase",
        "obj_char_span": [190, 205],
        "rel_type": "inhibitor",
        "sbj_tok_span": [47, 52],
        "obj_tok_span": [38, 41],
        "new_sbj_tok_span": [49, 54],
        "new_obj_tok_span": [40, 43]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "DSS",
        "char_span": [117, 120],
        "sem_type": "Gene or Genome",
        "tok_span": [24, 25],
        "new_tok_span": [25, 26]
      }
    ],
    "new_text": "Treatment with Fc11a - 2 dose - dependently attenuated the loss of body weight and shortening of colon length induced by <START=Gene or Genome> DSS <END=Gene or Genome>. In addition, the disease activity index, histopathologic scores and myeloperoxidase activity were also significantly reduced by Fc11a - 2 treatment."
  },
  {
    "PMID": 12086935,
    "id": 7,
    "text": "Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Metformin",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [82, 89],
        "name": "glucose",
        "tok_span": [14, 15],
        "new_tok_span": [16, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [31, 35],
        "name": "AMPK",
        "tok_span": [6, 7],
        "new_tok_span": [8, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "Metformin",
        "sbj_char_span": [0, 9],
        "object": "AMPK",
        "obj_char_span": [31, 35],
        "rel_type": "activator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [6, 7],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [8, 9]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Metformin",
        "char_span": [0, 9],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "mention": "glycogen",
        "char_span": [110, 118],
        "sem_type": "Organic Chemical",
        "tok_span": [18, 19],
        "new_tok_span": [21, 22]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> Metformin <END=Pharmacologic Substance> - induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle <START=Organic Chemical> glycogen <END=Organic Chemical> concentrations."
  },
  {
    "PMID": 23164921,
    "id": 6,
    "text": "Collectively, these results suggest that catalpol can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of NF-κB could be the major determinant for its anti-inflammatory mechanism.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [41, 49],
        "name": "catalpol",
        "tok_span": [6, 8],
        "new_tok_span": [6, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [147, 152],
        "name": "NF-κB",
        "tok_span": [22, 26],
        "new_tok_span": [22, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "catalpol",
        "sbj_char_span": [41, 49],
        "object": "NF-κB",
        "obj_char_span": [147, 152],
        "rel_type": "inhibitor",
        "sbj_tok_span": [6, 8],
        "obj_tok_span": [22, 26],
        "new_sbj_tok_span": [6, 8],
        "new_obj_tok_span": [22, 26]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Collectively, these results suggest that catalpol can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of NF - κB could be the major determinant for its anti - inflammatory mechanism."
  },
  {
    "PMID": 17344208,
    "id": 8,
    "text": "This is significant because superoxide production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [28, 38],
        "name": "superoxide",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [72, 83],
        "name": "human PRODH",
        "tok_span": [11, 14],
        "new_tok_span": [13, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [87, 90],
        "name": "p53",
        "tok_span": [15, 17],
        "new_tok_span": [17, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [142, 188],
        "name": "eukaryotic and bacterial monofunctional PRODHs",
        "tok_span": [25, 33],
        "new_tok_span": [27, 35]
      }
    ],
    "relation_list": [
      {
        "subject": "superoxide",
        "sbj_char_span": [28, 38],
        "object": "human PRODH",
        "obj_char_span": [72, 83],
        "rel_type": "product or substrate",
        "sbj_tok_span": [4, 5],
        "obj_tok_span": [11, 14],
        "new_sbj_tok_span": [5, 6],
        "new_obj_tok_span": [13, 16]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "superoxide",
        "char_span": [28, 38],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      }
    ],
    "new_text": "This is significant because <START=Pharmacologic Substance> superoxide <END=Pharmacologic Substance> production underlies the role of human PRODH in p53 - mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs."
  },
  {
    "PMID": 12414329,
    "id": 3,
    "text": "The key second messenger in the mediation of penile erection is cGMP. PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [128, 132],
        "name": "cGMP",
        "tok_span": [31, 33],
        "new_tok_span": [31, 33]
      },
      {
        "ent_type": "GENE",
        "char_span": [70, 74],
        "name": "PDE5",
        "tok_span": [17, 19],
        "new_tok_span": [17, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [94, 97],
        "name": "PDE",
        "tok_span": [22, 23],
        "new_tok_span": [22, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "cGMP",
        "sbj_char_span": [128, 132],
        "object": "PDE5",
        "obj_char_span": [70, 74],
        "rel_type": "product or substrate",
        "sbj_tok_span": [31, 33],
        "obj_tok_span": [17, 19],
        "new_sbj_tok_span": [31, 33],
        "new_obj_tok_span": [17, 19]
      },
      {
        "subject": "cGMP",
        "sbj_char_span": [128, 132],
        "object": "PDE",
        "obj_char_span": [94, 97],
        "rel_type": "product or substrate",
        "sbj_tok_span": [31, 33],
        "obj_tok_span": [22, 23],
        "new_sbj_tok_span": [31, 33],
        "new_obj_tok_span": [22, 23]
      }
    ],
    "umls_entity_list": [],
    "new_text": "The key second messenger in the mediation of penile erection is cGMP. PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate."
  },
  {
    "PMID": 17768678,
    "id": 2,
    "text": "PLZ is also a substrate for MAO, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 3],
        "name": "PLZ",
        "tok_span": [0, 2],
        "new_tok_span": [0, 2]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [110, 113],
        "name": "PLZ",
        "tok_span": [24, 26],
        "new_tok_span": [24, 26]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [153, 157],
        "name": "GABA",
        "tok_span": [33, 34],
        "new_tok_span": [33, 34]
      },
      {
        "ent_type": "GENE",
        "char_span": [28, 31],
        "name": "MAO",
        "tok_span": [7, 9],
        "new_tok_span": [7, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "PLZ",
        "sbj_char_span": [0, 3],
        "object": "MAO",
        "obj_char_span": [28, 31],
        "rel_type": "product or substrate",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [7, 9],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [7, 9]
      }
    ],
    "umls_entity_list": [],
    "new_text": "PLZ is also a substrate for MAO, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed."
  },
  {
    "PMID": 11474486,
    "id": 2,
    "text": "Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and thiazolidinediones are ligands of PPAR-gamma.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 8],
        "name": "Fibrates",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [82, 100],
        "name": "thiazolidinediones",
        "tok_span": [20, 25],
        "new_tok_span": [20, 25]
      },
      {
        "ent_type": "GENE",
        "char_span": [21, 76],
        "name": "peroxisome proliferator-activated receptor (PPAR)-alpha",
        "tok_span": [6, 18],
        "new_tok_span": [6, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [116, 126],
        "name": "PPAR-gamma",
        "tok_span": [28, 31],
        "new_tok_span": [28, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "Fibrates",
        "sbj_char_span": [0, 8],
        "object": "peroxisome proliferator-activated receptor (PPAR)-alpha",
        "obj_char_span": [21, 76],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [6, 18],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [6, 18]
      },
      {
        "subject": "thiazolidinediones",
        "sbj_char_span": [82, 100],
        "object": "PPAR-gamma",
        "obj_char_span": [116, 126],
        "rel_type": "regulator",
        "sbj_tok_span": [20, 25],
        "obj_tok_span": [28, 31],
        "new_sbj_tok_span": [20, 25],
        "new_obj_tok_span": [28, 31]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Fibrates bind to the peroxisome proliferator - activated receptor ( PPAR ) - alpha, and thiazolidinediones are ligands of PPAR - gamma."
  },
  {
    "PMID": 11730729,
    "id": 0,
    "text": "Effect of fenoterol-induced constitutive beta(2)-adrenoceptor activity on contractile receptor function in airway smooth muscle.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [10, 19],
        "name": "fenoterol",
        "tok_span": [2, 5],
        "new_tok_span": [3, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [41, 61],
        "name": "beta(2)-adrenoceptor",
        "tok_span": [8, 16],
        "new_tok_span": [10, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "fenoterol",
        "sbj_char_span": [10, 19],
        "object": "beta(2)-adrenoceptor",
        "obj_char_span": [41, 61],
        "rel_type": "activator",
        "sbj_tok_span": [2, 5],
        "obj_tok_span": [8, 16],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [10, 18]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "fenoterol",
        "char_span": [10, 19],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [2, 5],
        "new_tok_span": [3, 6]
      }
    ],
    "new_text": "Effect of <START=Pharmacologic Substance> fenoterol <END=Pharmacologic Substance> - induced constitutive beta ( 2 ) - adrenoceptor activity on contractile receptor function in airway smooth muscle."
  },
  {
    "PMID": 23439561,
    "id": 3,
    "text": "We have shown that COX-2 mediates acid-induced PGE2 production.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [47, 51],
        "name": "PGE2",
        "tok_span": [11, 13],
        "new_tok_span": [13, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [19, 24],
        "name": "COX-2",
        "tok_span": [4, 7],
        "new_tok_span": [4, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "PGE2",
        "sbj_char_span": [47, 51],
        "object": "COX-2",
        "obj_char_span": [19, 24],
        "rel_type": "product or substrate",
        "sbj_tok_span": [11, 13],
        "obj_tok_span": [4, 7],
        "new_sbj_tok_span": [13, 15],
        "new_obj_tok_span": [4, 7]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PGE2",
        "char_span": [47, 51],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [11, 13],
        "new_tok_span": [13, 15]
      },
      {
        "mention": "PGE2",
        "char_span": [47, 51],
        "sem_type": "Organic Chemical",
        "tok_span": [11, 13],
        "new_tok_span": [13, 15]
      }
    ],
    "new_text": "We have shown that COX - 2 mediates acid - induced <START=Pharmacologic Substance> <START=Organic Chemical> PGE2 <END=Pharmacologic Substance> <END=Organic Chemical> production."
  },
  {
    "PMID": 16344985,
    "id": 3,
    "text": "MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that valproic acid is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [65, 90],
        "name": "long-chain fatty acyl-CoA",
        "tok_span": [13, 21],
        "new_tok_span": [15, 23]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [133, 146],
        "name": "valproic acid",
        "tok_span": [34, 38],
        "new_tok_span": [36, 40]
      },
      {
        "ent_type": "GENE",
        "char_span": [44, 102],
        "name": "rat brain microsomal long-chain fatty acyl-CoA synthetases",
        "tok_span": [9, 24],
        "new_tok_span": [11, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [104, 108],
        "name": "Acsl",
        "tok_span": [25, 27],
        "new_tok_span": [27, 29]
      },
      {
        "ent_type": "GENE",
        "char_span": [181, 185],
        "name": "Acsl",
        "tok_span": [45, 47],
        "new_tok_span": [47, 49]
      }
    ],
    "relation_list": [
      {
        "subject": "valproic acid",
        "sbj_char_span": [133, 146],
        "object": "Acsl",
        "obj_char_span": [181, 185],
        "rel_type": "inhibitor",
        "sbj_tok_span": [34, 38],
        "obj_tok_span": [45, 47],
        "new_sbj_tok_span": [36, 40],
        "new_obj_tok_span": [47, 49]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "isolating",
        "char_span": [34, 43],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [7, 9],
        "new_tok_span": [8, 10]
      }
    ],
    "new_text": "MATERIALS AND METHODS / RESULTS : By <START=Pharmacologic Substance> isolating <END=Pharmacologic Substance> rat brain microsomal long - chain fatty acyl - CoA synthetases ( Acsl ), we show in vitro that valproic acid is a non - competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme."
  },
  {
    "PMID": 1435788,
    "id": 3,
    "text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic amino acid residues, an event necessary for the maturation of a variety of important biologically active proteins, such as insulin and nerve growth factor.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [93, 103],
        "name": "amino acid",
        "tok_span": [17, 19],
        "new_tok_span": [17, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [216, 223],
        "name": "insulin",
        "tok_span": [38, 39],
        "new_tok_span": [38, 39]
      },
      {
        "ent_type": "GENE",
        "char_span": [228, 247],
        "name": "nerve growth factor",
        "tok_span": [40, 43],
        "new_tok_span": [41, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "amino acid",
        "sbj_char_span": [93, 103],
        "object": "insulin",
        "obj_char_span": [216, 223],
        "rel_type": "part of",
        "sbj_tok_span": [17, 19],
        "obj_tok_span": [38, 39],
        "new_sbj_tok_span": [17, 19],
        "new_obj_tok_span": [38, 39]
      },
      {
        "subject": "amino acid",
        "sbj_char_span": [93, 103],
        "object": "nerve growth factor",
        "obj_char_span": [228, 247],
        "rel_type": "part of",
        "sbj_tok_span": [17, 19],
        "obj_tok_span": [40, 43],
        "new_sbj_tok_span": [17, 19],
        "new_obj_tok_span": [41, 44]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "nerve growth factor",
        "char_span": [228, 247],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [40, 43],
        "new_tok_span": [41, 44]
      }
    ],
    "new_text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic amino acid residues, an event necessary for the maturation of a variety of important biologically active proteins, such as insulin and <START=Amino Acid, Peptide, or Protein> nerve growth factor <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 20104269,
    "id": 5,
    "text": "CDCA induced dose-dependent expression of Cdx2 and MUC2 at both the mRNA and protein levels.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 4],
        "name": "CDCA",
        "tok_span": [0, 2],
        "new_tok_span": [0, 2]
      },
      {
        "ent_type": "GENE",
        "char_span": [42, 46],
        "name": "Cdx2",
        "tok_span": [8, 11],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [51, 55],
        "name": "MUC2",
        "tok_span": [12, 15],
        "new_tok_span": [14, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "CDCA",
        "sbj_char_span": [0, 4],
        "object": "Cdx2",
        "obj_char_span": [42, 46],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [8, 11],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [8, 11]
      },
      {
        "subject": "CDCA",
        "sbj_char_span": [0, 4],
        "object": "MUC2",
        "obj_char_span": [51, 55],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [12, 15],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [14, 17]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "MUC2",
        "char_span": [51, 55],
        "sem_type": "Gene or Genome",
        "tok_span": [12, 15],
        "new_tok_span": [14, 17]
      },
      {
        "mention": "MUC2",
        "char_span": [51, 55],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [12, 15],
        "new_tok_span": [14, 17]
      }
    ],
    "new_text": "CDCA induced dose - dependent expression of Cdx2 and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MUC2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> at both the mRNA and protein levels."
  },
  {
    "PMID": 23600914,
    "id": 3,
    "text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR. When the expression of ABCA1 and ABCG1 was induced, 24-OHC efflux was stimulated in the presence of high density lipoprotein (HDL), whereas apolipoprotein A-I was not an efficient acceptor.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [49, 55],
        "name": "24-OHC",
        "tok_span": [13, 17],
        "new_tok_span": [17, 21]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [68, 76],
        "name": "TO901317",
        "tok_span": [21, 25],
        "new_tok_span": [26, 30]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [81, 94],
        "name": "retinoic acid",
        "tok_span": [26, 29],
        "new_tok_span": [32, 35]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [200, 206],
        "name": "24-OHC",
        "tok_span": [57, 61],
        "new_tok_span": [73, 77]
      },
      {
        "ent_type": "GENE",
        "char_span": [18, 23],
        "name": "ABCA1",
        "tok_span": [3, 6],
        "new_tok_span": [3, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [28, 33],
        "name": "ABCG1",
        "tok_span": [7, 10],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [121, 138],
        "name": "nuclear receptors",
        "tok_span": [35, 37],
        "new_tok_span": [41, 43]
      },
      {
        "ent_type": "GENE",
        "char_span": [139, 142],
        "name": "LXR",
        "tok_span": [37, 39],
        "new_tok_span": [46, 48]
      },
      {
        "ent_type": "GENE",
        "char_span": [143, 146],
        "name": "RXR",
        "tok_span": [40, 42],
        "new_tok_span": [51, 53]
      },
      {
        "ent_type": "GENE",
        "char_span": [171, 176],
        "name": "ABCA1",
        "tok_span": [47, 50],
        "new_tok_span": [59, 62]
      },
      {
        "ent_type": "GENE",
        "char_span": [181, 186],
        "name": "ABCG1",
        "tok_span": [51, 54],
        "new_tok_span": [65, 68]
      },
      {
        "ent_type": "GENE",
        "char_span": [248, 272],
        "name": "high density lipoprotein",
        "tok_span": [68, 71],
        "new_tok_span": [85, 88]
      },
      {
        "ent_type": "GENE",
        "char_span": [274, 277],
        "name": "HDL",
        "tok_span": [72, 73],
        "new_tok_span": [90, 91]
      },
      {
        "ent_type": "GENE",
        "char_span": [288, 306],
        "name": "apolipoprotein A-I",
        "tok_span": [76, 82],
        "new_tok_span": [96, 102]
      }
    ],
    "relation_list": [
      {
        "subject": "24-OHC",
        "sbj_char_span": [49, 55],
        "object": "ABCA1",
        "obj_char_span": [18, 23],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [3, 6],
        "new_sbj_tok_span": [17, 21],
        "new_obj_tok_span": [3, 6]
      },
      {
        "subject": "24-OHC",
        "sbj_char_span": [49, 55],
        "object": "ABCG1",
        "obj_char_span": [28, 33],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [7, 10],
        "new_sbj_tok_span": [17, 21],
        "new_obj_tok_span": [9, 12]
      },
      {
        "subject": "TO901317",
        "sbj_char_span": [68, 76],
        "object": "ABCA1",
        "obj_char_span": [18, 23],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [3, 6],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [3, 6]
      },
      {
        "subject": "TO901317",
        "sbj_char_span": [68, 76],
        "object": "ABCG1",
        "obj_char_span": [28, 33],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [7, 10],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [9, 12]
      },
      {
        "subject": "retinoic acid",
        "sbj_char_span": [81, 94],
        "object": "ABCA1",
        "obj_char_span": [18, 23],
        "rel_type": "regulator",
        "sbj_tok_span": [26, 29],
        "obj_tok_span": [3, 6],
        "new_sbj_tok_span": [32, 35],
        "new_obj_tok_span": [3, 6]
      },
      {
        "subject": "retinoic acid",
        "sbj_char_span": [81, 94],
        "object": "ABCG1",
        "obj_char_span": [28, 33],
        "rel_type": "regulator",
        "sbj_tok_span": [26, 29],
        "obj_tok_span": [7, 10],
        "new_sbj_tok_span": [32, 35],
        "new_obj_tok_span": [9, 12]
      },
      {
        "subject": "TO901317",
        "sbj_char_span": [68, 76],
        "object": "nuclear receptors",
        "obj_char_span": [121, 138],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [35, 37],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [41, 43]
      },
      {
        "subject": "TO901317",
        "sbj_char_span": [68, 76],
        "object": "LXR",
        "obj_char_span": [139, 142],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [37, 39],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [46, 48]
      },
      {
        "subject": "TO901317",
        "sbj_char_span": [68, 76],
        "object": "RXR",
        "obj_char_span": [143, 146],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [40, 42],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [51, 53]
      },
      {
        "subject": "retinoic acid",
        "sbj_char_span": [81, 94],
        "object": "nuclear receptors",
        "obj_char_span": [121, 138],
        "rel_type": "regulator",
        "sbj_tok_span": [26, 29],
        "obj_tok_span": [35, 37],
        "new_sbj_tok_span": [32, 35],
        "new_obj_tok_span": [41, 43]
      },
      {
        "subject": "retinoic acid",
        "sbj_char_span": [81, 94],
        "object": "LXR",
        "obj_char_span": [139, 142],
        "rel_type": "regulator",
        "sbj_tok_span": [26, 29],
        "obj_tok_span": [37, 39],
        "new_sbj_tok_span": [32, 35],
        "new_obj_tok_span": [46, 48]
      },
      {
        "subject": "retinoic acid",
        "sbj_char_span": [81, 94],
        "object": "RXR",
        "obj_char_span": [143, 146],
        "rel_type": "regulator",
        "sbj_tok_span": [26, 29],
        "obj_tok_span": [40, 42],
        "new_sbj_tok_span": [32, 35],
        "new_obj_tok_span": [51, 53]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "ABCG1",
        "char_span": [28, 33],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [7, 10],
        "new_tok_span": [9, 12]
      },
      {
        "mention": "ABCG1",
        "char_span": [181, 186],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [51, 54],
        "new_tok_span": [65, 68]
      },
      {
        "mention": "ABCG1",
        "char_span": [28, 33],
        "sem_type": "Gene or Genome",
        "tok_span": [7, 10],
        "new_tok_span": [9, 12]
      },
      {
        "mention": "ABCG1",
        "char_span": [181, 186],
        "sem_type": "Gene or Genome",
        "tok_span": [51, 54],
        "new_tok_span": [65, 68]
      },
      {
        "mention": "TO901317",
        "char_span": [68, 76],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [21, 25],
        "new_tok_span": [26, 30]
      },
      {
        "mention": "eceptors",
        "char_span": [130, 138],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [36, 37],
        "new_tok_span": [43, 44]
      },
      {
        "mention": "LXR",
        "char_span": [139, 142],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 39],
        "new_tok_span": [46, 48]
      },
      {
        "mention": "RXR",
        "char_span": [143, 146],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [40, 42],
        "new_tok_span": [51, 53]
      },
      {
        "mention": "high density lipoprotein",
        "char_span": [248, 272],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [68, 71],
        "new_tok_span": [85, 88]
      },
      {
        "mention": "apolipoprotein",
        "char_span": [288, 302],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [76, 79],
        "new_tok_span": [96, 99]
      },
      {
        "mention": "apolipoprotein A-I",
        "char_span": [288, 306],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [76, 82],
        "new_tok_span": [96, 102]
      }
    ],
    "new_text": "The expression of ABCA1 and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ABCG1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> was induced by 24 - OHC, as well as <START=Pharmacologic Substance> TO901317 <END=Pharmacologic Substance> and retinoic acid, which are ligands of the nuclear <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> LXR <END=Amino Acid, Peptide, or Protein> / <START=Amino Acid, Peptide, or Protein> RXR <END=Amino Acid, Peptide, or Protein>. When the expression of ABCA1 and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ABCG1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> was induced, 24 - OHC efflux was stimulated in the presence of <START=Amino Acid, Peptide, or Protein> high density lipoprotein <END=Amino Acid, Peptide, or Protein> ( HDL ), whereas <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> apolipoprotein <END=Amino Acid, Peptide, or Protein> A - I <END=Amino Acid, Peptide, or Protein> was not an efficient acceptor."
  },
  {
    "PMID": 1686208,
    "id": 0,
    "text": "Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. 1.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [107, 119],
        "name": "dimethindene",
        "tok_span": [25, 29],
        "new_tok_span": [26, 30]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [13, 22],
        "name": "histamine",
        "tok_span": [3, 4],
        "new_tok_span": [3, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [86, 102],
        "name": "chlorpheniramine",
        "tok_span": [19, 24],
        "new_tok_span": [19, 24]
      },
      {
        "ent_type": "GENE",
        "char_span": [13, 34],
        "name": "histamine H1-receptor",
        "tok_span": [3, 8],
        "new_tok_span": [3, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "chlorpheniramine",
        "sbj_char_span": [86, 102],
        "object": "histamine H1-receptor",
        "obj_char_span": [13, 34],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [19, 24],
        "obj_tok_span": [3, 8],
        "new_sbj_tok_span": [19, 24],
        "new_obj_tok_span": [3, 8]
      },
      {
        "subject": "dimethindene",
        "sbj_char_span": [107, 119],
        "object": "histamine H1-receptor",
        "obj_char_span": [13, 34],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [25, 29],
        "obj_tok_span": [3, 8],
        "new_sbj_tok_span": [26, 30],
        "new_obj_tok_span": [3, 8]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "dimethindene",
        "char_span": [107, 119],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [25, 29],
        "new_tok_span": [26, 30]
      }
    ],
    "new_text": "Sedation and histamine H1 - receptor antagonism : studies in man with the enantiomers of chlorpheniramine and <START=Pharmacologic Substance> dimethindene <END=Pharmacologic Substance>. 1."
  },
  {
    "PMID": 16516814,
    "id": 4,
    "text": "Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [372, 376],
        "name": "PGE1",
        "tok_span": [79, 81],
        "new_tok_span": [94, 96]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [401, 403],
        "name": "Na",
        "tok_span": [84, 85],
        "new_tok_span": [100, 101]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [404, 405],
        "name": "K",
        "tok_span": [86, 87],
        "new_tok_span": [102, 103]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [480, 501],
        "name": "17-phenyl trinor PGE2",
        "tok_span": [99, 107],
        "new_tok_span": [121, 129]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [540, 548],
        "name": "SC-51089",
        "tok_span": [115, 119],
        "new_tok_span": [138, 142]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [73, 77],
        "name": "PGE1",
        "tok_span": [15, 17],
        "new_tok_span": [18, 20]
      },
      {
        "ent_type": "GENE",
        "char_span": [351, 364],
        "name": "EP1 receptors",
        "tok_span": [74, 77],
        "new_tok_span": [87, 90]
      },
      {
        "ent_type": "GENE",
        "char_span": [401, 417],
        "name": "Na,K-ATPase beta",
        "tok_span": [84, 90],
        "new_tok_span": [100, 106]
      },
      {
        "ent_type": "GENE",
        "char_span": [35, 37],
        "name": "Gs",
        "tok_span": [5, 7],
        "new_tok_span": [5, 7]
      },
      {
        "ent_type": "GENE",
        "char_span": [46, 59],
        "name": "EP2 receptors",
        "tok_span": [8, 11],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [110, 114],
        "name": "PKAI",
        "tok_span": [22, 24],
        "new_tok_span": [26, 28]
      },
      {
        "ent_type": "GENE",
        "char_span": [147, 188],
        "name": "protein kinase A (PKA) inhibitory protein",
        "tok_span": [29, 37],
        "new_tok_span": [34, 42]
      },
      {
        "ent_type": "GENE",
        "char_span": [209, 244],
        "name": "myristolated PKA inhibitory peptide",
        "tok_span": [44, 51],
        "new_tok_span": [52, 59]
      },
      {
        "ent_type": "GENE",
        "char_span": [303, 316],
        "name": "EP2 receptors",
        "tok_span": [64, 67],
        "new_tok_span": [75, 78]
      }
    ],
    "relation_list": [
      {
        "subject": "PGE1",
        "sbj_char_span": [372, 376],
        "object": "Na,K-ATPase beta",
        "obj_char_span": [401, 417],
        "rel_type": "regulator",
        "sbj_tok_span": [79, 81],
        "obj_tok_span": [84, 90],
        "new_sbj_tok_span": [94, 96],
        "new_obj_tok_span": [100, 106]
      },
      {
        "subject": "17-phenyl trinor PGE2",
        "sbj_char_span": [480, 501],
        "object": "Na,K-ATPase beta",
        "obj_char_span": [401, 417],
        "rel_type": "regulator",
        "sbj_tok_span": [99, 107],
        "obj_tok_span": [84, 90],
        "new_sbj_tok_span": [121, 129],
        "new_obj_tok_span": [100, 106]
      },
      {
        "subject": "SC-51089",
        "sbj_char_span": [540, 548],
        "object": "Na,K-ATPase beta",
        "obj_char_span": [401, 417],
        "rel_type": "regulator",
        "sbj_tok_span": [115, 119],
        "obj_tok_span": [84, 90],
        "new_sbj_tok_span": [138, 142],
        "new_obj_tok_span": [100, 106]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PGE1",
        "char_span": [73, 77],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [15, 17],
        "new_tok_span": [18, 20]
      },
      {
        "mention": "PGE1",
        "char_span": [372, 376],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [79, 81],
        "new_tok_span": [94, 96]
      },
      {
        "mention": "PKA inhibitor",
        "char_span": [222, 235],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [48, 50],
        "new_tok_span": [57, 59]
      },
      {
        "mention": "protein",
        "char_span": [147, 154],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [29, 30],
        "new_tok_span": [34, 35]
      },
      {
        "mention": "protein",
        "char_span": [181, 188],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [36, 37],
        "new_tok_span": [43, 44]
      },
      {
        "mention": "EP2",
        "char_span": [46, 49],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 10],
        "new_tok_span": [9, 11]
      },
      {
        "mention": "EP2",
        "char_span": [303, 306],
        "sem_type": "Gene or Genome",
        "tok_span": [64, 66],
        "new_tok_span": [75, 77]
      },
      {
        "mention": "EP1",
        "char_span": [351, 354],
        "sem_type": "Gene or Genome",
        "tok_span": [74, 76],
        "new_tok_span": [87, 89]
      },
      {
        "mention": "ATPase",
        "char_span": [406, 412],
        "sem_type": "Gene or Genome",
        "tok_span": [88, 89],
        "new_tok_span": [106, 107]
      },
      {
        "mention": "ATPase",
        "char_span": [406, 412],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [88, 89],
        "new_tok_span": [106, 107]
      },
      {
        "mention": "sc",
        "char_span": [435, 437],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [92, 93],
        "new_tok_span": [113, 114]
      },
      {
        "mention": "SC",
        "char_span": [540, 542],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [115, 116],
        "new_tok_span": [138, 139]
      }
    ],
    "new_text": "Consistent with the involvement of Gs coupled <START=Gene or Genome> EP2 <END=Gene or Genome> receptors, is that the <START=Pharmacologic Substance> PGE1 <END=Pharmacologic Substance> stimulation is inhibited by the PKAI expression vector ( encoding the <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> kinase A ( PKA ) inhibitory <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> ), as well as by the myristolated <START=Amino Acid, Peptide, or Protein> PKA inhibitory <END=Amino Acid, Peptide, or Protein> peptide PKI. In addition to this evidence ( for the involvement of <START=Gene or Genome> EP2 <END=Gene or Genome> receptors ), evidence for the involvement of <START=Gene or Genome> EP1 <END=Gene or Genome> receptors in the <START=Pharmacologic Substance> PGE1 <END=Pharmacologic Substance> mediated stimulation of Na, K - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ATPase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> beta subunit gene <START=Pharmacologic Substance> transcription <END=Pharmacologic Substance> includes the stimulatory effect of 17 - phenyl trinor PGE2, as well as the inhibitory effects of <START=Pharmacologic Substance> SC <END=Pharmacologic Substance> - 51089."
  },
  {
    "PMID": 12070353,
    "id": 7,
    "text": "Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [33, 45],
        "name": "theophylline",
        "tok_span": [8, 11],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [148, 163],
        "name": "corticosteroids",
        "tok_span": [27, 28],
        "new_tok_span": [31, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [108, 112],
        "name": "HDAC",
        "tok_span": [21, 22],
        "new_tok_span": [23, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "theophylline",
        "sbj_char_span": [33, 45],
        "object": "HDAC",
        "obj_char_span": [108, 112],
        "rel_type": "activator",
        "sbj_tok_span": [8, 11],
        "obj_tok_span": [21, 22],
        "new_sbj_tok_span": [8, 11],
        "new_obj_tok_span": [23, 24]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "HDAC",
        "char_span": [108, 112],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [21, 22],
        "new_tok_span": [23, 24]
      },
      {
        "mention": "HDAC",
        "char_span": [108, 112],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 22],
        "new_tok_span": [23, 24]
      }
    ],
    "new_text": "Thus we have shown that low - dose theophylline exerts an anti - asthma effect through increasing activation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> HDAC <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> which is subsequently recruited by corticosteroids to suppress inflammatory genes."
  },
  {
    "PMID": 15985706,
    "id": 4,
    "text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 124],
        "name": "cAMP",
        "tok_span": [24, 25],
        "new_tok_span": [32, 33]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [136, 145],
        "name": "adenylate",
        "tok_span": [28, 30],
        "new_tok_span": [36, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [165, 174],
        "name": "forskolin",
        "tok_span": [33, 36],
        "new_tok_span": [41, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [39, 44],
        "name": "mucin",
        "tok_span": [9, 11],
        "new_tok_span": [10, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [136, 153],
        "name": "adenylate cyclase",
        "tok_span": [28, 31],
        "new_tok_span": [36, 39]
      }
    ],
    "relation_list": [
      {
        "subject": "forskolin",
        "sbj_char_span": [165, 174],
        "object": "adenylate cyclase",
        "obj_char_span": [136, 153],
        "rel_type": "activator",
        "sbj_tok_span": [33, 36],
        "obj_tok_span": [28, 31],
        "new_sbj_tok_span": [41, 44],
        "new_obj_tok_span": [36, 39]
      },
      {
        "subject": "cAMP",
        "sbj_char_span": [120, 124],
        "object": "adenylate cyclase",
        "obj_char_span": [136, 153],
        "rel_type": "product or substrate",
        "sbj_tok_span": [24, 25],
        "obj_tok_span": [28, 31],
        "new_sbj_tok_span": [32, 33],
        "new_obj_tok_span": [36, 39]
      },
      {
        "subject": "forskolin",
        "sbj_char_span": [165, 174],
        "object": "mucin",
        "obj_char_span": [39, 44],
        "rel_type": "regulator",
        "sbj_tok_span": [33, 36],
        "obj_tok_span": [9, 11],
        "new_sbj_tok_span": [41, 44],
        "new_obj_tok_span": [10, 12]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "mucin",
        "char_span": [39, 44],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [9, 11],
        "new_tok_span": [10, 12]
      },
      {
        "mention": "beta-adrenergic agonist",
        "char_span": [68, 91],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [14, 19],
        "new_tok_span": [18, 23]
      },
      {
        "mention": "messenger",
        "char_span": [109, 118],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [22, 23],
        "new_tok_span": [29, 30]
      },
      {
        "mention": "beta-adrenergic agonist",
        "char_span": [68, 91],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [14, 19],
        "new_tok_span": [18, 23]
      }
    ],
    "new_text": "Both inhibitors, moreover, blunted the <START=Amino Acid, Peptide, or Protein> mucin <END=Amino Acid, Peptide, or Protein> secretory responses to <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> beta - adrenergic agonist <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> - generated second <START=Amino Acid, Peptide, or Protein> messenger <END=Amino Acid, Peptide, or Protein>, cAMP as well as adenylate cyclase activator, forskolin."
  },
  {
    "PMID": 9310349,
    "id": 11,
    "text": "PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [18, 33],
        "name": "hisphosphonates",
        "tok_span": [3, 7],
        "new_tok_span": [7, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [37, 45],
        "name": "vanadate",
        "tok_span": [8, 11],
        "new_tok_span": [12, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [90, 94],
        "name": "EDTA",
        "tok_span": [19, 20],
        "new_tok_span": [26, 27]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [121, 135],
        "name": "dithiothreitol",
        "tok_span": [26, 31],
        "new_tok_span": [35, 40]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [188, 196],
        "name": "cysteine",
        "tok_span": [42, 43],
        "new_tok_span": [52, 53]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 3],
        "name": "PTP",
        "tok_span": [0, 1],
        "new_tok_span": [2, 3]
      }
    ],
    "relation_list": [
      {
        "subject": "hisphosphonates",
        "sbj_char_span": [18, 33],
        "object": "PTP",
        "obj_char_span": [0, 3],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [0, 1],
        "new_sbj_tok_span": [7, 11],
        "new_obj_tok_span": [2, 3]
      },
      {
        "subject": "vanadate",
        "sbj_char_span": [37, 45],
        "object": "PTP",
        "obj_char_span": [0, 3],
        "rel_type": "inhibitor",
        "sbj_tok_span": [8, 11],
        "obj_tok_span": [0, 1],
        "new_sbj_tok_span": [12, 15],
        "new_obj_tok_span": [2, 3]
      },
      {
        "subject": "cysteine",
        "sbj_char_span": [188, 196],
        "object": "PTP",
        "obj_char_span": [0, 3],
        "rel_type": "part of",
        "sbj_tok_span": [42, 43],
        "obj_tok_span": [0, 1],
        "new_sbj_tok_span": [52, 53],
        "new_obj_tok_span": [2, 3]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PTP",
        "char_span": [0, 3],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 1],
        "new_tok_span": [2, 3]
      },
      {
        "mention": "PTP",
        "char_span": [0, 3],
        "sem_type": "Gene or Genome",
        "tok_span": [0, 1],
        "new_tok_span": [2, 3]
      },
      {
        "mention": "metal chelating agent",
        "char_span": [68, 89],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [15, 19],
        "new_tok_span": [20, 24]
      },
      {
        "mention": "EDTA",
        "char_span": [90, 94],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [19, 20],
        "new_tok_span": [26, 27]
      },
      {
        "mention": "dithiothreitol",
        "char_span": [121, 135],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [26, 31],
        "new_tok_span": [35, 40]
      }
    ],
    "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PTP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> inhibition by hisphosphonates or vanadate was diminished by the <START=Pharmacologic Substance> metal chelating agent <END=Pharmacologic Substance> <START=Pharmacologic Substance> EDTA <END=Pharmacologic Substance>, or by the reducing agent <START=Pharmacologic Substance> dithiothreitol <END=Pharmacologic Substance>, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition."
  },
  {
    "PMID": 15452358,
    "id": 6,
    "text": "A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that [3H]CP-101,606 bound to the brain NR2B receptor with a greater extent compared to the spinal cord one.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [101, 115],
        "name": "[3H]CP-101,606",
        "tok_span": [15, 25],
        "new_tok_span": [15, 25]
      },
      {
        "ent_type": "GENE",
        "char_span": [135, 139],
        "name": "NR2B",
        "tok_span": [29, 32],
        "new_tok_span": [33, 36]
      }
    ],
    "relation_list": [
      {
        "subject": "[3H]CP-101,606",
        "sbj_char_span": [101, 115],
        "object": "NR2B",
        "obj_char_span": [135, 139],
        "rel_type": "regulator",
        "sbj_tok_span": [15, 25],
        "obj_tok_span": [29, 32],
        "new_sbj_tok_span": [15, 25],
        "new_obj_tok_span": [33, 36]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "CP",
        "char_span": [105, 107],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [19, 20],
        "new_tok_span": [20, 21]
      },
      {
        "mention": "NR2B",
        "char_span": [135, 139],
        "sem_type": "Gene or Genome",
        "tok_span": [29, 32],
        "new_tok_span": [33, 36]
      },
      {
        "mention": "NR2B",
        "char_span": [135, 139],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [29, 32],
        "new_tok_span": [33, 36]
      }
    ],
    "new_text": "A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that [ 3H ] <START=Pharmacologic Substance> CP <END=Pharmacologic Substance> - 101, 606 bound to the brain <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> receptor with a greater extent compared to the spinal cord one."
  },
  {
    "PMID": 16213084,
    "id": 5,
    "text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and/or MCT2. These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [8, 17],
        "name": "l-lactate",
        "tok_span": [1, 4],
        "new_tok_span": [2, 5]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [40, 50],
        "name": "nicotinate",
        "tok_span": [10, 12],
        "new_tok_span": [13, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [92, 102],
        "name": "nicotinate",
        "tok_span": [22, 24],
        "new_tok_span": [27, 29]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [209, 213],
        "name": "H(+)",
        "tok_span": [48, 52],
        "new_tok_span": [58, 62]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [284, 299],
        "name": "monocarboxylate",
        "tok_span": [67, 70],
        "new_tok_span": [78, 81]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [334, 338],
        "name": "H(+)",
        "tok_span": [77, 81],
        "new_tok_span": [95, 99]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [347, 362],
        "name": "monocarboxylate",
        "tok_span": [83, 86],
        "new_tok_span": [102, 105]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [385, 395],
        "name": "nicotinate",
        "tok_span": [90, 92],
        "new_tok_span": [111, 113]
      },
      {
        "ent_type": "GENE",
        "char_span": [143, 147],
        "name": "MCT1",
        "tok_span": [31, 34],
        "new_tok_span": [39, 42]
      },
      {
        "ent_type": "GENE",
        "char_span": [155, 159],
        "name": "MCT2",
        "tok_span": [37, 40],
        "new_tok_span": [47, 50]
      },
      {
        "ent_type": "GENE",
        "char_span": [271, 311],
        "name": "low-affinity monocarboxylate transporter",
        "tok_span": [64, 71],
        "new_tok_span": [74, 81]
      },
      {
        "ent_type": "GENE",
        "char_span": [312, 316],
        "name": "MCT4",
        "tok_span": [71, 74],
        "new_tok_span": [86, 89]
      },
      {
        "ent_type": "GENE",
        "char_span": [334, 379],
        "name": "H(+)-coupled monocarboxylate transport system",
        "tok_span": [77, 88],
        "new_tok_span": [95, 106]
      }
    ],
    "relation_list": [
      {
        "subject": "nicotinate",
        "sbj_char_span": [92, 102],
        "object": "MCT1",
        "obj_char_span": [143, 147],
        "rel_type": "product or substrate",
        "sbj_tok_span": [22, 24],
        "obj_tok_span": [31, 34],
        "new_sbj_tok_span": [27, 29],
        "new_obj_tok_span": [39, 42]
      },
      {
        "subject": "nicotinate",
        "sbj_char_span": [92, 102],
        "object": "MCT2",
        "obj_char_span": [155, 159],
        "rel_type": "product or substrate",
        "sbj_tok_span": [22, 24],
        "obj_tok_span": [37, 40],
        "new_sbj_tok_span": [27, 29],
        "new_obj_tok_span": [47, 50]
      },
      {
        "subject": "nicotinate",
        "sbj_char_span": [385, 395],
        "object": "H(+)-coupled monocarboxylate transport system",
        "obj_char_span": [334, 379],
        "rel_type": "product or substrate",
        "sbj_tok_span": [90, 92],
        "obj_tok_span": [77, 88],
        "new_sbj_tok_span": [111, 113],
        "new_obj_tok_span": [95, 106]
      },
      {
        "subject": "nicotinate",
        "sbj_char_span": [385, 395],
        "object": "low-affinity monocarboxylate transporter",
        "obj_char_span": [271, 311],
        "rel_type": "product or substrate",
        "sbj_tok_span": [90, 92],
        "obj_tok_span": [64, 71],
        "new_sbj_tok_span": [111, 113],
        "new_obj_tok_span": [74, 81]
      },
      {
        "subject": "nicotinate",
        "sbj_char_span": [385, 395],
        "object": "MCT4",
        "obj_char_span": [312, 316],
        "rel_type": "product or substrate",
        "sbj_tok_span": [90, 92],
        "obj_tok_span": [71, 74],
        "new_sbj_tok_span": [111, 113],
        "new_obj_tok_span": [86, 89]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "l-lactate",
        "char_span": [8, 17],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [1, 4],
        "new_tok_span": [2, 5]
      },
      {
        "mention": "nicotinate",
        "char_span": [40, 50],
        "sem_type": "Organic Chemical",
        "tok_span": [10, 12],
        "new_tok_span": [13, 15]
      },
      {
        "mention": "nicotinate",
        "char_span": [92, 102],
        "sem_type": "Organic Chemical",
        "tok_span": [22, 24],
        "new_tok_span": [27, 29]
      },
      {
        "mention": "nicotinate",
        "char_span": [385, 395],
        "sem_type": "Organic Chemical",
        "tok_span": [90, 92],
        "new_tok_span": [111, 113]
      },
      {
        "mention": "MCT1",
        "char_span": [143, 147],
        "sem_type": "Gene or Genome",
        "tok_span": [31, 34],
        "new_tok_span": [39, 42]
      },
      {
        "mention": "MCT1",
        "char_span": [143, 147],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [31, 34],
        "new_tok_span": [39, 42]
      },
      {
        "mention": "monocarboxylate",
        "char_span": [284, 299],
        "sem_type": "Organic Chemical",
        "tok_span": [67, 70],
        "new_tok_span": [78, 81]
      },
      {
        "mention": "monocarboxylate",
        "char_span": [347, 362],
        "sem_type": "Organic Chemical",
        "tok_span": [83, 86],
        "new_tok_span": [102, 105]
      },
      {
        "mention": "transporter",
        "char_span": [300, 311],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [70, 71],
        "new_tok_span": [83, 84]
      },
      {
        "mention": "MCT4",
        "char_span": [312, 316],
        "sem_type": "Gene or Genome",
        "tok_span": [71, 74],
        "new_tok_span": [86, 89]
      },
      {
        "mention": "unknown",
        "char_span": [326, 333],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [76, 77],
        "new_tok_span": [93, 94]
      }
    ],
    "new_text": "Because <START=Pharmacologic Substance> l - lactate <END=Pharmacologic Substance> reduced to 67 % of the <START=Organic Chemical> nicotinate <END=Organic Chemical> uptake even at 10mM, it is unlikely that <START=Organic Chemical> nicotinate <END=Organic Chemical> uptake in rat astrocytes is mediated by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MCT1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and / or MCT2. These results provide biochemical evidence of a H ( + ) - coupled and saturable transport system, presumed to be a low - affinity <START=Organic Chemical> monocarboxylate <END=Organic Chemical> <START=Amino Acid, Peptide, or Protein> transporter <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MCT4 <END=Gene or Genome> or other <START=Amino Acid, Peptide, or Protein> unknown <END=Amino Acid, Peptide, or Protein> H ( + ) - coupled <START=Organic Chemical> monocarboxylate <END=Organic Chemical> transport system, for <START=Organic Chemical> nicotinate <END=Organic Chemical> in rat cerebrocortical astrocytes."
  },
  {
    "PMID": 23432124,
    "id": 1,
    "text": "IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as AMPA receptor-selective antagonists.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 7],
        "name": "IKM-159",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [115, 119],
        "name": "AMPA",
        "tok_span": [25, 27],
        "new_tok_span": [29, 31]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [83, 92],
        "name": "glutamate",
        "tok_span": [20, 21],
        "new_tok_span": [23, 24]
      },
      {
        "ent_type": "GENE",
        "char_span": [115, 128],
        "name": "AMPA receptor",
        "tok_span": [25, 28],
        "new_tok_span": [29, 32]
      }
    ],
    "relation_list": [
      {
        "subject": "IKM-159",
        "sbj_char_span": [0, 7],
        "object": "AMPA receptor",
        "obj_char_span": [115, 128],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [25, 28],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [29, 32]
      },
      {
        "subject": "glutamate",
        "sbj_char_span": [83, 92],
        "object": "AMPA receptor",
        "obj_char_span": [115, 128],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [20, 21],
        "obj_tok_span": [25, 28],
        "new_sbj_tok_span": [23, 24],
        "new_obj_tok_span": [29, 32]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "IKM",
        "char_span": [0, 3],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "mention": "glutamate",
        "char_span": [83, 92],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [20, 21],
        "new_tok_span": [23, 24]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> IKM <END=Pharmacologic Substance> - 159 was developed and identified as a member of a new class of heterotricyclic <START=Amino Acid, Peptide, or Protein> glutamate <END=Amino Acid, Peptide, or Protein> analogues that act as AMPA receptor - selective antagonists."
  },
  {
    "PMID": 23550066,
    "id": 4,
    "text": "We examined the N-demethylation of individual ketamine enantiomers using human liver microsomes (HLMs) genotyped for the CYP2B6*6 allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [46, 54],
        "name": "ketamine",
        "tok_span": [10, 11],
        "new_tok_span": [10, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [121, 129],
        "name": "CYP2B6*6",
        "tok_span": [26, 32],
        "new_tok_span": [26, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [172, 178],
        "name": "CYP2B6",
        "tok_span": [38, 42],
        "new_tok_span": [40, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [183, 189],
        "name": "CYP3A4",
        "tok_span": [43, 47],
        "new_tok_span": [45, 49]
      },
      {
        "ent_type": "GENE",
        "char_span": [235, 243],
        "name": "CYP2B6.1",
        "tok_span": [55, 61],
        "new_tok_span": [57, 63]
      },
      {
        "ent_type": "GENE",
        "char_span": [248, 256],
        "name": "CYP2B6.6",
        "tok_span": [62, 68],
        "new_tok_span": [64, 70]
      }
    ],
    "relation_list": [
      {
        "subject": "ketamine",
        "sbj_char_span": [46, 54],
        "object": "CYP2B6*6",
        "obj_char_span": [121, 129],
        "rel_type": "product or substrate",
        "sbj_tok_span": [10, 11],
        "obj_tok_span": [26, 32],
        "new_sbj_tok_span": [10, 11],
        "new_obj_tok_span": [26, 32]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "insect",
        "char_span": [138, 144],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [34, 35],
        "new_tok_span": [35, 36]
      },
      {
        "mention": "protein variant",
        "char_span": [257, 272],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [68, 70],
        "new_tok_span": [71, 73]
      }
    ],
    "new_text": "We examined the N - demethylation of individual ketamine enantiomers using human liver microsomes ( HLMs ) genotyped for the CYP2B6 * 6 allele, <START=Pharmacologic Substance> insect <END=Pharmacologic Substance> cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS - 1 cell expressed recombinant CYP2B6. 1 and CYP2B6. 6 <START=Amino Acid, Peptide, or Protein> protein variant <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 10225363,
    "id": 4,
    "text": "Sumatriptan and LY 344864 decreased the number of capsaicin-induced c-fos-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 11],
        "name": "Sumatriptan",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [16, 25],
        "name": "LY 344864",
        "tok_span": [5, 9],
        "new_tok_span": [5, 9]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [50, 59],
        "name": "capsaicin",
        "tok_span": [13, 16],
        "new_tok_span": [14, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [68, 73],
        "name": "c-fos",
        "tok_span": [18, 21],
        "new_tok_span": [20, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "capsaicin",
        "sbj_char_span": [50, 59],
        "object": "c-fos",
        "obj_char_span": [68, 73],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 16],
        "obj_tok_span": [18, 21],
        "new_sbj_tok_span": [14, 17],
        "new_obj_tok_span": [20, 23]
      },
      {
        "subject": "Sumatriptan",
        "sbj_char_span": [0, 11],
        "object": "c-fos",
        "obj_char_span": [68, 73],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [18, 21],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [20, 23]
      },
      {
        "subject": "LY 344864",
        "sbj_char_span": [16, 25],
        "object": "c-fos",
        "obj_char_span": [68, 73],
        "rel_type": "regulator",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [18, 21],
        "new_sbj_tok_span": [5, 9],
        "new_obj_tok_span": [20, 23]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "capsaicin",
        "char_span": [50, 59],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [13, 16],
        "new_tok_span": [14, 17]
      }
    ],
    "new_text": "Sumatriptan and LY 344864 decreased the number of <START=Pharmacologic Substance> capsaicin <END=Pharmacologic Substance> - induced c - fos - like immunoreactive cells within trigeminal nucleus caudalis ( ID50 = 0. 04 and 0. 6 mg kg ( - 1 ) )."
  },
  {
    "PMID": 23534442,
    "id": 7,
    "text": "Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of nitrooxyalkyl ester and ether side chain of these molecules within the COX-2 active site to be assessed.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [135, 164],
        "name": "nitrooxyalkyl ester and ether",
        "tok_span": [37, 44],
        "new_tok_span": [39, 46]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [32, 36],
        "name": "(1)H",
        "tok_span": [5, 9],
        "new_tok_span": [5, 9]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [42, 47],
        "name": "(13)C",
        "tok_span": [11, 15],
        "new_tok_span": [11, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [206, 211],
        "name": "COX-2",
        "tok_span": [51, 54],
        "new_tok_span": [57, 60]
      }
    ],
    "relation_list": [
      {
        "subject": "nitrooxyalkyl ester and ether",
        "sbj_char_span": [135, 164],
        "object": "COX-2",
        "obj_char_span": [206, 211],
        "rel_type": "regulator",
        "sbj_tok_span": [37, 44],
        "obj_tok_span": [51, 54],
        "new_sbj_tok_span": [39, 46],
        "new_obj_tok_span": [57, 60]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "NMR",
        "char_span": [48, 51],
        "sem_type": "Gene or Genome",
        "tok_span": [16, 17],
        "new_tok_span": [17, 18]
      },
      {
        "mention": "ester",
        "char_span": [149, 154],
        "sem_type": "Organic Chemical",
        "tok_span": [41, 42],
        "new_tok_span": [44, 45]
      },
      {
        "mention": "ether",
        "char_span": [159, 164],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [43, 44],
        "new_tok_span": [48, 49]
      }
    ],
    "new_text": "Finally, molecular modeling and ( 1 ) H - and ( 13 ) C - <START=Gene or Genome> NMR <END=Gene or Genome> studies performed on compounds 6c, d, 9c, and 10b allowed the right conformation of nitrooxyalkyl <START=Organic Chemical> ester <END=Organic Chemical> and <START=Pharmacologic Substance> ether <END=Pharmacologic Substance> side chain of these molecules within the COX - 2 active site to be assessed."
  },
  {
    "PMID": 23439561,
    "id": 11,
    "text": "We conclude that mPGES1 mediates acid-induced increase in PGE2 production and cell proliferation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [58, 62],
        "name": "PGE2",
        "tok_span": [13, 15],
        "new_tok_span": [17, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [17, 23],
        "name": "mPGES1",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "PGE2",
        "sbj_char_span": [58, 62],
        "object": "mPGES1",
        "obj_char_span": [17, 23],
        "rel_type": "product or substrate",
        "sbj_tok_span": [13, 15],
        "obj_tok_span": [3, 7],
        "new_sbj_tok_span": [17, 19],
        "new_obj_tok_span": [4, 8]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "mPGES1",
        "char_span": [17, 23],
        "sem_type": "Gene or Genome",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "mention": "PGE2",
        "char_span": [58, 62],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [13, 15],
        "new_tok_span": [17, 19]
      },
      {
        "mention": "PGE2",
        "char_span": [58, 62],
        "sem_type": "Organic Chemical",
        "tok_span": [13, 15],
        "new_tok_span": [17, 19]
      }
    ],
    "new_text": "We conclude that <START=Gene or Genome> mPGES1 <END=Gene or Genome> mediates acid - induced increase in <START=Pharmacologic Substance> <START=Organic Chemical> PGE2 <END=Pharmacologic Substance> <END=Organic Chemical> production and cell proliferation."
  },
  {
    "PMID": 23123662,
    "id": 4,
    "text": "Cultured rat DRG neurons endogenously expressed rCtr1 protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper, but were resistant to copper toxicity.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [171, 177],
        "name": "copper",
        "tok_span": [31, 32],
        "new_tok_span": [33, 34]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [201, 207],
        "name": "copper",
        "tok_span": [37, 38],
        "new_tok_span": [39, 40]
      },
      {
        "ent_type": "GENE",
        "char_span": [48, 53],
        "name": "rCtr1",
        "tok_span": [9, 13],
        "new_tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "copper",
        "sbj_char_span": [171, 177],
        "object": "rCtr1",
        "obj_char_span": [48, 53],
        "rel_type": "product or substrate",
        "sbj_tok_span": [31, 32],
        "obj_tok_span": [9, 13],
        "new_sbj_tok_span": [33, 34],
        "new_obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "DRG",
        "char_span": [13, 16],
        "sem_type": "Gene or Genome",
        "tok_span": [3, 5],
        "new_tok_span": [4, 6]
      }
    ],
    "new_text": "Cultured rat <START=Gene or Genome> DRG <END=Gene or Genome> neurons endogenously expressed rCtr1 protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up copper, but were resistant to copper toxicity."
  },
  {
    "PMID": 23322769,
    "id": 9,
    "text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [75, 86],
        "name": "manumycin A",
        "tok_span": [17, 21],
        "new_tok_span": [22, 26]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [189, 206],
        "name": "cholesterol ester",
        "tok_span": [42, 44],
        "new_tok_span": [53, 55]
      },
      {
        "ent_type": "GENE",
        "char_span": [14, 33],
        "name": "farnesyltransferase",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [35, 39],
        "name": "FNTA",
        "tok_span": [8, 10],
        "new_tok_span": [10, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [107, 113],
        "name": "ApoA-I",
        "tok_span": [24, 28],
        "new_tok_span": [31, 35]
      },
      {
        "ent_type": "GENE",
        "char_span": [177, 184],
        "name": "hApoA-I",
        "tok_span": [36, 41],
        "new_tok_span": [44, 49]
      }
    ],
    "relation_list": [
      {
        "subject": "manumycin A",
        "sbj_char_span": [75, 86],
        "object": "farnesyltransferase",
        "obj_char_span": [14, 33],
        "rel_type": "inhibitor",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [3, 7],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [4, 8]
      },
      {
        "subject": "manumycin A",
        "sbj_char_span": [75, 86],
        "object": "FNTA",
        "obj_char_span": [35, 39],
        "rel_type": "inhibitor",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [10, 12]
      },
      {
        "subject": "manumycin A",
        "sbj_char_span": [75, 86],
        "object": "ApoA-I",
        "obj_char_span": [107, 113],
        "rel_type": "regulator",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [24, 28],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [31, 35]
      },
      {
        "subject": "manumycin A",
        "sbj_char_span": [75, 86],
        "object": "hApoA-I",
        "obj_char_span": [177, 184],
        "rel_type": "regulator",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [36, 41],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [44, 49]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "farnesyltransferase",
        "char_span": [14, 33],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "mention": "enzyme inhibitor",
        "char_span": [58, 74],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [15, 17],
        "new_tok_span": [18, 20]
      },
      {
        "mention": "manumycin",
        "char_span": [75, 84],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [17, 20],
        "new_tok_span": [22, 25]
      },
      {
        "mention": "ApoA-I",
        "char_span": [107, 113],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [24, 28],
        "new_tok_span": [31, 35]
      },
      {
        "mention": "ApoA-I",
        "char_span": [178, 184],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 41],
        "new_tok_span": [46, 50]
      },
      {
        "mention": "cholesterol ester transfer protein",
        "char_span": [189, 223],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [42, 46],
        "new_tok_span": [53, 57]
      },
      {
        "mention": "transgenes",
        "char_span": [224, 234],
        "sem_type": "Gene or Genome",
        "tok_span": [46, 48],
        "new_tok_span": [59, 61]
      }
    ],
    "new_text": "Repression of <START=Amino Acid, Peptide, or Protein> farnesyltransferase <END=Amino Acid, Peptide, or Protein> ( FNTA ) by siRNA and the <START=Pharmacologic Substance> enzyme inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> manumycin <END=Pharmacologic Substance> A caused elevation of <START=Amino Acid, Peptide, or Protein> ApoA - I <END=Amino Acid, Peptide, or Protein> secretion from hepatocytes and from transgenic mice expressing h <START=Amino Acid, Peptide, or Protein>ApoA - I <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> cholesterol ester transfer protein <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> transgenes <END=Gene or Genome>."
  },
  {
    "PMID": 23127600,
    "id": 6,
    "text": "These findings demonstrate that cinnamon polyphenols can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, NF-κB activation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [41, 52],
        "name": "polyphenols",
        "tok_span": [7, 9],
        "new_tok_span": [9, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [303, 307],
        "name": "iNOS",
        "tok_span": [52, 53],
        "new_tok_span": [56, 57]
      },
      {
        "ent_type": "GENE",
        "char_span": [309, 314],
        "name": "NF-κB",
        "tok_span": [54, 58],
        "new_tok_span": [58, 62]
      }
    ],
    "relation_list": [
      {
        "subject": "polyphenols",
        "sbj_char_span": [41, 52],
        "object": "iNOS",
        "obj_char_span": [303, 307],
        "rel_type": "inhibitor",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [52, 53],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [56, 57]
      },
      {
        "subject": "polyphenols",
        "sbj_char_span": [41, 52],
        "object": "NF-κB",
        "obj_char_span": [309, 314],
        "rel_type": "inhibitor",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [54, 58],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [58, 62]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "cinnamon",
        "char_span": [32, 40],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 7],
        "new_tok_span": [5, 8]
      },
      {
        "mention": "hypoglycemic",
        "char_span": [67, 79],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [12, 14],
        "new_tok_span": [15, 17]
      }
    ],
    "new_text": "These findings demonstrate that <START=Pharmacologic Substance> cinnamon <END=Pharmacologic Substance> polyphenols can exert the <START=Pharmacologic Substance> hypoglycemic <END=Pharmacologic Substance> and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti - oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, NF - κB activation."
  },
  {
    "PMID": 22718571,
    "id": 0,
    "text": "Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, Gentianine, that Upregulates PPAR-γ Gene Expression in 3T3-L1 cells.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [26, 38],
        "name": "Swertiamarin",
        "tok_span": [5, 10],
        "new_tok_span": [6, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [71, 81],
        "name": "Gentianine",
        "tok_span": [18, 21],
        "new_tok_span": [21, 24]
      },
      {
        "ent_type": "GENE",
        "char_span": [100, 106],
        "name": "PPAR-γ",
        "tok_span": [26, 29],
        "new_tok_span": [30, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "Gentianine",
        "sbj_char_span": [71, 81],
        "object": "PPAR-γ",
        "obj_char_span": [100, 106],
        "rel_type": "regulator",
        "sbj_tok_span": [18, 21],
        "obj_tok_span": [26, 29],
        "new_sbj_tok_span": [21, 24],
        "new_obj_tok_span": [30, 33]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Swertiamarin",
        "char_span": [26, 38],
        "sem_type": "Organic Chemical",
        "tok_span": [5, 10],
        "new_tok_span": [6, 11]
      },
      {
        "mention": "Gentianine",
        "char_span": [71, 81],
        "sem_type": "Organic Chemical",
        "tok_span": [18, 21],
        "new_tok_span": [21, 24]
      }
    ],
    "new_text": "Anti - diabetic Activity of <START=Organic Chemical> Swertiamarin <END=Organic Chemical> is due to an Active Metabolite, <START=Organic Chemical> Gentianine <END=Organic Chemical>, that Upregulates PPAR - γ Gene Expression in 3T3 - L1 cells."
  },
  {
    "PMID": 9003761,
    "id": 6,
    "text": "TREK-1 currents are insensitive to pharmacological agents that block TWIK-1 activity such as quinine and quinidine.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [93, 100],
        "name": "quinine",
        "tok_span": [19, 21],
        "new_tok_span": [26, 28]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [105, 114],
        "name": "quinidine",
        "tok_span": [22, 24],
        "new_tok_span": [30, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 6],
        "name": "TREK-1",
        "tok_span": [0, 4],
        "new_tok_span": [2, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [69, 75],
        "name": "TWIK-1",
        "tok_span": [12, 16],
        "new_tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "quinine",
        "sbj_char_span": [93, 100],
        "object": "TWIK-1",
        "obj_char_span": [69, 75],
        "rel_type": "inhibitor",
        "sbj_tok_span": [19, 21],
        "obj_tok_span": [12, 16],
        "new_sbj_tok_span": [26, 28],
        "new_obj_tok_span": [17, 21]
      },
      {
        "subject": "quinidine",
        "sbj_char_span": [105, 114],
        "object": "TWIK-1",
        "obj_char_span": [69, 75],
        "rel_type": "inhibitor",
        "sbj_tok_span": [22, 24],
        "obj_tok_span": [12, 16],
        "new_sbj_tok_span": [30, 32],
        "new_obj_tok_span": [17, 21]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "TREK-1",
        "char_span": [0, 6],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 4],
        "new_tok_span": [2, 6]
      },
      {
        "mention": "TREK-1",
        "char_span": [0, 6],
        "sem_type": "Gene or Genome",
        "tok_span": [0, 4],
        "new_tok_span": [2, 6]
      },
      {
        "mention": "TWIK-1",
        "char_span": [69, 75],
        "sem_type": "Gene or Genome",
        "tok_span": [12, 16],
        "new_tok_span": [17, 21]
      },
      {
        "mention": "quinine",
        "char_span": [93, 100],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [19, 21],
        "new_tok_span": [26, 28]
      }
    ],
    "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> TREK - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> currents are insensitive to pharmacological agents that block <START=Gene or Genome> TWIK - 1 <END=Gene or Genome> activity such as <START=Pharmacologic Substance> quinine <END=Pharmacologic Substance> and quinidine."
  },
  {
    "PMID": 15452358,
    "id": 1,
    "text": "In order to examine the site of action of an NR2B subtype-selective NMDA antagonist CP-101,606, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [68, 72],
        "name": "NMDA",
        "tok_span": [16, 17],
        "new_tok_span": [21, 22]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [84, 94],
        "name": "CP-101,606",
        "tok_span": [18, 24],
        "new_tok_span": [27, 33]
      },
      {
        "ent_type": "GENE",
        "char_span": [45, 49],
        "name": "NR2B",
        "tok_span": [10, 13],
        "new_tok_span": [12, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [68, 72],
        "name": "NMDA",
        "tok_span": [16, 17],
        "new_tok_span": [21, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "CP-101,606",
        "sbj_char_span": [84, 94],
        "object": "NR2B",
        "obj_char_span": [45, 49],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [18, 24],
        "obj_tok_span": [10, 13],
        "new_sbj_tok_span": [27, 33],
        "new_obj_tok_span": [12, 15]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "NR2B",
        "char_span": [45, 49],
        "sem_type": "Gene or Genome",
        "tok_span": [10, 13],
        "new_tok_span": [12, 15]
      },
      {
        "mention": "NMDA",
        "char_span": [68, 72],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [16, 17],
        "new_tok_span": [21, 22]
      },
      {
        "mention": "CP",
        "char_span": [84, 86],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [18, 19],
        "new_tok_span": [27, 28]
      },
      {
        "mention": "antagonist",
        "char_span": [73, 83],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [17, 18],
        "new_tok_span": [24, 25]
      },
      {
        "mention": "NR2B",
        "char_span": [45, 49],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [10, 13],
        "new_tok_span": [12, 15]
      }
    ],
    "new_text": "In order to examine the site of action of an <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> subtype - selective <START=Amino Acid, Peptide, or Protein> NMDA <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance> <START=Pharmacologic Substance> CP <END=Pharmacologic Substance> - 101, 606, we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration."
  },
  {
    "PMID": 12724156,
    "id": 12,
    "text": "However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [9, 19],
        "name": "topiramate",
        "tok_span": [2, 6],
        "new_tok_span": [2, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [74, 81],
        "name": "kainate",
        "tok_span": [16, 18],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [243, 250],
        "name": "kainate",
        "tok_span": [48, 50],
        "new_tok_span": [48, 50]
      },
      {
        "ent_type": "GENE",
        "char_span": [68, 73],
        "name": "GluR5",
        "tok_span": [13, 16],
        "new_tok_span": [13, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [74, 90],
        "name": "kainate receptor",
        "tok_span": [16, 19],
        "new_tok_span": [16, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [237, 242],
        "name": "GluR5",
        "tok_span": [45, 48],
        "new_tok_span": [45, 48]
      },
      {
        "ent_type": "GENE",
        "char_span": [243, 259],
        "name": "kainate receptor",
        "tok_span": [48, 51],
        "new_tok_span": [48, 51]
      }
    ],
    "relation_list": [
      {
        "subject": "topiramate",
        "sbj_char_span": [9, 19],
        "object": "GluR5",
        "obj_char_span": [68, 73],
        "rel_type": "inhibitor",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [13, 16]
      },
      {
        "subject": "topiramate",
        "sbj_char_span": [9, 19],
        "object": "kainate receptor",
        "obj_char_span": [74, 90],
        "rel_type": "inhibitor",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [16, 19],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [16, 19]
      },
      {
        "subject": "topiramate",
        "sbj_char_span": [9, 19],
        "object": "GluR5",
        "obj_char_span": [237, 242],
        "rel_type": "inhibitor",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [45, 48],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [45, 48]
      },
      {
        "subject": "topiramate",
        "sbj_char_span": [9, 19],
        "object": "kainate receptor",
        "obj_char_span": [243, 259],
        "rel_type": "inhibitor",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [48, 51],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [48, 51]
      }
    ],
    "umls_entity_list": [],
    "new_text": "However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor - mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."
  },
  {
    "PMID": 23625804,
    "id": 4,
    "text": "Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the copper-transfer process from hCCS to hSOD1.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [167, 173],
        "name": "copper",
        "tok_span": [34, 35],
        "new_tok_span": [36, 37]
      },
      {
        "ent_type": "GENE",
        "char_span": [34, 38],
        "name": "hCCS",
        "tok_span": [6, 9],
        "new_tok_span": [7, 10]
      },
      {
        "ent_type": "GENE",
        "char_span": [43, 48],
        "name": "hSOD1",
        "tok_span": [10, 13],
        "new_tok_span": [12, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [95, 100],
        "name": "CCSD1",
        "tok_span": [21, 24],
        "new_tok_span": [23, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [196, 200],
        "name": "hCCS",
        "tok_span": [39, 42],
        "new_tok_span": [42, 45]
      },
      {
        "ent_type": "GENE",
        "char_span": [204, 209],
        "name": "hSOD1",
        "tok_span": [43, 46],
        "new_tok_span": [47, 50]
      }
    ],
    "relation_list": [
      {
        "subject": "copper",
        "sbj_char_span": [167, 173],
        "object": "hCCS",
        "obj_char_span": [196, 200],
        "rel_type": "regulator",
        "sbj_tok_span": [34, 35],
        "obj_tok_span": [39, 42],
        "new_sbj_tok_span": [36, 37],
        "new_obj_tok_span": [42, 45]
      },
      {
        "subject": "copper",
        "sbj_char_span": [167, 173],
        "object": "hSOD1",
        "obj_char_span": [204, 209],
        "rel_type": "regulator",
        "sbj_tok_span": [34, 35],
        "obj_tok_span": [43, 46],
        "new_sbj_tok_span": [36, 37],
        "new_obj_tok_span": [47, 50]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "hCCS",
        "char_span": [34, 38],
        "sem_type": "Gene or Genome",
        "tok_span": [6, 9],
        "new_tok_span": [7, 10]
      },
      {
        "mention": "hCCS",
        "char_span": [196, 200],
        "sem_type": "Gene or Genome",
        "tok_span": [39, 42],
        "new_tok_span": [42, 45]
      }
    ],
    "new_text": "Together, the information on both <START=Gene or Genome> hCCS <END=Gene or Genome> and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the copper - transfer process from <START=Gene or Genome> hCCS <END=Gene or Genome> to hSOD1."
  },
  {
    "PMID": 8606397,
    "id": 4,
    "text": "One group of experimental animals was treated with 5-lipoxygenase (5-LO) inhibitor, diethylcarbamazine (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.), immediately before blast.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [84, 102],
        "name": "diethylcarbamazine",
        "tok_span": [19, 25],
        "new_tok_span": [23, 29]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [104, 107],
        "name": "DEC",
        "tok_span": [26, 27],
        "new_tok_span": [31, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [51, 65],
        "name": "5-lipoxygenase",
        "tok_span": [8, 12],
        "new_tok_span": [10, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [67, 71],
        "name": "5-LO",
        "tok_span": [13, 16],
        "new_tok_span": [17, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "diethylcarbamazine",
        "sbj_char_span": [84, 102],
        "object": "5-lipoxygenase",
        "obj_char_span": [51, 65],
        "rel_type": "inhibitor",
        "sbj_tok_span": [19, 25],
        "obj_tok_span": [8, 12],
        "new_sbj_tok_span": [23, 29],
        "new_obj_tok_span": [10, 14]
      },
      {
        "subject": "diethylcarbamazine",
        "sbj_char_span": [84, 102],
        "object": "5-LO",
        "obj_char_span": [67, 71],
        "rel_type": "inhibitor",
        "sbj_tok_span": [19, 25],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [23, 29],
        "new_obj_tok_span": [17, 20]
      },
      {
        "subject": "DEC",
        "sbj_char_span": [104, 107],
        "object": "5-lipoxygenase",
        "obj_char_span": [51, 65],
        "rel_type": "inhibitor",
        "sbj_tok_span": [26, 27],
        "obj_tok_span": [8, 12],
        "new_sbj_tok_span": [31, 32],
        "new_obj_tok_span": [10, 14]
      },
      {
        "subject": "DEC",
        "sbj_char_span": [104, 107],
        "object": "5-LO",
        "obj_char_span": [67, 71],
        "rel_type": "inhibitor",
        "sbj_tok_span": [26, 27],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [31, 32],
        "new_obj_tok_span": [17, 20]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "animals",
        "char_span": [26, 33],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      },
      {
        "mention": "lipoxygenase",
        "char_span": [53, 65],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [10, 12],
        "new_tok_span": [13, 15]
      },
      {
        "mention": "DEC",
        "char_span": [104, 107],
        "sem_type": "Gene or Genome",
        "tok_span": [26, 27],
        "new_tok_span": [31, 32]
      },
      {
        "mention": "blast",
        "char_span": [174, 179],
        "sem_type": "Gene or Genome",
        "tok_span": [51, 52],
        "new_tok_span": [58, 59]
      }
    ],
    "new_text": "One group of experimental <START=Pharmacologic Substance> animals <END=Pharmacologic Substance> was treated with 5 - <START=Amino Acid, Peptide, or Protein> lipoxygenase <END=Amino Acid, Peptide, or Protein> ( 5 - LO ) inhibitor, diethylcarbamazine ( <START=Gene or Genome> DEC <END=Gene or Genome>, Sigma, St. Louis, Missouri ) ( 50 mg / kg, i. v. ), immediately before <START=Gene or Genome> blast <END=Gene or Genome>."
  },
  {
    "PMID": 16784786,
    "id": 4,
    "text": "In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [470, 477],
        "name": "nitrate",
        "tok_span": [108, 109],
        "new_tok_span": [123, 124]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [531, 539],
        "name": "nitrogen",
        "tok_span": [119, 120],
        "new_tok_span": [135, 136]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [34, 36],
        "name": "Mo",
        "tok_span": [6, 7],
        "new_tok_span": [6, 7]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [123, 129],
        "name": "sulfur",
        "tok_span": [27, 28],
        "new_tok_span": [32, 33]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [141, 152],
        "name": "amino acids",
        "tok_span": [30, 32],
        "new_tok_span": [36, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [191, 198],
        "name": "sulfite",
        "tok_span": [39, 41],
        "new_tok_span": [45, 47]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [204, 212],
        "name": "xanthine",
        "tok_span": [45, 48],
        "new_tok_span": [51, 54]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [249, 255],
        "name": "purine",
        "tok_span": [54, 56],
        "new_tok_span": [61, 63]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [280, 286],
        "name": "oxygen",
        "tok_span": [60, 61],
        "new_tok_span": [69, 70]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [303, 311],
        "name": "aldehyde",
        "tok_span": [66, 70],
        "new_tok_span": [76, 80]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [349, 358],
        "name": "aldehydes",
        "tok_span": [78, 82],
        "new_tok_span": [89, 93]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [417, 430],
        "name": "abscisic acid",
        "tok_span": [94, 98],
        "new_tok_span": [108, 112]
      },
      {
        "ent_type": "GENE",
        "char_span": [470, 487],
        "name": "nitrate reductase",
        "tok_span": [108, 110],
        "new_tok_span": [123, 125]
      },
      {
        "ent_type": "GENE",
        "char_span": [53, 68],
        "name": "sulfite oxidase",
        "tok_span": [13, 16],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [204, 226],
        "name": "xanthine dehydrogenase",
        "tok_span": [45, 49],
        "new_tok_span": [51, 55]
      },
      {
        "ent_type": "GENE",
        "char_span": [303, 319],
        "name": "aldehyde oxidase",
        "tok_span": [66, 71],
        "new_tok_span": [76, 81]
      }
    ],
    "relation_list": [
      {
        "subject": "sulfur",
        "sbj_char_span": [123, 129],
        "object": "sulfite oxidase",
        "obj_char_span": [53, 68],
        "rel_type": "product or substrate",
        "sbj_tok_span": [27, 28],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [32, 33],
        "new_obj_tok_span": [15, 18]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "sulfite oxidase",
        "char_span": [53, 68],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [13, 16],
        "new_tok_span": [15, 18]
      },
      {
        "mention": "sulfite oxidase",
        "char_span": [53, 68],
        "sem_type": "Gene or Genome",
        "tok_span": [13, 16],
        "new_tok_span": [15, 18]
      },
      {
        "mention": "sulfur",
        "char_span": [123, 129],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [27, 28],
        "new_tok_span": [32, 33]
      },
      {
        "mention": "purine",
        "char_span": [249, 255],
        "sem_type": "Organic Chemical",
        "tok_span": [54, 56],
        "new_tok_span": [61, 63]
      },
      {
        "mention": "oxygen",
        "char_span": [280, 286],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [60, 61],
        "new_tok_span": [69, 70]
      },
      {
        "mention": "aldehydes",
        "char_span": [349, 358],
        "sem_type": "Organic Chemical",
        "tok_span": [78, 82],
        "new_tok_span": [89, 93]
      },
      {
        "mention": "phytohormone",
        "char_span": [404, 416],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [90, 94],
        "new_tok_span": [103, 107]
      },
      {
        "mention": "nitrate reductase",
        "char_span": [470, 487],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [108, 110],
        "new_tok_span": [123, 125]
      }
    ],
    "new_text": "In eukaryotes, the most prominent Mo - enzymes are ( 1 ) <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> sulfite oxidase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, which catalyzes the final step in the degradation of <START=Pharmacologic Substance> sulfur <END=Pharmacologic Substance> - containing amino acids and is involved in detoxifying excess sulfite, ( 2 ) xanthine dehydrogenase, which is involved in <START=Organic Chemical> purine <END=Organic Chemical> catabolism and reactive <START=Pharmacologic Substance> oxygen <END=Pharmacologic Substance> production, ( 3 ) aldehyde oxidase, which oxidizes a variety of <START=Organic Chemical> aldehydes <END=Organic Chemical> and is essential for the biosynthesis of the <START=Amino Acid, Peptide, or Protein> phytohormone <END=Amino Acid, Peptide, or Protein> abscisic acid, and in autotrophic organisms also ( 4 ) <START=Amino Acid, Peptide, or Protein> nitrate reductase <END=Amino Acid, Peptide, or Protein>, which catalyzes the key step in inorganic nitrogen assimilation."
  },
  {
    "PMID": 15121646,
    "id": 1,
    "text": "OBJECTIVE: Ziprasidone is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with dopamine D(2) receptors in vitro.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [100, 104],
        "name": "5-HT",
        "tok_span": [20, 23],
        "new_tok_span": [22, 25]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [11, 22],
        "name": "Ziprasidone",
        "tok_span": [2, 7],
        "new_tok_span": [2, 7]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [132, 140],
        "name": "dopamine",
        "tok_span": [29, 30],
        "new_tok_span": [31, 32]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [90, 99],
        "name": "serotonin",
        "tok_span": [19, 20],
        "new_tok_span": [21, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [100, 117],
        "name": "5-HT(2) receptors",
        "tok_span": [20, 27],
        "new_tok_span": [22, 29]
      },
      {
        "ent_type": "GENE",
        "char_span": [132, 155],
        "name": "dopamine D(2) receptors",
        "tok_span": [29, 35],
        "new_tok_span": [31, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "Ziprasidone",
        "sbj_char_span": [11, 22],
        "object": "5-HT(2) receptors",
        "obj_char_span": [100, 117],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 7],
        "obj_tok_span": [20, 27],
        "new_sbj_tok_span": [2, 7],
        "new_obj_tok_span": [22, 29]
      },
      {
        "subject": "Ziprasidone",
        "sbj_char_span": [11, 22],
        "object": "dopamine D(2) receptors",
        "obj_char_span": [132, 155],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 7],
        "obj_tok_span": [29, 35],
        "new_sbj_tok_span": [2, 7],
        "new_obj_tok_span": [31, 37]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "atypical antipsychotic drug",
        "char_span": [29, 56],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [9, 13],
        "new_tok_span": [10, 14]
      }
    ],
    "new_text": "OBJECTIVE : Ziprasidone is an <START=Pharmacologic Substance> atypical antipsychotic drug <END=Pharmacologic Substance> that shows a higher affinity for serotonin 5 - HT ( 2 ) receptors compared with dopamine D ( 2 ) receptors in vitro."
  },
  {
    "PMID": 23542578,
    "id": 2,
    "text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH. The successful preparation of the two complete antigens was confirmed by UV spectral scanning, HPLC, production of antibodies with titer of 1.28 × 10(4) from mice immunized with the two complete antigens, indirect ELISA and Western-blot.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [16, 31],
        "name": "GTX2,3-aldehyde",
        "tok_span": [2, 12],
        "new_tok_span": [2, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [72, 75],
        "name": "NH2",
        "tok_span": [18, 20],
        "new_tok_span": [22, 24]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [101, 111],
        "name": "amino acid",
        "tok_span": [28, 30],
        "new_tok_span": [34, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [142, 151],
        "name": "aldehydes",
        "tok_span": [34, 38],
        "new_tok_span": [42, 46]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [189, 204],
        "name": "GTX2,3-aldehyde",
        "tok_span": [43, 53],
        "new_tok_span": [53, 63]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [236, 251],
        "name": "GTX2,3-aldehyde",
        "tok_span": [61, 71],
        "new_tok_span": [75, 85]
      },
      {
        "ent_type": "GENE",
        "char_span": [205, 225],
        "name": "bovine serum albumin",
        "tok_span": [54, 57],
        "new_tok_span": [67, 70]
      },
      {
        "ent_type": "GENE",
        "char_span": [227, 230],
        "name": "BSA",
        "tok_span": [58, 59],
        "new_tok_span": [72, 73]
      },
      {
        "ent_type": "GENE",
        "char_span": [253, 278],
        "name": "keyhole limpet hemocyanin",
        "tok_span": [72, 79],
        "new_tok_span": [88, 95]
      },
      {
        "ent_type": "GENE",
        "char_span": [280, 283],
        "name": "KLH",
        "tok_span": [80, 82],
        "new_tok_span": [96, 98]
      },
      {
        "ent_type": "GENE",
        "char_span": [343, 346],
        "name": "BSA",
        "tok_span": [93, 94],
        "new_tok_span": [109, 110]
      },
      {
        "ent_type": "GENE",
        "char_span": [350, 353],
        "name": "KLH",
        "tok_span": [95, 97],
        "new_tok_span": [111, 113]
      }
    ],
    "relation_list": [
      {
        "subject": "GTX2,3-aldehyde",
        "sbj_char_span": [236, 251],
        "object": "keyhole limpet hemocyanin",
        "obj_char_span": [253, 278],
        "rel_type": "regulator",
        "sbj_tok_span": [61, 71],
        "obj_tok_span": [72, 79],
        "new_sbj_tok_span": [75, 85],
        "new_obj_tok_span": [88, 95]
      },
      {
        "subject": "GTX2,3-aldehyde",
        "sbj_char_span": [236, 251],
        "object": "KLH",
        "obj_char_span": [280, 283],
        "rel_type": "regulator",
        "sbj_tok_span": [61, 71],
        "obj_tok_span": [80, 82],
        "new_sbj_tok_span": [75, 85],
        "new_obj_tok_span": [96, 98]
      },
      {
        "subject": "GTX2,3-aldehyde",
        "sbj_char_span": [189, 204],
        "object": "bovine serum albumin",
        "obj_char_span": [205, 225],
        "rel_type": "regulator",
        "sbj_tok_span": [43, 53],
        "obj_tok_span": [54, 57],
        "new_sbj_tok_span": [53, 63],
        "new_obj_tok_span": [67, 70]
      },
      {
        "subject": "GTX2,3-aldehyde",
        "sbj_char_span": [189, 204],
        "object": "BSA",
        "obj_char_span": [227, 230],
        "rel_type": "regulator",
        "sbj_tok_span": [43, 53],
        "obj_tok_span": [58, 59],
        "new_sbj_tok_span": [53, 63],
        "new_obj_tok_span": [72, 73]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "aldehyde",
        "char_span": [23, 31],
        "sem_type": "Organic Chemical",
        "tok_span": [8, 12],
        "new_tok_span": [9, 13]
      },
      {
        "mention": "aldehyde",
        "char_span": [142, 150],
        "sem_type": "Organic Chemical",
        "tok_span": [34, 38],
        "new_tok_span": [42, 46]
      },
      {
        "mention": "aldehyde",
        "char_span": [196, 204],
        "sem_type": "Organic Chemical",
        "tok_span": [49, 53],
        "new_tok_span": [60, 64]
      },
      {
        "mention": "aldehyde",
        "char_span": [243, 251],
        "sem_type": "Organic Chemical",
        "tok_span": [67, 71],
        "new_tok_span": [82, 86]
      },
      {
        "mention": "NH2",
        "char_span": [72, 75],
        "sem_type": "Organic Chemical",
        "tok_span": [18, 20],
        "new_tok_span": [22, 24]
      },
      {
        "mention": "NH2",
        "char_span": [72, 75],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [18, 20],
        "new_tok_span": [22, 24]
      },
      {
        "mention": "aldehydes",
        "char_span": [142, 151],
        "sem_type": "Organic Chemical",
        "tok_span": [34, 38],
        "new_tok_span": [42, 46]
      },
      {
        "mention": "bovine serum albumin",
        "char_span": [205, 225],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [54, 57],
        "new_tok_span": [67, 70]
      }
    ],
    "new_text": "An intermediate GTX2, 3 - <START=Organic Chemical> aldehyde <END=Organic Chemical> was first synthesized by activating the <START=Organic Chemical> <START=Pharmacologic Substance> NH2 <END=Organic Chemical> <END=Pharmacologic Substance> group of the 2nd and 8th amino acid residues with three different <START=Organic Chemical> <START=Organic Chemical> aldehydes <END=Organic Chemical> <END=Organic Chemical> and two artificial complete antigens GTX2, 3 - <START=Organic Chemical> aldehyde <END=Organic Chemical> - <START=Amino Acid, Peptide, or Protein> bovine serum albumin <END=Amino Acid, Peptide, or Protein> ( BSA ) and GTX2, 3 - <START=Organic Chemical> aldehyde <END=Organic Chemical> - keyhole limpet hemocyanin ( KLH ) were then prepared by cross - linking the intermediate with BSA or KLH. The successful preparation of the two complete antigens was confirmed by UV spectral scanning, HPLC, production of antibodies with titer of 1. 28 × 10 ( 4 ) from mice immunized with the two complete antigens, indirect ELISA and Western - blot."
  },
  {
    "PMID": 17350061,
    "id": 7,
    "text": "Estrogen-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 8],
        "name": "Estrogen",
        "tok_span": [0, 2],
        "new_tok_span": [0, 2]
      },
      {
        "ent_type": "GENE",
        "char_span": [56, 62],
        "name": "Cyp2a4",
        "tok_span": [13, 17],
        "new_tok_span": [13, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [93, 100],
        "name": "Cyp3a25",
        "tok_span": [23, 27],
        "new_tok_span": [23, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [35, 51],
        "name": "cytokeratin 1-19",
        "tok_span": [6, 12],
        "new_tok_span": [6, 12]
      }
    ],
    "relation_list": [
      {
        "subject": "Estrogen",
        "sbj_char_span": [0, 8],
        "object": "cytokeratin 1-19",
        "obj_char_span": [35, 51],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [6, 12],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [6, 12]
      },
      {
        "subject": "Estrogen",
        "sbj_char_span": [0, 8],
        "object": "Cyp2a4",
        "obj_char_span": [56, 62],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [13, 17],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [13, 17]
      },
      {
        "subject": "Estrogen",
        "sbj_char_span": [0, 8],
        "object": "Cyp3a25",
        "obj_char_span": [93, 100],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [23, 27],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [23, 27]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Estrogen - regulated genes including cytokeratin 1 - 19 and Cyp2a4 were over - expressed, although Cyp3a25 was suppressed."
  },
  {
    "PMID": 17382376,
    "id": 10,
    "text": "Thus, H(1) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [104, 113],
        "name": "clozapine",
        "tok_span": [25, 28],
        "new_tok_span": [25, 28]
      },
      {
        "ent_type": "GENE",
        "char_span": [6, 10],
        "name": "H(1)",
        "tok_span": [2, 6],
        "new_tok_span": [2, 6]
      }
    ],
    "relation_list": [
      {
        "subject": "clozapine",
        "sbj_char_span": [104, 113],
        "object": "H(1)",
        "obj_char_span": [6, 10],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [25, 28],
        "obj_tok_span": [2, 6],
        "new_sbj_tok_span": [25, 28],
        "new_obj_tok_span": [2, 6]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Thus, H ( 1 ) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine."
  },
  {
    "PMID": 23128353,
    "id": 6,
    "text": "In addition, glucosamine attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [13, 24],
        "name": "glucosamine",
        "tok_span": [3, 7],
        "new_tok_span": [3, 7]
      },
      {
        "ent_type": "GENE",
        "char_span": [36, 39],
        "name": "p21",
        "tok_span": [8, 10],
        "new_tok_span": [10, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [119, 122],
        "name": "p21",
        "tok_span": [24, 26],
        "new_tok_span": [32, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "glucosamine",
        "sbj_char_span": [13, 24],
        "object": "p21",
        "obj_char_span": [36, 39],
        "rel_type": "regulator",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [10, 12]
      },
      {
        "subject": "glucosamine",
        "sbj_char_span": [13, 24],
        "object": "p21",
        "obj_char_span": [119, 122],
        "rel_type": "regulator",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [24, 26],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [32, 34]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "p21",
        "char_span": [36, 39],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [8, 10],
        "new_tok_span": [10, 12]
      },
      {
        "mention": "p21",
        "char_span": [119, 122],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [24, 26],
        "new_tok_span": [32, 34]
      },
      {
        "mention": "proteolytic",
        "char_span": [78, 89],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [17, 18],
        "new_tok_span": [22, 23]
      },
      {
        "mention": "p21",
        "char_span": [36, 39],
        "sem_type": "Gene or Genome",
        "tok_span": [8, 10],
        "new_tok_span": [10, 12]
      },
      {
        "mention": "p21",
        "char_span": [119, 122],
        "sem_type": "Gene or Genome",
        "tok_span": [24, 26],
        "new_tok_span": [32, 34]
      }
    ],
    "new_text": "In addition, glucosamine attenuated <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p21 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> protein stability via the proteasomal <START=Amino Acid, Peptide, or Protein> proteolytic <END=Amino Acid, Peptide, or Protein> pathway, as well as inducing <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p21 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> nuclear accumulation."
  },
  {
    "PMID": 15352500,
    "id": 0,
    "text": "A novel membrane sensor for histamine H1-receptor antagonist \"fexofenadine\".",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [28, 37],
        "name": "histamine",
        "tok_span": [5, 6],
        "new_tok_span": [5, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [62, 74],
        "name": "fexofenadine",
        "tok_span": [12, 17],
        "new_tok_span": [13, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [28, 49],
        "name": "histamine H1-receptor",
        "tok_span": [5, 10],
        "new_tok_span": [5, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "fexofenadine",
        "sbj_char_span": [62, 74],
        "object": "histamine H1-receptor",
        "obj_char_span": [28, 49],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [12, 17],
        "obj_tok_span": [5, 10],
        "new_sbj_tok_span": [13, 18],
        "new_obj_tok_span": [5, 10]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "fexofenadine",
        "char_span": [62, 74],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [12, 17],
        "new_tok_span": [13, 18]
      }
    ],
    "new_text": "A novel membrane sensor for histamine H1 - receptor antagonist \" <START=Pharmacologic Substance> fexofenadine <END=Pharmacologic Substance> \"."
  },
  {
    "PMID": 9310349,
    "id": 6,
    "text": "Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [16, 31],
        "name": "bisphosphonates",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [41, 52],
        "name": "alendronate",
        "tok_span": [9, 13],
        "new_tok_span": [11, 15]
      },
      {
        "ent_type": "GENE",
        "char_span": [87, 94],
        "name": "PTPmeg1",
        "tok_span": [19, 23],
        "new_tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "alendronate",
        "sbj_char_span": [41, 52],
        "object": "PTPmeg1",
        "obj_char_span": [87, 94],
        "rel_type": "inhibitor",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [19, 23],
        "new_sbj_tok_span": [11, 15],
        "new_obj_tok_span": [21, 25]
      },
      {
        "subject": "bisphosphonates",
        "sbj_char_span": [16, 31],
        "object": "PTPmeg1",
        "obj_char_span": [87, 94],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [19, 23],
        "new_sbj_tok_span": [4, 8],
        "new_obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "bisphosphonates",
        "char_span": [16, 31],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "mention": "meg1",
        "char_span": [90, 94],
        "sem_type": "Gene or Genome",
        "tok_span": [20, 23],
        "new_tok_span": [23, 26]
      }
    ],
    "new_text": "Among the other <START=Pharmacologic Substance> bisphosphonates <END=Pharmacologic Substance> studied, alendronate was more potent and selective for PTP <START=Gene or Genome>meg1 <END=Gene or Genome>."
  },
  {
    "PMID": 16618126,
    "id": 10,
    "text": "Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak Atp8a1 activators.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [28, 30],
        "name": "PE",
        "tok_span": [6, 7],
        "new_tok_span": [8, 9]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [32, 61],
        "name": "phosphatidylhydroxypropionate",
        "tok_span": [8, 13],
        "new_tok_span": [10, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [67, 89],
        "name": "phosphatidylhomoserine",
        "tok_span": [15, 19],
        "new_tok_span": [17, 21]
      },
      {
        "ent_type": "GENE",
        "char_span": [105, 111],
        "name": "Atp8a1",
        "tok_span": [23, 28],
        "new_tok_span": [26, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "PE",
        "sbj_char_span": [28, 30],
        "object": "Atp8a1",
        "obj_char_span": [105, 111],
        "rel_type": "activator",
        "sbj_tok_span": [6, 7],
        "obj_tok_span": [23, 28],
        "new_sbj_tok_span": [8, 9],
        "new_obj_tok_span": [26, 31]
      },
      {
        "subject": "phosphatidylhydroxypropionate",
        "sbj_char_span": [32, 61],
        "object": "Atp8a1",
        "obj_char_span": [105, 111],
        "rel_type": "activator",
        "sbj_tok_span": [8, 13],
        "obj_tok_span": [23, 28],
        "new_sbj_tok_span": [10, 15],
        "new_obj_tok_span": [26, 31]
      },
      {
        "subject": "phosphatidylhomoserine",
        "sbj_char_span": [67, 89],
        "object": "Atp8a1",
        "obj_char_span": [105, 111],
        "rel_type": "activator",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [23, 28],
        "new_sbj_tok_span": [17, 21],
        "new_obj_tok_span": [26, 31]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "lipids",
        "char_span": [20, 26],
        "sem_type": "Organic Chemical",
        "tok_span": [4, 5],
        "new_tok_span": [5, 6]
      },
      {
        "mention": "Atp8a1",
        "char_span": [105, 111],
        "sem_type": "Gene or Genome",
        "tok_span": [23, 28],
        "new_tok_span": [26, 31]
      }
    ],
    "new_text": "Weakly translocated <START=Organic Chemical> lipids <END=Organic Chemical> ( PE, phosphatidylhydroxypropionate, and phosphatidylhomoserine ) are also weak <START=Gene or Genome> Atp8a1 <END=Gene or Genome> activators."
  },
  {
    "PMID": 23423570,
    "id": 9,
    "text": "In conclusion, IL-8 production and neutrophil infiltration are increased in high-glucose environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [81, 88],
        "name": "glucose",
        "tok_span": [15, 16],
        "new_tok_span": [15, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [15, 19],
        "name": "IL-8",
        "tok_span": [3, 6],
        "new_tok_span": [3, 6]
      }
    ],
    "relation_list": [
      {
        "subject": "glucose",
        "sbj_char_span": [81, 88],
        "object": "IL-8",
        "obj_char_span": [15, 19],
        "rel_type": "regulator",
        "sbj_tok_span": [15, 16],
        "obj_tok_span": [3, 6],
        "new_sbj_tok_span": [15, 16],
        "new_obj_tok_span": [3, 6]
      }
    ],
    "umls_entity_list": [],
    "new_text": "In conclusion, IL - 8 production and neutrophil infiltration are increased in high - glucose environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin."
  },
  {
    "PMID": 9310349,
    "id": 3,
    "text": "Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1).",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [20, 31],
        "name": "alendronate",
        "tok_span": [4, 8],
        "new_tok_span": [4, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [69, 77],
        "name": "tyrosine",
        "tok_span": [16, 17],
        "new_tok_span": [17, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [61, 94],
        "name": "protein-tyrosine-phosphatase-meg1",
        "tok_span": [14, 22],
        "new_tok_span": [15, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [96, 103],
        "name": "PTPmeg1",
        "tok_span": [23, 27],
        "new_tok_span": [25, 29]
      }
    ],
    "relation_list": [
      {
        "subject": "alendronate",
        "sbj_char_span": [20, 31],
        "object": "protein-tyrosine-phosphatase-meg1",
        "obj_char_span": [61, 94],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [14, 22],
        "new_sbj_tok_span": [4, 8],
        "new_obj_tok_span": [15, 23]
      },
      {
        "subject": "alendronate",
        "sbj_char_span": [20, 31],
        "object": "PTPmeg1",
        "obj_char_span": [96, 103],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [23, 27],
        "new_sbj_tok_span": [4, 8],
        "new_obj_tok_span": [25, 29]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "protein-tyrosine-phosphatase-meg1",
        "char_span": [61, 94],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [14, 22],
        "new_tok_span": [15, 23]
      }
    ],
    "new_text": "Here we report that alendronate is a potent inhibitor of the <START=Amino Acid, Peptide, or Protein> protein - tyrosine - phosphatase - meg1 <END=Amino Acid, Peptide, or Protein> ( PTPmeg1 )."
  },
  {
    "PMID": 23298677,
    "id": 0,
    "text": "Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [61, 68],
        "name": "ethanol",
        "tok_span": [15, 16],
        "new_tok_span": [20, 21]
      },
      {
        "ent_type": "GENE",
        "char_span": [13, 17],
        "name": "HO-1",
        "tok_span": [2, 5],
        "new_tok_span": [2, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [26, 29],
        "name": "p38",
        "tok_span": [6, 8],
        "new_tok_span": [6, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [30, 34],
        "name": "MAPK",
        "tok_span": [8, 9],
        "new_tok_span": [8, 9]
      },
      {
        "ent_type": "GENE",
        "char_span": [35, 39],
        "name": "Nrf2",
        "tok_span": [10, 12],
        "new_tok_span": [12, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "ethanol",
        "sbj_char_span": [61, 68],
        "object": "HO-1",
        "obj_char_span": [13, 17],
        "rel_type": "activator",
        "sbj_tok_span": [15, 16],
        "obj_tok_span": [2, 5],
        "new_sbj_tok_span": [20, 21],
        "new_obj_tok_span": [2, 5]
      },
      {
        "subject": "ethanol",
        "sbj_char_span": [61, 68],
        "object": "p38",
        "obj_char_span": [26, 29],
        "rel_type": "activator",
        "sbj_tok_span": [15, 16],
        "obj_tok_span": [6, 8],
        "new_sbj_tok_span": [20, 21],
        "new_obj_tok_span": [6, 8]
      },
      {
        "subject": "ethanol",
        "sbj_char_span": [61, 68],
        "object": "MAPK",
        "obj_char_span": [30, 34],
        "rel_type": "activator",
        "sbj_tok_span": [15, 16],
        "obj_tok_span": [8, 9],
        "new_sbj_tok_span": [20, 21],
        "new_obj_tok_span": [8, 9]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "ethanol",
        "char_span": [61, 68],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [15, 16],
        "new_tok_span": [20, 21]
      },
      {
        "mention": "Nrf2",
        "char_span": [35, 39],
        "sem_type": "Gene or Genome",
        "tok_span": [10, 12],
        "new_tok_span": [12, 14]
      },
      {
        "mention": "Nrf2",
        "char_span": [35, 39],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [10, 12],
        "new_tok_span": [12, 14]
      }
    ],
    "new_text": "Induction of HO - 1 through p38 MAPK / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Nrf2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> signaling pathway by <START=Pharmacologic Substance> ethanol <END=Pharmacologic Substance> extract of Inula helenium L. reduces inflammation in LPS - activated RAW 264. 7 cells and CLP - induced septic mice."
  },
  {
    "PMID": 16424790,
    "id": 8,
    "text": "However, there were some significant differences among Captopril (30 mg/kg or 45 mg/kg), enalapril (20 mg/kg), and N-acetylcysteine particular in the activity of PON1 and ACE. These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [55, 64],
        "name": "Captopril",
        "tok_span": [8, 11],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [89, 98],
        "name": "enalapril",
        "tok_span": [23, 27],
        "new_tok_span": [23, 27]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [115, 131],
        "name": "N-acetylcysteine",
        "tok_span": [35, 40],
        "new_tok_span": [35, 40]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [205, 214],
        "name": "Captopril",
        "tok_span": [55, 58],
        "new_tok_span": [63, 66]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [283, 295],
        "name": "L-methionine",
        "tok_span": [68, 71],
        "new_tok_span": [76, 79]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [335, 344],
        "name": "Captopril",
        "tok_span": [79, 82],
        "new_tok_span": [89, 92]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [409, 411],
        "name": "NO",
        "tok_span": [96, 97],
        "new_tok_span": [110, 111]
      },
      {
        "ent_type": "GENE",
        "char_span": [162, 166],
        "name": "PON1",
        "tok_span": [45, 48],
        "new_tok_span": [49, 52]
      },
      {
        "ent_type": "GENE",
        "char_span": [171, 174],
        "name": "ACE",
        "tok_span": [49, 50],
        "new_tok_span": [56, 57]
      },
      {
        "ent_type": "GENE",
        "char_span": [391, 395],
        "name": "PON1",
        "tok_span": [91, 94],
        "new_tok_span": [103, 106]
      }
    ],
    "relation_list": [
      {
        "subject": "Captopril",
        "sbj_char_span": [335, 344],
        "object": "PON1",
        "obj_char_span": [391, 395],
        "rel_type": "activator",
        "sbj_tok_span": [79, 82],
        "obj_tok_span": [91, 94],
        "new_sbj_tok_span": [89, 92],
        "new_obj_tok_span": [103, 106]
      },
      {
        "subject": "L-methionine",
        "sbj_char_span": [283, 295],
        "object": "PON1",
        "obj_char_span": [391, 395],
        "rel_type": "inhibitor",
        "sbj_tok_span": [68, 71],
        "obj_tok_span": [91, 94],
        "new_sbj_tok_span": [76, 79],
        "new_obj_tok_span": [103, 106]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PON1",
        "char_span": [162, 166],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [45, 48],
        "new_tok_span": [49, 52]
      },
      {
        "mention": "PON1",
        "char_span": [391, 395],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [91, 94],
        "new_tok_span": [103, 106]
      },
      {
        "mention": "PON1",
        "char_span": [162, 166],
        "sem_type": "Gene or Genome",
        "tok_span": [45, 48],
        "new_tok_span": [49, 52]
      },
      {
        "mention": "PON1",
        "char_span": [391, 395],
        "sem_type": "Gene or Genome",
        "tok_span": [91, 94],
        "new_tok_span": [103, 106]
      },
      {
        "mention": "ace",
        "char_span": [117, 120],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 38],
        "new_tok_span": [38, 39]
      },
      {
        "mention": "ACE",
        "char_span": [171, 174],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [49, 50],
        "new_tok_span": [56, 57]
      },
      {
        "mention": "methionine",
        "char_span": [285, 295],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [70, 71],
        "new_tok_span": [79, 80]
      }
    ],
    "new_text": "However, there were some significant differences among Captopril ( 30 mg / kg or 45 mg / kg ), enalapril ( 20 mg / kg ), and N - <START=Amino Acid, Peptide, or Protein> acetyl <END=Amino Acid, Peptide, or Protein>cysteine particular in the activity of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PON1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> ACE <END=Amino Acid, Peptide, or Protein>. These results suggested that Captopril can protect the vascular endothelium against the damages induced by L - <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PON1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activity and NO levels."
  },
  {
    "PMID": 12217700,
    "id": 4,
    "text": "The comparison between MalP structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of Glc1P substrate, triggers a conformational change of the 380s loop.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [91, 101],
        "name": "6-hydroxyl",
        "tok_span": [18, 21],
        "new_tok_span": [18, 21]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [111, 116],
        "name": "Glc1P",
        "tok_span": [23, 27],
        "new_tok_span": [23, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [23, 27],
        "name": "MalP",
        "tok_span": [3, 5],
        "new_tok_span": [3, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "Glc1P",
        "sbj_char_span": [111, 116],
        "object": "MalP",
        "obj_char_span": [23, 27],
        "rel_type": "regulator",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [3, 5],
        "new_sbj_tok_span": [23, 27],
        "new_obj_tok_span": [3, 5]
      },
      {
        "subject": "6-hydroxyl",
        "sbj_char_span": [91, 101],
        "object": "MalP",
        "obj_char_span": [23, 27],
        "rel_type": "regulator",
        "sbj_tok_span": [18, 21],
        "obj_tok_span": [3, 5],
        "new_sbj_tok_span": [18, 21],
        "new_obj_tok_span": [3, 5]
      }
    ],
    "umls_entity_list": [],
    "new_text": "The comparison between MalP structures shows that His377, through a hydrogen bond with the 6 - hydroxyl group of Glc1P substrate, triggers a conformational change of the 380s loop."
  },
  {
    "PMID": 10742288,
    "id": 5,
    "text": "The selective alpha(2)-adrenoceptor ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43. 4.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [43, 54],
        "name": "rauwolscine",
        "tok_span": [11, 16],
        "new_tok_span": [12, 17]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [178, 191],
        "name": "noradrenaline",
        "tok_span": [42, 45],
        "new_tok_span": [46, 49]
      },
      {
        "ent_type": "GENE",
        "char_span": [14, 35],
        "name": "alpha(2)-adrenoceptor",
        "tok_span": [2, 10],
        "new_tok_span": [2, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "rauwolscine",
        "sbj_char_span": [43, 54],
        "object": "alpha(2)-adrenoceptor",
        "obj_char_span": [14, 35],
        "rel_type": "regulator",
        "sbj_tok_span": [11, 16],
        "obj_tok_span": [2, 10],
        "new_sbj_tok_span": [12, 17],
        "new_obj_tok_span": [2, 10]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "rauwolscine",
        "char_span": [43, 54],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [11, 16],
        "new_tok_span": [12, 17]
      },
      {
        "mention": "pK",
        "char_span": [163, 165],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [35, 37],
        "new_tok_span": [38, 40]
      }
    ],
    "new_text": "The selective alpha ( 2 ) - adrenoceptor ligand <START=Pharmacologic Substance> rauwolscine <END=Pharmacologic Substance> antagonized acidification rate changes with an affinity independent of the agonist used ; the affinity ( mean <START=Amino Acid, Peptide, or Protein> pK <END=Amino Acid, Peptide, or Protein> ( B ) ) against noradrenaline was 8. 43. 4."
  },
  {
    "PMID": 10546982,
    "id": 5,
    "text": "Following 6 h of in vivo intracerebroventricular injections of 100 nmol of RTI-76, there was a dose- and time-dependent reduction (- 60%) of SERT binding in hippocampus and striatum, without a change in the Kd. SERT binding densities recovered over several days, reaching control levels by day 14.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [75, 81],
        "name": "RTI-76",
        "tok_span": [17, 21],
        "new_tok_span": [18, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [141, 145],
        "name": "SERT",
        "tok_span": [38, 40],
        "new_tok_span": [40, 42]
      },
      {
        "ent_type": "GENE",
        "char_span": [211, 215],
        "name": "SERT",
        "tok_span": [53, 55],
        "new_tok_span": [57, 59]
      }
    ],
    "relation_list": [
      {
        "subject": "RTI-76",
        "sbj_char_span": [75, 81],
        "object": "SERT",
        "obj_char_span": [141, 145],
        "rel_type": "regulator",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [38, 40],
        "new_sbj_tok_span": [18, 22],
        "new_obj_tok_span": [40, 42]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "RTI",
        "char_span": [75, 78],
        "sem_type": "Organic Chemical",
        "tok_span": [17, 19],
        "new_tok_span": [18, 20]
      },
      {
        "mention": "Kd",
        "char_span": [207, 209],
        "sem_type": "Gene or Genome",
        "tok_span": [51, 52],
        "new_tok_span": [54, 55]
      }
    ],
    "new_text": "Following 6 h of in vivo intracerebroventricular injections of 100 nmol of <START=Organic Chemical> RTI <END=Organic Chemical> - 76, there was a dose - and time - dependent reduction ( - 60 % ) of SERT binding in hippocampus and striatum, without a change in the <START=Gene or Genome> Kd <END=Gene or Genome>. SERT binding densities recovered over several days, reaching control levels by day 14."
  },
  {
    "PMID": 12901032,
    "id": 2,
    "text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [164, 173],
        "name": "salsalate",
        "tok_span": [30, 33],
        "new_tok_span": [33, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [178, 191],
        "name": "acetaminophen",
        "tok_span": [35, 38],
        "new_tok_span": [39, 42]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [211, 220],
        "name": "celecoxib",
        "tok_span": [41, 45],
        "new_tok_span": [45, 49]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [235, 244],
        "name": "rofecoxib",
        "tok_span": [50, 54],
        "new_tok_span": [54, 58]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [19, 27],
        "name": "warfarin",
        "tok_span": [3, 4],
        "new_tok_span": [3, 4]
      },
      {
        "ent_type": "GENE",
        "char_span": [62, 78],
        "name": "cyclooxygenase-2",
        "tok_span": [9, 13],
        "new_tok_span": [9, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [80, 85],
        "name": "COX-2",
        "tok_span": [14, 17],
        "new_tok_span": [14, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "salsalate",
        "sbj_char_span": [164, 173],
        "object": "cyclooxygenase-2",
        "obj_char_span": [62, 78],
        "rel_type": "inhibitor",
        "sbj_tok_span": [30, 33],
        "obj_tok_span": [9, 13],
        "new_sbj_tok_span": [33, 36],
        "new_obj_tok_span": [9, 13]
      },
      {
        "subject": "salsalate",
        "sbj_char_span": [164, 173],
        "object": "COX-2",
        "obj_char_span": [80, 85],
        "rel_type": "inhibitor",
        "sbj_tok_span": [30, 33],
        "obj_tok_span": [14, 17],
        "new_sbj_tok_span": [33, 36],
        "new_obj_tok_span": [14, 17]
      },
      {
        "subject": "acetaminophen",
        "sbj_char_span": [178, 191],
        "object": "cyclooxygenase-2",
        "obj_char_span": [62, 78],
        "rel_type": "inhibitor",
        "sbj_tok_span": [35, 38],
        "obj_tok_span": [9, 13],
        "new_sbj_tok_span": [39, 42],
        "new_obj_tok_span": [9, 13]
      },
      {
        "subject": "acetaminophen",
        "sbj_char_span": [178, 191],
        "object": "COX-2",
        "obj_char_span": [80, 85],
        "rel_type": "inhibitor",
        "sbj_tok_span": [35, 38],
        "obj_tok_span": [14, 17],
        "new_sbj_tok_span": [39, 42],
        "new_obj_tok_span": [14, 17]
      },
      {
        "subject": "celecoxib",
        "sbj_char_span": [211, 220],
        "object": "cyclooxygenase-2",
        "obj_char_span": [62, 78],
        "rel_type": "inhibitor",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [9, 13],
        "new_sbj_tok_span": [45, 49],
        "new_obj_tok_span": [9, 13]
      },
      {
        "subject": "celecoxib",
        "sbj_char_span": [211, 220],
        "object": "COX-2",
        "obj_char_span": [80, 85],
        "rel_type": "inhibitor",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [14, 17],
        "new_sbj_tok_span": [45, 49],
        "new_obj_tok_span": [14, 17]
      },
      {
        "subject": "rofecoxib",
        "sbj_char_span": [235, 244],
        "object": "cyclooxygenase-2",
        "obj_char_span": [62, 78],
        "rel_type": "inhibitor",
        "sbj_tok_span": [50, 54],
        "obj_tok_span": [9, 13],
        "new_sbj_tok_span": [54, 58],
        "new_obj_tok_span": [9, 13]
      },
      {
        "subject": "rofecoxib",
        "sbj_char_span": [235, 244],
        "object": "COX-2",
        "obj_char_span": [80, 85],
        "rel_type": "inhibitor",
        "sbj_tok_span": [50, 54],
        "obj_tok_span": [14, 17],
        "new_sbj_tok_span": [54, 58],
        "new_obj_tok_span": [14, 17]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "nonsteroidal antiinflammatory medications",
        "char_span": [121, 162],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [23, 29],
        "new_tok_span": [24, 30]
      },
      {
        "mention": "salsalate",
        "char_span": [164, 173],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [30, 33],
        "new_tok_span": [33, 36]
      }
    ],
    "new_text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase - 2 ( COX - 2 ) inhibitor comparator ( traditional <START=Pharmacologic Substance> nonsteroidal antiinflammatory medications <END=Pharmacologic Substance>, <START=Pharmacologic Substance> salsalate <END=Pharmacologic Substance>, or acetaminophen ) randomly received celecoxib 200 mg / day or rofecoxib 25 mg / day for three weeks."
  },
  {
    "PMID": 12181285,
    "id": 1,
    "text": "Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT, uptake 1).",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 133],
        "name": "noradrenaline",
        "tok_span": [27, 30],
        "new_tok_span": [27, 30]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [26, 39],
        "name": "noradrenaline",
        "tok_span": [5, 8],
        "new_tok_span": [5, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [41, 43],
        "name": "NA",
        "tok_span": [9, 10],
        "new_tok_span": [9, 10]
      },
      {
        "ent_type": "GENE",
        "char_span": [120, 145],
        "name": "noradrenaline transporter",
        "tok_span": [27, 31],
        "new_tok_span": [27, 31]
      },
      {
        "ent_type": "GENE",
        "char_span": [147, 150],
        "name": "NAT",
        "tok_span": [32, 33],
        "new_tok_span": [32, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "noradrenaline",
        "sbj_char_span": [26, 39],
        "object": "noradrenaline transporter",
        "obj_char_span": [120, 145],
        "rel_type": "product or substrate",
        "sbj_tok_span": [5, 8],
        "obj_tok_span": [27, 31],
        "new_sbj_tok_span": [5, 8],
        "new_obj_tok_span": [27, 31]
      },
      {
        "subject": "noradrenaline",
        "sbj_char_span": [26, 39],
        "object": "NAT",
        "obj_char_span": [147, 150],
        "rel_type": "product or substrate",
        "sbj_tok_span": [5, 8],
        "obj_tok_span": [32, 33],
        "new_sbj_tok_span": [5, 8],
        "new_obj_tok_span": [32, 33]
      },
      {
        "subject": "NA",
        "sbj_char_span": [41, 43],
        "object": "noradrenaline transporter",
        "obj_char_span": [120, 145],
        "rel_type": "product or substrate",
        "sbj_tok_span": [9, 10],
        "obj_tok_span": [27, 31],
        "new_sbj_tok_span": [9, 10],
        "new_obj_tok_span": [27, 31]
      },
      {
        "subject": "NA",
        "sbj_char_span": [41, 43],
        "object": "NAT",
        "obj_char_span": [147, 150],
        "rel_type": "product or substrate",
        "sbj_tok_span": [9, 10],
        "obj_tok_span": [32, 33],
        "new_sbj_tok_span": [9, 10],
        "new_obj_tok_span": [32, 33]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Reuptake of extracellular noradrenaline ( NA ) into superior cervical ganglion ( SCG ) neurones is mediated by means of the noradrenaline transporter ( NAT, uptake 1 )."
  },
  {
    "PMID": 15474503,
    "id": 3,
    "text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the apoA-I induction pitavastatin (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM). The induction of apoA-I by statins disappeared with addition of mevalonate, which indicates that the effect is HMG-CoA reductase inhibition-dependent.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [114, 126],
        "name": "pitavastatin",
        "tok_span": [28, 32],
        "new_tok_span": [35, 39]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [138, 149],
        "name": "simvastatin",
        "tok_span": [38, 40],
        "new_tok_span": [46, 48]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [162, 174],
        "name": "atorvastatin",
        "tok_span": [46, 49],
        "new_tok_span": [54, 57]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [252, 262],
        "name": "mevalonate",
        "tok_span": [68, 71],
        "new_tok_span": [79, 82]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [299, 306],
        "name": "HMG-CoA",
        "tok_span": [78, 83],
        "new_tok_span": [90, 95]
      },
      {
        "ent_type": "GENE",
        "char_span": [20, 26],
        "name": "apoA-I",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [97, 103],
        "name": "apoA-I",
        "tok_span": [23, 27],
        "new_tok_span": [28, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [205, 211],
        "name": "apoA-I",
        "tok_span": [58, 62],
        "new_tok_span": [67, 71]
      },
      {
        "ent_type": "GENE",
        "char_span": [299, 316],
        "name": "HMG-CoA reductase",
        "tok_span": [78, 84],
        "new_tok_span": [90, 96]
      }
    ],
    "relation_list": [
      {
        "subject": "pitavastatin",
        "sbj_char_span": [114, 126],
        "object": "apoA-I",
        "obj_char_span": [97, 103],
        "rel_type": "regulator",
        "sbj_tok_span": [28, 32],
        "obj_tok_span": [23, 27],
        "new_sbj_tok_span": [35, 39],
        "new_obj_tok_span": [28, 32]
      },
      {
        "subject": "simvastatin",
        "sbj_char_span": [138, 149],
        "object": "apoA-I",
        "obj_char_span": [97, 103],
        "rel_type": "regulator",
        "sbj_tok_span": [38, 40],
        "obj_tok_span": [23, 27],
        "new_sbj_tok_span": [46, 48],
        "new_obj_tok_span": [28, 32]
      },
      {
        "subject": "atorvastatin",
        "sbj_char_span": [162, 174],
        "object": "apoA-I",
        "obj_char_span": [97, 103],
        "rel_type": "regulator",
        "sbj_tok_span": [46, 49],
        "obj_tok_span": [23, 27],
        "new_sbj_tok_span": [54, 57],
        "new_obj_tok_span": [28, 32]
      },
      {
        "subject": "mevalonate",
        "sbj_char_span": [252, 262],
        "object": "apoA-I",
        "obj_char_span": [205, 211],
        "rel_type": "regulator",
        "sbj_tok_span": [68, 71],
        "obj_tok_span": [58, 62],
        "new_sbj_tok_span": [79, 82],
        "new_obj_tok_span": [67, 71]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "apoA-I",
        "char_span": [20, 26],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [3, 7],
        "new_tok_span": [4, 8]
      },
      {
        "mention": "apoA-I",
        "char_span": [97, 103],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [23, 27],
        "new_tok_span": [28, 32]
      },
      {
        "mention": "apoA-I",
        "char_span": [205, 211],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [58, 62],
        "new_tok_span": [67, 71]
      },
      {
        "mention": "rank",
        "char_span": [79, 83],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [19, 20],
        "new_tok_span": [22, 23]
      },
      {
        "mention": "pitavastatin",
        "char_span": [114, 126],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [28, 32],
        "new_tok_span": [35, 39]
      },
      {
        "mention": "mevalonate",
        "char_span": [252, 262],
        "sem_type": "Organic Chemical",
        "tok_span": [68, 71],
        "new_tok_span": [79, 82]
      }
    ],
    "new_text": "Each statin induced <START=Amino Acid, Peptide, or Protein> apoA - I <END=Amino Acid, Peptide, or Protein> expression ( mRNA and protein ) dose - dependently : the <START=Amino Acid, Peptide, or Protein> rank <END=Amino Acid, Peptide, or Protein> order of the <START=Amino Acid, Peptide, or Protein> apoA - I <END=Amino Acid, Peptide, or Protein> induction <START=Pharmacologic Substance> pitavastatin <END=Pharmacologic Substance> ( 3 microM ) > simvastatin ( 10 microM ) > atorvastatin ( 30 microM ). The induction of <START=Amino Acid, Peptide, or Protein> apoA - I <END=Amino Acid, Peptide, or Protein> by statins disappeared with addition of <START=Organic Chemical> mevalonate <END=Organic Chemical>, which indicates that the effect is HMG - CoA reductase inhibition - dependent."
  },
  {
    "PMID": 3345199,
    "id": 3,
    "text": "The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of soman-inhibited, solubilized AChE from human erythrocytes was investigated in vitro.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [23, 55],
        "name": "mono- and bisquaternary ammonium",
        "tok_span": [5, 13],
        "new_tok_span": [5, 13]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [66, 85],
        "name": "tetramethylammonium",
        "tok_span": [14, 18],
        "new_tok_span": [17, 21]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [87, 90],
        "name": "TMA",
        "tok_span": [19, 21],
        "new_tok_span": [24, 26]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [93, 106],
        "name": "hexamethonium",
        "tok_span": [23, 27],
        "new_tok_span": [29, 33]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [108, 121],
        "name": "decamethonium",
        "tok_span": [28, 32],
        "new_tok_span": [34, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [126, 139],
        "name": "suxamethonium",
        "tok_span": [33, 38],
        "new_tok_span": [40, 45]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [167, 172],
        "name": "soman",
        "tok_span": [45, 47],
        "new_tok_span": [54, 56]
      },
      {
        "ent_type": "GENE",
        "char_span": [196, 200],
        "name": "AChE",
        "tok_span": [52, 54],
        "new_tok_span": [62, 64]
      }
    ],
    "relation_list": [
      {
        "subject": "soman",
        "sbj_char_span": [167, 172],
        "object": "AChE",
        "obj_char_span": [196, 200],
        "rel_type": "inhibitor",
        "sbj_tok_span": [45, 47],
        "obj_tok_span": [52, 54],
        "new_sbj_tok_span": [54, 56],
        "new_obj_tok_span": [62, 64]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "bisquaternary ammonium compounds",
        "char_span": [33, 65],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [8, 14],
        "new_tok_span": [9, 15]
      },
      {
        "mention": "tetramethylammonium",
        "char_span": [66, 85],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [14, 18],
        "new_tok_span": [17, 21]
      },
      {
        "mention": "TMA",
        "char_span": [87, 90],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [19, 21],
        "new_tok_span": [24, 26]
      },
      {
        "mention": "suxamethonium",
        "char_span": [126, 139],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [33, 38],
        "new_tok_span": [40, 45]
      },
      {
        "mention": "soman",
        "char_span": [167, 172],
        "sem_type": "Organic Chemical",
        "tok_span": [45, 47],
        "new_tok_span": [54, 56]
      }
    ],
    "new_text": "The effect of the four mono - and <START=Pharmacologic Substance> bisquaternary ammonium compounds <END=Pharmacologic Substance> <START=Pharmacologic Substance> tetramethylammonium <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> TMA <END=Pharmacologic Substance> ), hexamethonium, decamethonium and <START=Pharmacologic Substance> suxamethonium <END=Pharmacologic Substance> on the reactivatability of <START=Organic Chemical> soman <END=Organic Chemical> - inhibited, solubilized AChE from human erythrocytes was investigated in vitro."
  },
  {
    "PMID": 23395914,
    "id": 7,
    "text": "Involvement of P450 mediated metabolism in the absorption of darunavir could not be demonstrated in this rat model.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [61, 70],
        "name": "darunavir",
        "tok_span": [12, 15],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [15, 19],
        "name": "P450",
        "tok_span": [4, 6],
        "new_tok_span": [5, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "darunavir",
        "sbj_char_span": [61, 70],
        "object": "P450",
        "obj_char_span": [15, 19],
        "rel_type": "product or substrate",
        "sbj_tok_span": [12, 15],
        "obj_tok_span": [4, 6],
        "new_sbj_tok_span": [15, 18],
        "new_obj_tok_span": [5, 7]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "P450",
        "char_span": [15, 19],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [4, 6],
        "new_tok_span": [5, 7]
      },
      {
        "mention": "darunavir",
        "char_span": [61, 70],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [12, 15],
        "new_tok_span": [15, 18]
      }
    ],
    "new_text": "Involvement of <START=Amino Acid, Peptide, or Protein> P450 <END=Amino Acid, Peptide, or Protein> mediated metabolism in the absorption of <START=Pharmacologic Substance> darunavir <END=Pharmacologic Substance> could not be demonstrated in this rat model."
  },
  {
    "PMID": 23623750,
    "id": 8,
    "text": "Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [9, 20],
        "name": "benzydamine",
        "tok_span": [2, 5],
        "new_tok_span": [3, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [21, 22],
        "name": "N",
        "tok_span": [5, 6],
        "new_tok_span": [7, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [228, 239],
        "name": "benzydamine",
        "tok_span": [50, 53],
        "new_tok_span": [57, 60]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [240, 241],
        "name": "N",
        "tok_span": [53, 54],
        "new_tok_span": [61, 62]
      },
      {
        "ent_type": "GENE",
        "char_span": [49, 53],
        "name": "FMO3",
        "tok_span": [11, 14],
        "new_tok_span": [14, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [156, 160],
        "name": "FMO3",
        "tok_span": [36, 39],
        "new_tok_span": [41, 44]
      },
      {
        "ent_type": "GENE",
        "char_span": [300, 304],
        "name": "FMO3",
        "tok_span": [64, 67],
        "new_tok_span": [73, 76]
      }
    ],
    "relation_list": [
      {
        "subject": "benzydamine",
        "sbj_char_span": [9, 20],
        "object": "FMO3",
        "obj_char_span": [49, 53],
        "rel_type": "product or substrate",
        "sbj_tok_span": [2, 5],
        "obj_tok_span": [11, 14],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [14, 17]
      },
      {
        "subject": "N",
        "sbj_char_span": [21, 22],
        "object": "FMO3",
        "obj_char_span": [49, 53],
        "rel_type": "product or substrate",
        "sbj_tok_span": [5, 6],
        "obj_tok_span": [11, 14],
        "new_sbj_tok_span": [7, 8],
        "new_obj_tok_span": [14, 17]
      },
      {
        "subject": "benzydamine",
        "sbj_char_span": [228, 239],
        "object": "FMO3",
        "obj_char_span": [300, 304],
        "rel_type": "product or substrate",
        "sbj_tok_span": [50, 53],
        "obj_tok_span": [64, 67],
        "new_sbj_tok_span": [57, 60],
        "new_obj_tok_span": [73, 76]
      },
      {
        "subject": "N",
        "sbj_char_span": [240, 241],
        "object": "FMO3",
        "obj_char_span": [300, 304],
        "rel_type": "product or substrate",
        "sbj_tok_span": [53, 54],
        "obj_tok_span": [64, 67],
        "new_sbj_tok_span": [61, 62],
        "new_obj_tok_span": [73, 76]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "benzydamine",
        "char_span": [9, 20],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [2, 5],
        "new_tok_span": [3, 6]
      },
      {
        "mention": "benzydamine",
        "char_span": [228, 239],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [50, 53],
        "new_tok_span": [57, 60]
      },
      {
        "mention": "FMO3",
        "char_span": [49, 53],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [11, 14],
        "new_tok_span": [14, 17]
      },
      {
        "mention": "FMO3",
        "char_span": [156, 160],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [36, 39],
        "new_tok_span": [41, 44]
      },
      {
        "mention": "FMO3",
        "char_span": [300, 304],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [64, 67],
        "new_tok_span": [73, 76]
      }
    ],
    "new_text": "Rates of <START=Pharmacologic Substance> benzydamine <END=Pharmacologic Substance> N - oxygenation ( catalyzed by <START=Pharmacologic Substance> FMO3 <END=Pharmacologic Substance> ) varied ( approximately 20 - fold ) among the 28 cynomolgus livers and were significantly correlated with <START=Pharmacologic Substance> FMO3 <END=Pharmacologic Substance> protein expression, indicating that the inter - animal variations in <START=Pharmacologic Substance> benzydamine <END=Pharmacologic Substance> N - oxygenation might be partly accounted for by the variable <START=Pharmacologic Substance> FMO3 <END=Pharmacologic Substance> expression."
  },
  {
    "PMID": 23099431,
    "id": 1,
    "text": "GHRP-6 is a growth hormone secretagogue that also enhances tissue viability in different organs.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 6],
        "name": "GHRP-6",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [12, 26],
        "name": "growth hormone",
        "tok_span": [6, 8],
        "new_tok_span": [9, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "GHRP-6",
        "sbj_char_span": [0, 6],
        "object": "growth hormone",
        "obj_char_span": [12, 26],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [6, 8],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [9, 11]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "GHRP-6",
        "char_span": [0, 6],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "mention": "growth hormone secretagogue",
        "char_span": [12, 39],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [6, 11],
        "new_tok_span": [9, 14]
      }
    ],
    "new_text": "<START=Amino Acid, Peptide, or Protein> GHRP - 6 <END=Amino Acid, Peptide, or Protein> is a <START=Amino Acid, Peptide, or Protein> growth hormone secretagogue <END=Amino Acid, Peptide, or Protein> that also enhances tissue viability in different organs."
  },
  {
    "PMID": 23044488,
    "id": 0,
    "text": "Amino acid residues at the N- and C-termini are essential for the folding of active human butyrylcholinesterase polypeptide.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 10],
        "name": "Amino acid",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [84, 111],
        "name": "human butyrylcholinesterase",
        "tok_span": [20, 27],
        "new_tok_span": [20, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "Amino acid",
        "sbj_char_span": [0, 10],
        "object": "human butyrylcholinesterase",
        "obj_char_span": [84, 111],
        "rel_type": "part of",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [20, 27],
        "new_sbj_tok_span": [0, 3],
        "new_obj_tok_span": [20, 27]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "butyrylcholinesterase",
        "char_span": [90, 111],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [21, 27],
        "new_tok_span": [23, 29]
      },
      {
        "mention": "polypeptide",
        "char_span": [112, 123],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [27, 28],
        "new_tok_span": [32, 33]
      },
      {
        "mention": "butyrylcholinesterase",
        "char_span": [90, 111],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 27],
        "new_tok_span": [23, 29]
      }
    ],
    "new_text": "Amino acid residues at the N - and C - termini are essential for the folding of active human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> butyrylcholinesterase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> polypeptide <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 23146664,
    "id": 11,
    "text": "PAK1 expression was elevated in APC(min) polyps and 5-ASA treatment reduced its expression.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [52, 57],
        "name": "5-ASA",
        "tok_span": [13, 16],
        "new_tok_span": [21, 24]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 4],
        "name": "PAK1",
        "tok_span": [0, 3],
        "new_tok_span": [2, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "5-ASA",
        "sbj_char_span": [52, 57],
        "object": "PAK1",
        "obj_char_span": [0, 4],
        "rel_type": "regulator",
        "sbj_tok_span": [13, 16],
        "obj_tok_span": [0, 3],
        "new_sbj_tok_span": [21, 24],
        "new_obj_tok_span": [2, 5]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PAK1",
        "char_span": [0, 4],
        "sem_type": "Gene or Genome",
        "tok_span": [0, 3],
        "new_tok_span": [2, 5]
      },
      {
        "mention": "PAK1",
        "char_span": [0, 4],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 3],
        "new_tok_span": [2, 5]
      },
      {
        "mention": "APC",
        "char_span": [32, 35],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [7, 8],
        "new_tok_span": [13, 14]
      },
      {
        "mention": "APC",
        "char_span": [32, 35],
        "sem_type": "Gene or Genome",
        "tok_span": [7, 8],
        "new_tok_span": [13, 14]
      }
    ],
    "new_text": "<START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PAK1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> expression was elevated in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> APC <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( min ) polyps and 5 - ASA treatment reduced its expression."
  },
  {
    "PMID": 23523949,
    "id": 7,
    "text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN. In summary, DZN induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 6],
        "name": "Crocin",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [27, 36],
        "name": "vitamin E",
        "tok_span": [11, 13],
        "new_tok_span": [13, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [83, 86],
        "name": "MDA",
        "tok_span": [19, 20],
        "new_tok_span": [21, 22]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [108, 111],
        "name": "GSH",
        "tok_span": [26, 27],
        "new_tok_span": [30, 31]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [245, 248],
        "name": "DZN",
        "tok_span": [53, 56],
        "new_tok_span": [57, 60]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [262, 265],
        "name": "DZN",
        "tok_span": [60, 63],
        "new_tok_span": [64, 67]
      },
      {
        "ent_type": "GENE",
        "char_span": [91, 96],
        "name": "CK-MB",
        "tok_span": [21, 24],
        "new_tok_span": [24, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [151, 154],
        "name": "Bax",
        "tok_span": [33, 34],
        "new_tok_span": [37, 38]
      },
      {
        "ent_type": "GENE",
        "char_span": [155, 159],
        "name": "Bcl2",
        "tok_span": [35, 37],
        "new_tok_span": [39, 41]
      },
      {
        "ent_type": "GENE",
        "char_span": [181, 190],
        "name": "caspase 3",
        "tok_span": [41, 43],
        "new_tok_span": [45, 47]
      },
      {
        "ent_type": "GENE",
        "char_span": [206, 218],
        "name": "cytochrome c",
        "tok_span": [46, 48],
        "new_tok_span": [50, 52]
      }
    ],
    "relation_list": [
      {
        "subject": "DZN",
        "sbj_char_span": [245, 248],
        "object": "caspase 3",
        "obj_char_span": [181, 190],
        "rel_type": "activator",
        "sbj_tok_span": [53, 56],
        "obj_tok_span": [41, 43],
        "new_sbj_tok_span": [57, 60],
        "new_obj_tok_span": [45, 47]
      },
      {
        "subject": "Crocin",
        "sbj_char_span": [0, 6],
        "object": "caspase 3",
        "obj_char_span": [181, 190],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [41, 43],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [45, 47]
      },
      {
        "subject": "vitamin E",
        "sbj_char_span": [27, 36],
        "object": "caspase 3",
        "obj_char_span": [181, 190],
        "rel_type": "regulator",
        "sbj_tok_span": [11, 13],
        "obj_tok_span": [41, 43],
        "new_sbj_tok_span": [13, 15],
        "new_obj_tok_span": [45, 47]
      },
      {
        "subject": "DZN",
        "sbj_char_span": [245, 248],
        "object": "cytochrome c",
        "obj_char_span": [206, 218],
        "rel_type": "regulator",
        "sbj_tok_span": [53, 56],
        "obj_tok_span": [46, 48],
        "new_sbj_tok_span": [57, 60],
        "new_obj_tok_span": [50, 52]
      },
      {
        "subject": "Crocin",
        "sbj_char_span": [0, 6],
        "object": "CK-MB",
        "obj_char_span": [91, 96],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [21, 24],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [24, 27]
      },
      {
        "subject": "Crocin",
        "sbj_char_span": [0, 6],
        "object": "Bax",
        "obj_char_span": [151, 154],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [33, 34],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [37, 38]
      },
      {
        "subject": "Crocin",
        "sbj_char_span": [0, 6],
        "object": "Bcl2",
        "obj_char_span": [155, 159],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [35, 37],
        "new_sbj_tok_span": [1, 3],
        "new_obj_tok_span": [39, 41]
      },
      {
        "subject": "vitamin E",
        "sbj_char_span": [27, 36],
        "object": "CK-MB",
        "obj_char_span": [91, 96],
        "rel_type": "regulator",
        "sbj_tok_span": [11, 13],
        "obj_tok_span": [21, 24],
        "new_sbj_tok_span": [13, 15],
        "new_obj_tok_span": [24, 27]
      },
      {
        "subject": "vitamin E",
        "sbj_char_span": [27, 36],
        "object": "Bax",
        "obj_char_span": [151, 154],
        "rel_type": "regulator",
        "sbj_tok_span": [11, 13],
        "obj_tok_span": [33, 34],
        "new_sbj_tok_span": [13, 15],
        "new_obj_tok_span": [37, 38]
      },
      {
        "subject": "vitamin E",
        "sbj_char_span": [27, 36],
        "object": "Bcl2",
        "obj_char_span": [155, 159],
        "rel_type": "regulator",
        "sbj_tok_span": [11, 13],
        "obj_tok_span": [35, 37],
        "new_sbj_tok_span": [13, 15],
        "new_obj_tok_span": [39, 41]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Crocin",
        "char_span": [0, 6],
        "sem_type": "Organic Chemical",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "mention": "CK-MB",
        "char_span": [91, 96],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [21, 24],
        "new_tok_span": [24, 27]
      }
    ],
    "new_text": "<START=Organic Chemical> Crocin <END=Organic Chemical> ( 25 and 50mg / kg ) or vitamin E improved histopathological damages, decreased MDA and <START=Amino Acid, Peptide, or Protein> CK - MB <END=Amino Acid, Peptide, or Protein>, increased GSH content and attenuated the increase of Bax / Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN. In summary, DZN induced mitochondrial - mediated apoptosis in heart tissue of rat following subchronic exposure."
  },
  {
    "PMID": 22872607,
    "id": 1,
    "text": "Aldo-keto reductases (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Aldo-keto",
        "tok_span": [0, 5],
        "new_tok_span": [1, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [111, 115],
        "name": "PAHs",
        "tok_span": [25, 27],
        "new_tok_span": [27, 29]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [142, 152],
        "name": "o-quinones",
        "tok_span": [32, 36],
        "new_tok_span": [34, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [167, 173],
        "name": "oxygen",
        "tok_span": [39, 40],
        "new_tok_span": [41, 42]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [77, 109],
        "name": "polycyclic aromatic hydrocarbons",
        "tok_span": [20, 24],
        "new_tok_span": [22, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 20],
        "name": "Aldo-keto reductases",
        "tok_span": [0, 7],
        "new_tok_span": [1, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [22, 26],
        "name": "AKRs",
        "tok_span": [8, 10],
        "new_tok_span": [10, 12]
      }
    ],
    "relation_list": [
      {
        "subject": "oxygen",
        "sbj_char_span": [167, 173],
        "object": "Aldo-keto reductases",
        "obj_char_span": [0, 20],
        "rel_type": "product or substrate",
        "sbj_tok_span": [39, 40],
        "obj_tok_span": [0, 7],
        "new_sbj_tok_span": [41, 42],
        "new_obj_tok_span": [1, 8]
      },
      {
        "subject": "oxygen",
        "sbj_char_span": [167, 173],
        "object": "AKRs",
        "obj_char_span": [22, 26],
        "rel_type": "product or substrate",
        "sbj_tok_span": [39, 40],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [41, 42],
        "new_obj_tok_span": [10, 12]
      },
      {
        "subject": "polycyclic aromatic hydrocarbons",
        "sbj_char_span": [77, 109],
        "object": "Aldo-keto reductases",
        "obj_char_span": [0, 20],
        "rel_type": "product or substrate",
        "sbj_tok_span": [20, 24],
        "obj_tok_span": [0, 7],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [1, 8]
      },
      {
        "subject": "polycyclic aromatic hydrocarbons",
        "sbj_char_span": [77, 109],
        "object": "AKRs",
        "obj_char_span": [22, 26],
        "rel_type": "product or substrate",
        "sbj_tok_span": [20, 24],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [10, 12]
      },
      {
        "subject": "PAHs",
        "sbj_char_span": [111, 115],
        "object": "Aldo-keto reductases",
        "obj_char_span": [0, 20],
        "rel_type": "product or substrate",
        "sbj_tok_span": [25, 27],
        "obj_tok_span": [0, 7],
        "new_sbj_tok_span": [27, 29],
        "new_obj_tok_span": [1, 8]
      },
      {
        "subject": "PAHs",
        "sbj_char_span": [111, 115],
        "object": "AKRs",
        "obj_char_span": [22, 26],
        "rel_type": "product or substrate",
        "sbj_tok_span": [25, 27],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [27, 29],
        "new_obj_tok_span": [10, 12]
      },
      {
        "subject": "o-quinones",
        "sbj_char_span": [142, 152],
        "object": "Aldo-keto reductases",
        "obj_char_span": [0, 20],
        "rel_type": "product or substrate",
        "sbj_tok_span": [32, 36],
        "obj_tok_span": [0, 7],
        "new_sbj_tok_span": [34, 38],
        "new_obj_tok_span": [1, 8]
      },
      {
        "subject": "o-quinones",
        "sbj_char_span": [142, 152],
        "object": "AKRs",
        "obj_char_span": [22, 26],
        "rel_type": "product or substrate",
        "sbj_tok_span": [32, 36],
        "obj_tok_span": [8, 10],
        "new_sbj_tok_span": [34, 38],
        "new_obj_tok_span": [10, 12]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Aldo-keto",
        "char_span": [0, 9],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 5],
        "new_tok_span": [1, 6]
      }
    ],
    "new_text": "<START=Amino Acid, Peptide, or Protein> Aldo - keto <END=Amino Acid, Peptide, or Protein> reductases ( AKRs ) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ( PAHs ), generating metabolites ( o - quinones ) and reactive oxygen species ( ROS ), which are capable of initiating and promoting carcinogenesis."
  },
  {
    "PMID": 15777622,
    "id": 5,
    "text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the SGLT1-dependent methyl alpha-D-glucopyranoside (AMG) uptake and levels of SGLT1 expression were determined.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [136, 139],
        "name": "GMC",
        "tok_span": [30, 32],
        "new_tok_span": [36, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [165, 195],
        "name": "methyl alpha-D-glucopyranoside",
        "tok_span": [40, 48],
        "new_tok_span": [50, 58]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [197, 200],
        "name": "AMG",
        "tok_span": [49, 51],
        "new_tok_span": [60, 62]
      },
      {
        "ent_type": "GENE",
        "char_span": [59, 64],
        "name": "apoE3",
        "tok_span": [9, 12],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [66, 77],
        "name": "lactoferrin",
        "tok_span": [13, 17],
        "new_tok_span": [15, 19]
      },
      {
        "ent_type": "GENE",
        "char_span": [82, 102],
        "name": "bovine serum albumin",
        "tok_span": [18, 21],
        "new_tok_span": [23, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [149, 154],
        "name": "SGLT1",
        "tok_span": [35, 38],
        "new_tok_span": [43, 46]
      },
      {
        "ent_type": "GENE",
        "char_span": [223, 228],
        "name": "SGLT1",
        "tok_span": [56, 59],
        "new_tok_span": [70, 73]
      }
    ],
    "relation_list": [
      {
        "subject": "methyl alpha-D-glucopyranoside",
        "sbj_char_span": [165, 195],
        "object": "SGLT1",
        "obj_char_span": [149, 154],
        "rel_type": "product or substrate",
        "sbj_tok_span": [40, 48],
        "obj_tok_span": [35, 38],
        "new_sbj_tok_span": [50, 58],
        "new_obj_tok_span": [43, 46]
      },
      {
        "subject": "AMG",
        "sbj_char_span": [197, 200],
        "object": "SGLT1",
        "obj_char_span": [149, 154],
        "rel_type": "product or substrate",
        "sbj_tok_span": [49, 51],
        "obj_tok_span": [35, 38],
        "new_sbj_tok_span": [60, 62],
        "new_obj_tok_span": [43, 46]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "lactoferrin",
        "char_span": [66, 77],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [13, 17],
        "new_tok_span": [15, 19]
      },
      {
        "mention": "lactoferrin",
        "char_span": [66, 77],
        "sem_type": "Gene or Genome",
        "tok_span": [13, 17],
        "new_tok_span": [15, 19]
      },
      {
        "mention": "bovine serum albumin",
        "char_span": [82, 102],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [18, 21],
        "new_tok_span": [23, 26]
      },
      {
        "mention": "SGLT1",
        "char_span": [149, 154],
        "sem_type": "Gene or Genome",
        "tok_span": [35, 38],
        "new_tok_span": [43, 46]
      },
      {
        "mention": "SGLT1",
        "char_span": [223, 228],
        "sem_type": "Gene or Genome",
        "tok_span": [56, 59],
        "new_tok_span": [70, 73]
      },
      {
        "mention": "SGLT1",
        "char_span": [149, 154],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [35, 38],
        "new_tok_span": [43, 46]
      },
      {
        "mention": "SGLT1",
        "char_span": [223, 228],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [56, 59],
        "new_tok_span": [70, 73]
      },
      {
        "mention": "AMG",
        "char_span": [197, 200],
        "sem_type": "Gene or Genome",
        "tok_span": [49, 51],
        "new_tok_span": [60, 62]
      }
    ],
    "new_text": "Then the cells were treated with various concentrations of apoE3, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> lactoferrin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> bovine serum albumin <END=Amino Acid, Peptide, or Protein> with or without 100 microg / ml of GMC, and the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SGLT1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - dependent methyl alpha - D - glucopyranoside ( <START=Gene or Genome> AMG <END=Gene or Genome> ) uptake and levels of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SGLT1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> expression were determined."
  },
  {
    "PMID": 17488480,
    "id": 5,
    "text": "Caerulein increased the levels of H(2)S and CSE mRNA expression while CBS mRNA expression was decreased.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Caerulein",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [34, 39],
        "name": "H(2)S",
        "tok_span": [8, 13],
        "new_tok_span": [8, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [44, 47],
        "name": "CSE",
        "tok_span": [14, 16],
        "new_tok_span": [14, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [70, 73],
        "name": "CBS",
        "tok_span": [19, 21],
        "new_tok_span": [19, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "Caerulein",
        "sbj_char_span": [0, 9],
        "object": "CSE",
        "obj_char_span": [44, 47],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [14, 16],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [14, 16]
      },
      {
        "subject": "Caerulein",
        "sbj_char_span": [0, 9],
        "object": "CBS",
        "obj_char_span": [70, 73],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [19, 21],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [19, 21]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Caerulein increased the levels of H ( 2 ) S and CSE mRNA expression while CBS mRNA expression was decreased."
  },
  {
    "PMID": 11775064,
    "id": 2,
    "text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T). 2.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [52, 56],
        "name": "GABA",
        "tok_span": [8, 9],
        "new_tok_span": [11, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [138, 142],
        "name": "GABA",
        "tok_span": [28, 29],
        "new_tok_span": [37, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [164, 168],
        "name": "GABA",
        "tok_span": [33, 34],
        "new_tok_span": [44, 45]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [18, 21],
        "name": "PLZ",
        "tok_span": [3, 5],
        "new_tok_span": [5, 7]
      },
      {
        "ent_type": "GENE",
        "char_span": [164, 181],
        "name": "GABA transaminase",
        "tok_span": [33, 36],
        "new_tok_span": [44, 47]
      },
      {
        "ent_type": "GENE",
        "char_span": [183, 189],
        "name": "GABA-T",
        "tok_span": [37, 40],
        "new_tok_span": [52, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "GABA",
        "sbj_char_span": [138, 142],
        "object": "GABA transaminase",
        "obj_char_span": [164, 181],
        "rel_type": "product or substrate",
        "sbj_tok_span": [28, 29],
        "obj_tok_span": [33, 36],
        "new_sbj_tok_span": [37, 38],
        "new_obj_tok_span": [44, 47]
      },
      {
        "subject": "GABA",
        "sbj_char_span": [138, 142],
        "object": "GABA-T",
        "obj_char_span": [183, 189],
        "rel_type": "product or substrate",
        "sbj_tok_span": [28, 29],
        "obj_tok_span": [37, 40],
        "new_sbj_tok_span": [37, 38],
        "new_obj_tok_span": [52, 55]
      },
      {
        "subject": "PLZ",
        "sbj_char_span": [18, 21],
        "object": "GABA transaminase",
        "obj_char_span": [164, 181],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 5],
        "obj_tok_span": [33, 36],
        "new_sbj_tok_span": [5, 7],
        "new_obj_tok_span": [44, 47]
      },
      {
        "subject": "PLZ",
        "sbj_char_span": [18, 21],
        "object": "GABA-T",
        "obj_char_span": [183, 189],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 5],
        "obj_tok_span": [37, 40],
        "new_sbj_tok_span": [5, 7],
        "new_obj_tok_span": [52, 55]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "GABA",
        "char_span": [52, 56],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [8, 9],
        "new_tok_span": [11, 12]
      },
      {
        "mention": "GABA",
        "char_span": [138, 142],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [28, 29],
        "new_tok_span": [37, 38]
      },
      {
        "mention": "GABA",
        "char_span": [164, 168],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [33, 34],
        "new_tok_span": [44, 45]
      },
      {
        "mention": "GABA",
        "char_span": [183, 187],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [37, 38],
        "new_tok_span": [52, 53]
      },
      {
        "mention": "an",
        "char_span": [6, 8],
        "sem_type": "Gene or Genome",
        "tok_span": [1, 2],
        "new_tok_span": [2, 3]
      },
      {
        "mention": "an",
        "char_span": [65, 67],
        "sem_type": "Gene or Genome",
        "tok_span": [11, 12],
        "new_tok_span": [16, 17]
      },
      {
        "mention": "an",
        "char_span": [101, 103],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 22],
        "new_tok_span": [28, 29]
      },
      {
        "mention": "an",
        "char_span": [171, 173],
        "sem_type": "Gene or Genome",
        "tok_span": [34, 35],
        "new_tok_span": [47, 48]
      }
    ],
    "new_text": "Acute <START=Gene or Genome> and <END=Gene or Genome> chronic PLZ administration increase brain <START=Amino Acid, Peptide, or Protein> GABA <END=Amino Acid, Peptide, or Protein> levels, <START=Gene or Genome> an <END=Gene or Genome> effect due, at least in part, to <START=Gene or Genome> an <END=Gene or Genome> inhibition of the activity of the <START=Amino Acid, Peptide, or Protein> GABA <END=Amino Acid, Peptide, or Protein> metabolizing enzyme, <START=Amino Acid, Peptide, or Protein> GABA <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> trans <END=Gene or Genome>aminase ( <START=Amino Acid, Peptide, or Protein> GABA <END=Amino Acid, Peptide, or Protein> - T ). 2."
  },
  {
    "PMID": 23618901,
    "id": 9,
    "text": "Suppression of TβR1 by the pharmacological inhibitor (SB431542) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by TβR1 siRNA. In contrast, nicotine inhibited VEGF release by HFL-1 in a dose and time dependent manner.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [54, 62],
        "name": "SB431542",
        "tok_span": [12, 16],
        "new_tok_span": [13, 17]
      },
      {
        "ent_type": "GENE",
        "char_span": [15, 19],
        "name": "TβR1",
        "tok_span": [3, 7],
        "new_tok_span": [3, 7]
      },
      {
        "ent_type": "GENE",
        "char_span": [81, 85],
        "name": "VEGF",
        "tok_span": [19, 20],
        "new_tok_span": [22, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [155, 159],
        "name": "TβR1",
        "tok_span": [37, 41],
        "new_tok_span": [43, 47]
      },
      {
        "ent_type": "GENE",
        "char_span": [199, 203],
        "name": "VEGF",
        "tok_span": [48, 49],
        "new_tok_span": [55, 56]
      }
    ],
    "relation_list": [
      {
        "subject": "SB431542",
        "sbj_char_span": [54, 62],
        "object": "TβR1",
        "obj_char_span": [15, 19],
        "rel_type": "inhibitor",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [3, 7],
        "new_sbj_tok_span": [13, 17],
        "new_obj_tok_span": [3, 7]
      },
      {
        "subject": "SB431542",
        "sbj_char_span": [54, 62],
        "object": "VEGF",
        "obj_char_span": [81, 85],
        "rel_type": "regulator",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [19, 20],
        "new_sbj_tok_span": [13, 17],
        "new_obj_tok_span": [22, 23]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "SB431542",
        "char_span": [54, 62],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [12, 16],
        "new_tok_span": [13, 17]
      },
      {
        "mention": "CSE",
        "char_span": [118, 121],
        "sem_type": "Gene or Genome",
        "tok_span": [29, 31],
        "new_tok_span": [34, 36]
      },
      {
        "mention": "VEGF",
        "char_span": [81, 85],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [19, 20],
        "new_tok_span": [22, 23]
      },
      {
        "mention": "VEGF",
        "char_span": [199, 203],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [48, 49],
        "new_tok_span": [55, 56]
      }
    ],
    "new_text": "Suppression of TβR1 by the pharmacological inhibitor ( <START=Pharmacologic Substance> SB431542 <END=Pharmacologic Substance> ) markedly reduced <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein> release by HFL - 1 in response to <START=Gene or Genome> CSE <END=Gene or Genome> and this effect was confirmed by TβR1 siRNA. In contrast, nicotine inhibited <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein> release by HFL - 1 in a dose and time dependent manner."
  },
  {
    "PMID": 9890894,
    "id": 5,
    "text": "Ig module I and the C-terminus of Ig module III are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [20, 21],
        "name": "C",
        "tok_span": [5, 6],
        "new_tok_span": [5, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [0, 11],
        "name": "Ig module I",
        "tok_span": [0, 3],
        "new_tok_span": [0, 3]
      },
      {
        "ent_type": "GENE",
        "char_span": [34, 47],
        "name": "Ig module III",
        "tok_span": [9, 12],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [93, 98],
        "name": "FGF-1",
        "tok_span": [21, 24],
        "new_tok_span": [23, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [100, 105],
        "name": "FGF-2",
        "tok_span": [25, 28],
        "new_tok_span": [29, 32]
      },
      {
        "ent_type": "GENE",
        "char_span": [111, 116],
        "name": "FGF-7",
        "tok_span": [30, 33],
        "new_tok_span": [34, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "C",
        "sbj_char_span": [20, 21],
        "object": "Ig module III",
        "obj_char_span": [34, 47],
        "rel_type": "part of",
        "sbj_tok_span": [5, 6],
        "obj_tok_span": [9, 12],
        "new_sbj_tok_span": [5, 6],
        "new_obj_tok_span": [9, 12]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "FGF-1",
        "char_span": [93, 98],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [21, 24],
        "new_tok_span": [23, 26]
      },
      {
        "mention": "FGF-1",
        "char_span": [93, 98],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 24],
        "new_tok_span": [23, 26]
      }
    ],
    "new_text": "Ig module I and the C - terminus of Ig module III are dispensable for high - affinity binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> FGF - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, FGF - 2, and FGF - 7."
  },
  {
    "PMID": 8294418,
    "id": 4,
    "text": "Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE. Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [8, 17],
        "name": "ryanodine",
        "tok_span": [1, 5],
        "new_tok_span": [2, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [22, 26],
        "name": "EGTA",
        "tok_span": [6, 8],
        "new_tok_span": [8, 10]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [73, 75],
        "name": "NE",
        "tok_span": [18, 19],
        "new_tok_span": [20, 21]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [77, 90],
        "name": "Actinomycin D",
        "tok_span": [20, 23],
        "new_tok_span": [22, 25]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [190, 193],
        "name": "H-7",
        "tok_span": [52, 55],
        "new_tok_span": [54, 57]
      },
      {
        "ent_type": "GENE",
        "char_span": [56, 64],
        "name": "alpha-AR",
        "tok_span": [13, 16],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [98, 106],
        "name": "alpha-AR",
        "tok_span": [24, 27],
        "new_tok_span": [26, 29]
      },
      {
        "ent_type": "GENE",
        "char_span": [212, 220],
        "name": "alpha-AR",
        "tok_span": [58, 61],
        "new_tok_span": [60, 63]
      }
    ],
    "relation_list": [
      {
        "subject": "EGTA",
        "sbj_char_span": [22, 26],
        "object": "alpha-AR",
        "obj_char_span": [56, 64],
        "rel_type": "regulator",
        "sbj_tok_span": [6, 8],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [8, 10],
        "new_obj_tok_span": [15, 18]
      },
      {
        "subject": "NE",
        "sbj_char_span": [73, 75],
        "object": "alpha-AR",
        "obj_char_span": [56, 64],
        "rel_type": "regulator",
        "sbj_tok_span": [18, 19],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [20, 21],
        "new_obj_tok_span": [15, 18]
      },
      {
        "subject": "ryanodine",
        "sbj_char_span": [8, 17],
        "object": "alpha-AR",
        "obj_char_span": [56, 64],
        "rel_type": "regulator",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [13, 16],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [15, 18]
      },
      {
        "subject": "Actinomycin D",
        "sbj_char_span": [77, 90],
        "object": "alpha-AR",
        "obj_char_span": [98, 106],
        "rel_type": "regulator",
        "sbj_tok_span": [20, 23],
        "obj_tok_span": [24, 27],
        "new_sbj_tok_span": [22, 25],
        "new_obj_tok_span": [26, 29]
      },
      {
        "subject": "Actinomycin D",
        "sbj_char_span": [77, 90],
        "object": "alpha-AR",
        "obj_char_span": [212, 220],
        "rel_type": "regulator",
        "sbj_tok_span": [20, 23],
        "obj_tok_span": [58, 61],
        "new_sbj_tok_span": [22, 25],
        "new_obj_tok_span": [60, 63]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "ryanodine",
        "char_span": [8, 17],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [1, 5],
        "new_tok_span": [2, 6]
      }
    ],
    "new_text": "Neither <START=Pharmacologic Substance> ryanodine <END=Pharmacologic Substance> nor EGTA inhibited down - regulation of alpha - AR mRNA by NE. Actinomycin D caused alpha - AR mRNA level to decrease with a half - life of 3. 2 + / - 0. 4 h and blocked the effect of H - 7 to decrease basal alpha - AR mRNA level."
  },
  {
    "PMID": 11792932,
    "id": 1,
    "text": "PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the aromatase inhibitor, testolactone, and resulting changes in semen parameters.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 132],
        "name": "testolactone",
        "tok_span": [23, 27],
        "new_tok_span": [24, 28]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [25, 34],
        "name": "estradiol",
        "tok_span": [7, 8],
        "new_tok_span": [7, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [9, 21],
        "name": "Testosterone",
        "tok_span": [2, 4],
        "new_tok_span": [2, 4]
      },
      {
        "ent_type": "GENE",
        "char_span": [99, 108],
        "name": "aromatase",
        "tok_span": [19, 21],
        "new_tok_span": [19, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "testolactone",
        "sbj_char_span": [120, 132],
        "object": "aromatase",
        "obj_char_span": [99, 108],
        "rel_type": "inhibitor",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [19, 21],
        "new_sbj_tok_span": [24, 28],
        "new_obj_tok_span": [19, 21]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "testolactone",
        "char_span": [120, 132],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [23, 27],
        "new_tok_span": [24, 28]
      }
    ],
    "new_text": "PURPOSE : Testosterone - to - estradiol ratio levels in infertile men improve during treatment with the aromatase inhibitor, <START=Pharmacologic Substance> testolactone <END=Pharmacologic Substance>, and resulting changes in semen parameters."
  },
  {
    "PMID": 14757703,
    "id": 8,
    "text": "CGP 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta(1)-adrenoceptor overexpression. 5. (125)I-Cyanopindolol saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in beta(1)-adrenoceptors. (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of beta(1)-adrenoceptors. 6.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 10],
        "name": "CGP 12177A",
        "tok_span": [0, 5],
        "new_tok_span": [1, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [19, 31],
        "name": "isoprenaline",
        "tok_span": [7, 10],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [128, 148],
        "name": "(125)I-Cyanopindolol",
        "tok_span": [28, 39],
        "new_tok_span": [30, 41]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [262, 277],
        "name": "(3)H-CGP 12177A",
        "tok_span": [66, 76],
        "new_tok_span": [70, 80]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [317, 328],
        "name": "propranolol",
        "tok_span": [83, 87],
        "new_tok_span": [89, 93]
      },
      {
        "ent_type": "GENE",
        "char_span": [88, 108],
        "name": "beta(1)-adrenoceptor",
        "tok_span": [16, 24],
        "new_tok_span": [18, 26]
      },
      {
        "ent_type": "GENE",
        "char_span": [239, 260],
        "name": "beta(1)-adrenoceptors",
        "tok_span": [56, 65],
        "new_tok_span": [60, 69]
      },
      {
        "ent_type": "GENE",
        "char_span": [389, 410],
        "name": "beta(1)-adrenoceptors",
        "tok_span": [96, 105],
        "new_tok_span": [102, 111]
      }
    ],
    "relation_list": [
      {
        "subject": "CGP 12177A",
        "sbj_char_span": [0, 10],
        "object": "beta(1)-adrenoceptor",
        "obj_char_span": [88, 108],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 5],
        "obj_tok_span": [16, 24],
        "new_sbj_tok_span": [1, 6],
        "new_obj_tok_span": [18, 26]
      },
      {
        "subject": "(125)I-Cyanopindolol",
        "sbj_char_span": [128, 148],
        "object": "beta(1)-adrenoceptors",
        "obj_char_span": [239, 260],
        "rel_type": "regulator",
        "sbj_tok_span": [28, 39],
        "obj_tok_span": [56, 65],
        "new_sbj_tok_span": [30, 41],
        "new_obj_tok_span": [60, 69]
      },
      {
        "subject": "(3)H-CGP 12177A",
        "sbj_char_span": [262, 277],
        "object": "beta(1)-adrenoceptors",
        "obj_char_span": [389, 410],
        "rel_type": "regulator",
        "sbj_tok_span": [66, 76],
        "obj_tok_span": [96, 105],
        "new_sbj_tok_span": [70, 80],
        "new_obj_tok_span": [102, 111]
      },
      {
        "subject": "propranolol",
        "sbj_char_span": [317, 328],
        "object": "beta(1)-adrenoceptors",
        "obj_char_span": [389, 410],
        "rel_type": "regulator",
        "sbj_tok_span": [83, 87],
        "obj_tok_span": [96, 105],
        "new_sbj_tok_span": [89, 93],
        "new_obj_tok_span": [102, 111]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Cyanopindolol",
        "char_span": [135, 148],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [33, 39],
        "new_tok_span": [36, 42]
      },
      {
        "mention": "CGP",
        "char_span": [0, 3],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 2],
        "new_tok_span": [1, 3]
      },
      {
        "mention": "CGP",
        "char_span": [267, 270],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [71, 73],
        "new_tok_span": [76, 78]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> CGP <END=Pharmacologic Substance> 12177A but not isoprenaline initiated arrhythmias at lower concentrations following beta ( 1 ) - adrenoceptor overexpression. 5. ( 125 ) I - <START=Pharmacologic Substance> Cyanopindolol <END=Pharmacologic Substance> saturation binding in Adv. beta ( 1 ) myocytes demonstrated approximately 18 - fold increase in beta ( 1 ) - adrenoceptors. ( 3 ) H - <START=Pharmacologic Substance> CGP <END=Pharmacologic Substance> 12177A saturation binding, in the presence of propranolol, increased approximately 5 - fold following overexpression of beta ( 1 ) - adrenoceptors. 6."
  },
  {
    "PMID": 11161433,
    "id": 4,
    "text": "When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [34, 51],
        "name": "aminoglutethimide",
        "tok_span": [7, 11],
        "new_tok_span": [10, 14]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [105, 119],
        "name": "corticosterone",
        "tok_span": [27, 29],
        "new_tok_span": [34, 36]
      },
      {
        "ent_type": "GENE",
        "char_span": [53, 60],
        "name": "CYP11A1",
        "tok_span": [12, 16],
        "new_tok_span": [17, 21]
      },
      {
        "ent_type": "GENE",
        "char_span": [158, 165],
        "name": "CYP11A1",
        "tok_span": [36, 40],
        "new_tok_span": [45, 49]
      }
    ],
    "relation_list": [
      {
        "subject": "aminoglutethimide",
        "sbj_char_span": [34, 51],
        "object": "CYP11A1",
        "obj_char_span": [53, 60],
        "rel_type": "inhibitor",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [12, 16],
        "new_sbj_tok_span": [10, 14],
        "new_obj_tok_span": [17, 21]
      },
      {
        "subject": "aminoglutethimide",
        "sbj_char_span": [34, 51],
        "object": "CYP11A1",
        "obj_char_span": [158, 165],
        "rel_type": "regulator",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [36, 40],
        "new_sbj_tok_span": [10, 14],
        "new_obj_tok_span": [45, 49]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "corticosterone",
        "char_span": [14, 28],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 6],
        "new_tok_span": [5, 7]
      },
      {
        "mention": "corticosterone",
        "char_span": [105, 119],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [27, 29],
        "new_tok_span": [34, 36]
      },
      {
        "mention": "aminoglutethimide",
        "char_span": [34, 51],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [7, 11],
        "new_tok_span": [10, 14]
      },
      {
        "mention": "CYP11A1",
        "char_span": [53, 60],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [12, 16],
        "new_tok_span": [17, 21]
      },
      {
        "mention": "CYP11A1",
        "char_span": [158, 165],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [36, 40],
        "new_tok_span": [45, 49]
      },
      {
        "mention": "tumor inoculation",
        "char_span": [214, 231],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [48, 50],
        "new_tok_span": [59, 61]
      }
    ],
    "new_text": "When the anti - <START=Pharmacologic Substance> corticosterone <END=Pharmacologic Substance> drug <START=Pharmacologic Substance> aminoglutethimide <END=Pharmacologic Substance> ( <START=Amino Acid, Peptide, or Protein> CYP11A1 <END=Amino Acid, Peptide, or Protein> inhibitor ) was administered to B16F10 mice, <START=Pharmacologic Substance> corticosterone <END=Pharmacologic Substance> levels in splenic tissue or serum and <START=Amino Acid, Peptide, or Protein> CYP11A1 <END=Amino Acid, Peptide, or Protein> mRNA expression were decreased at 14 days after <START=Amino Acid, Peptide, or Protein> tumor inoculation <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 17015640,
    "id": 9,
    "text": "Rofecoxib only diminished COX-2 protein expression and MCP-1 gene expression in vascular atheroma.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Rofecoxib",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [26, 31],
        "name": "COX-2",
        "tok_span": [6, 9],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [55, 60],
        "name": "MCP-1",
        "tok_span": [12, 15],
        "new_tok_span": [14, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "Rofecoxib",
        "sbj_char_span": [0, 9],
        "object": "COX-2",
        "obj_char_span": [26, 31],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [6, 9],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [8, 11]
      },
      {
        "subject": "Rofecoxib",
        "sbj_char_span": [0, 9],
        "object": "MCP-1",
        "obj_char_span": [55, 60],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [12, 15],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [14, 17]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Rofecoxib",
        "char_span": [0, 9],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> Rofecoxib <END=Pharmacologic Substance> only diminished COX - 2 protein expression and MCP - 1 gene expression in vascular atheroma."
  },
  {
    "PMID": 23542114,
    "id": 0,
    "text": "Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 16],
        "name": "Arsenic trioxide",
        "tok_span": [0, 5],
        "new_tok_span": [0, 5]
      },
      {
        "ent_type": "GENE",
        "char_span": [137, 142],
        "name": "Notch",
        "tok_span": [27, 28],
        "new_tok_span": [27, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "Arsenic trioxide",
        "sbj_char_span": [0, 16],
        "object": "Notch",
        "obj_char_span": [137, 142],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 5],
        "obj_tok_span": [27, 28],
        "new_sbj_tok_span": [0, 5],
        "new_obj_tok_span": [27, 28]
      }
    ],
    "umls_entity_list": [],
    "new_text": "Arsenic trioxide depletes cancer stem - like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway."
  },
  {
    "PMID": 11009561,
    "id": 6,
    "text": "The BH(4) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [109, 121],
        "name": "triglyceride",
        "tok_span": [21, 22],
        "new_tok_span": [24, 25]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [144, 152],
        "name": "fructose",
        "tok_span": [26, 27],
        "new_tok_span": [30, 31]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [4, 9],
        "name": "BH(4)",
        "tok_span": [1, 5],
        "new_tok_span": [2, 6]
      },
      {
        "ent_type": "GENE",
        "char_span": [48, 55],
        "name": "insulin",
        "tok_span": [10, 11],
        "new_tok_span": [12, 13]
      }
    ],
    "relation_list": [
      {
        "subject": "BH(4)",
        "sbj_char_span": [4, 9],
        "object": "insulin",
        "obj_char_span": [48, 55],
        "rel_type": "regulator",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [10, 11],
        "new_sbj_tok_span": [2, 6],
        "new_obj_tok_span": [12, 13]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "BH",
        "char_span": [4, 6],
        "sem_type": "Gene or Genome",
        "tok_span": [1, 2],
        "new_tok_span": [2, 3]
      },
      {
        "mention": "triglyceride",
        "char_span": [109, 121],
        "sem_type": "Organic Chemical",
        "tok_span": [21, 22],
        "new_tok_span": [24, 25]
      }
    ],
    "new_text": "The <START=Gene or Genome> BH <END=Gene or Genome> ( 4 ) treatment also partially improved the insulin sensitivity and blood pressure, as well as the serum <START=Organic Chemical> triglyceride <END=Organic Chemical> concentration, in the fructose - fed rats."
  },
  {
    "PMID": 15908512,
    "id": 6,
    "text": "The selective betaAR agonist isoproterenol caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [29, 42],
        "name": "isoproterenol",
        "tok_span": [5, 9],
        "new_tok_span": [6, 10]
      },
      {
        "ent_type": "GENE",
        "char_span": [14, 20],
        "name": "betaAR",
        "tok_span": [2, 4],
        "new_tok_span": [2, 4]
      }
    ],
    "relation_list": [
      {
        "subject": "isoproterenol",
        "sbj_char_span": [29, 42],
        "object": "betaAR",
        "obj_char_span": [14, 20],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [2, 4],
        "new_sbj_tok_span": [6, 10],
        "new_obj_tok_span": [2, 4]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "isoproterenol",
        "char_span": [29, 42],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [5, 9],
        "new_tok_span": [6, 10]
      }
    ],
    "new_text": "The selective betaAR agonist <START=Pharmacologic Substance> isoproterenol <END=Pharmacologic Substance> caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region."
  },
  {
    "PMID": 12614192,
    "id": 8,
    "text": "With the use of sildenafil, it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [16, 26],
        "name": "sildenafil",
        "tok_span": [4, 7],
        "new_tok_span": [5, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [106, 110],
        "name": "PDE5",
        "tok_span": [20, 22],
        "new_tok_span": [22, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "sildenafil",
        "sbj_char_span": [16, 26],
        "object": "PDE5",
        "obj_char_span": [106, 110],
        "rel_type": "inhibitor",
        "sbj_tok_span": [4, 7],
        "obj_tok_span": [20, 22],
        "new_sbj_tok_span": [5, 8],
        "new_obj_tok_span": [22, 24]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "sildenafil",
        "char_span": [16, 26],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 7],
        "new_tok_span": [5, 8]
      }
    ],
    "new_text": "With the use of <START=Pharmacologic Substance> sildenafil <END=Pharmacologic Substance>, it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities."
  },
  {
    "PMID": 7986344,
    "id": 0,
    "text": "Folding pathway of guanidine-denatured disulfide-intact wild-type and mutant bovine pancreatic ribonuclease A.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [19, 28],
        "name": "guanidine",
        "tok_span": [4, 6],
        "new_tok_span": [6, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [39, 48],
        "name": "disulfide",
        "tok_span": [9, 10],
        "new_tok_span": [13, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [77, 109],
        "name": "bovine pancreatic ribonuclease A",
        "tok_span": [17, 22],
        "new_tok_span": [21, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "disulfide",
        "sbj_char_span": [39, 48],
        "object": "bovine pancreatic ribonuclease A",
        "obj_char_span": [77, 109],
        "rel_type": "regulator",
        "sbj_tok_span": [9, 10],
        "obj_tok_span": [17, 22],
        "new_sbj_tok_span": [13, 14],
        "new_obj_tok_span": [21, 26]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "guanidine",
        "char_span": [19, 28],
        "sem_type": "Organic Chemical",
        "tok_span": [4, 6],
        "new_tok_span": [6, 8]
      },
      {
        "mention": "guanidine",
        "char_span": [19, 28],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [4, 6],
        "new_tok_span": [6, 8]
      },
      {
        "mention": "pancreatic",
        "char_span": [84, 94],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [18, 19],
        "new_tok_span": [23, 24]
      }
    ],
    "new_text": "Folding pathway of <START=Organic Chemical> <START=Pharmacologic Substance> guanidine <END=Organic Chemical> <END=Pharmacologic Substance> - denatured disulfide - intact wild - type and mutant bovine <START=Amino Acid, Peptide, or Protein> pancreatic <END=Amino Acid, Peptide, or Protein> ribonuclease A."
  },
  {
    "PMID": 17090056,
    "id": 1,
    "text": "Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human 5'-methylthioadenosine phosphorylase (MTAP). KIEs were measured on the arsenolysis of 5'-methylthioadenosine (MTA) catalyzed by MTAP and were corrected for the forward commitment to catalysis.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [140, 162],
        "name": "5'-methylthioadenosine",
        "tok_span": [25, 33],
        "new_tok_span": [25, 33]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [226, 248],
        "name": "5'-methylthioadenosine",
        "tok_span": [49, 57],
        "new_tok_span": [53, 61]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [250, 253],
        "name": "MTA",
        "tok_span": [58, 60],
        "new_tok_span": [62, 64]
      },
      {
        "ent_type": "GENE",
        "char_span": [134, 176],
        "name": "human 5'-methylthioadenosine phosphorylase",
        "tok_span": [24, 35],
        "new_tok_span": [24, 35]
      },
      {
        "ent_type": "GENE",
        "char_span": [178, 182],
        "name": "MTAP",
        "tok_span": [36, 38],
        "new_tok_span": [40, 42]
      },
      {
        "ent_type": "GENE",
        "char_span": [268, 272],
        "name": "MTAP",
        "tok_span": [63, 65],
        "new_tok_span": [67, 69]
      }
    ],
    "relation_list": [
      {
        "subject": "5'-methylthioadenosine",
        "sbj_char_span": [226, 248],
        "object": "MTAP",
        "obj_char_span": [268, 272],
        "rel_type": "product or substrate",
        "sbj_tok_span": [49, 57],
        "obj_tok_span": [63, 65],
        "new_sbj_tok_span": [53, 61],
        "new_obj_tok_span": [67, 69]
      },
      {
        "subject": "MTA",
        "sbj_char_span": [250, 253],
        "object": "MTAP",
        "obj_char_span": [268, 272],
        "rel_type": "product or substrate",
        "sbj_tok_span": [58, 60],
        "obj_tok_span": [63, 65],
        "new_sbj_tok_span": [62, 64],
        "new_obj_tok_span": [67, 69]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "methylthioadenosine phosphorylase",
        "char_span": [143, 176],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [28, 35],
        "new_tok_span": [30, 37]
      },
      {
        "mention": "methylthioadenosine phosphorylase",
        "char_span": [143, 176],
        "sem_type": "Gene or Genome",
        "tok_span": [28, 35],
        "new_tok_span": [30, 37]
      }
    ],
    "new_text": "Kinetic isotope effects ( KIEs ) and computer modeling using density functional theory were used to approximate the transition state of human 5'- <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> methylthioadenosine phosphorylase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( MTAP ). KIEs were measured on the arsenolysis of 5'- methylthioadenosine ( MTA ) catalyzed by MTAP and were corrected for the forward commitment to catalysis."
  },
  {
    "PMID": 20421509,
    "id": 0,
    "text": "Phenothiazines inhibit S100A4 function by inducing protein oligomerization.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 14],
        "name": "Phenothiazines",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "GENE",
        "char_span": [23, 29],
        "name": "S100A4",
        "tok_span": [5, 9],
        "new_tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "Phenothiazines",
        "sbj_char_span": [0, 14],
        "object": "S100A4",
        "obj_char_span": [23, 29],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [5, 9],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "S100A4",
        "char_span": [23, 29],
        "sem_type": "Gene or Genome",
        "tok_span": [5, 9],
        "new_tok_span": [6, 10]
      }
    ],
    "new_text": "Phenothiazines inhibit <START=Gene or Genome> S100A4 <END=Gene or Genome> function by inducing protein oligomerization."
  },
  {
    "PMID": 23194825,
    "id": 10,
    "text": "Importantly, pre-treatment with buthionine sulfoximine (BSO), an inhibitor of γ-GCS, prevented α-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [32, 54],
        "name": "buthionine sulfoximine",
        "tok_span": [6, 13],
        "new_tok_span": [7, 14]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [56, 59],
        "name": "BSO",
        "tok_span": [14, 16],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [95, 101],
        "name": "α-MeDA",
        "tok_span": [27, 31],
        "new_tok_span": [29, 33]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [122, 125],
        "name": "GSH",
        "tok_span": [34, 35],
        "new_tok_span": [36, 37]
      },
      {
        "ent_type": "GENE",
        "char_span": [78, 83],
        "name": "γ-GCS",
        "tok_span": [21, 25],
        "new_tok_span": [23, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "buthionine sulfoximine",
        "sbj_char_span": [32, 54],
        "object": "γ-GCS",
        "obj_char_span": [78, 83],
        "rel_type": "inhibitor",
        "sbj_tok_span": [6, 13],
        "obj_tok_span": [21, 25],
        "new_sbj_tok_span": [7, 14],
        "new_obj_tok_span": [23, 27]
      },
      {
        "subject": "BSO",
        "sbj_char_span": [56, 59],
        "object": "γ-GCS",
        "obj_char_span": [78, 83],
        "rel_type": "inhibitor",
        "sbj_tok_span": [14, 16],
        "obj_tok_span": [21, 25],
        "new_sbj_tok_span": [16, 18],
        "new_obj_tok_span": [23, 27]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "buthionine sulfoximine",
        "char_span": [32, 54],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [6, 13],
        "new_tok_span": [7, 14]
      }
    ],
    "new_text": "Importantly, pre - treatment with <START=Amino Acid, Peptide, or Protein> buthionine sulfoximine <END=Amino Acid, Peptide, or Protein> ( BSO ), an inhibitor of γ - GCS, prevented α - MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity."
  },
  {
    "PMID": 12167474,
    "id": 5,
    "text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [17, 38],
        "name": "cysteine S-conjugates",
        "tok_span": [4, 8],
        "new_tok_span": [4, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [58, 78],
        "name": "cysteine S-conjugate",
        "tok_span": [12, 16],
        "new_tok_span": [12, 16]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [94, 102],
        "name": "pyruvate",
        "tok_span": [21, 22],
        "new_tok_span": [23, 24]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [104, 111],
        "name": "ammonia",
        "tok_span": [23, 24],
        "new_tok_span": [25, 26]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [120, 143],
        "name": "alpha-chloroenethiolate",
        "tok_span": [27, 34],
        "new_tok_span": [29, 36]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [150, 154],
        "name": "DCVC",
        "tok_span": [36, 38],
        "new_tok_span": [38, 40]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [162, 189],
        "name": "alpha-difluoroalkylthiolate",
        "tok_span": [41, 50],
        "new_tok_span": [43, 52]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [196, 200],
        "name": "TFEC",
        "tok_span": [52, 54],
        "new_tok_span": [55, 57]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [221, 227],
        "name": "halide",
        "tok_span": [58, 60],
        "new_tok_span": [62, 64]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [238, 253],
        "name": "thioacyl halide",
        "tok_span": [63, 69],
        "new_tok_span": [67, 73]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [273, 286],
        "name": "epsilon-amino",
        "tok_span": [74, 79],
        "new_tok_span": [80, 85]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [297, 303],
        "name": "lysine",
        "tok_span": [81, 82],
        "new_tok_span": [87, 88]
      },
      {
        "ent_type": "GENE",
        "char_span": [79, 90],
        "name": "beta-lyases",
        "tok_span": [16, 20],
        "new_tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "cysteine S-conjugates",
        "sbj_char_span": [17, 38],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [4, 8],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "pyruvate",
        "sbj_char_span": [94, 102],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [21, 22],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [23, 24],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "ammonia",
        "sbj_char_span": [104, 111],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [23, 24],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [25, 26],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "alpha-chloroenethiolate",
        "sbj_char_span": [120, 143],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [27, 34],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [29, 36],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "DCVC",
        "sbj_char_span": [150, 154],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [36, 38],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [38, 40],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "alpha-difluoroalkylthiolate",
        "sbj_char_span": [162, 189],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [41, 50],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [43, 52],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "TFEC",
        "sbj_char_span": [196, 200],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "product or substrate",
        "sbj_tok_span": [52, 54],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [55, 57],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "lysine",
        "sbj_char_span": [297, 303],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "part of",
        "sbj_tok_span": [81, 82],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [87, 88],
        "new_obj_tok_span": [16, 20]
      },
      {
        "subject": "epsilon-amino",
        "sbj_char_span": [273, 286],
        "object": "beta-lyases",
        "obj_char_span": [79, 90],
        "rel_type": "part of",
        "sbj_tok_span": [74, 79],
        "obj_tok_span": [16, 20],
        "new_sbj_tok_span": [80, 85],
        "new_obj_tok_span": [16, 20]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "lyases",
        "char_span": [84, 90],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [18, 20],
        "new_tok_span": [19, 21]
      },
      {
        "mention": "TFEC",
        "char_span": [196, 200],
        "sem_type": "Gene or Genome",
        "tok_span": [52, 54],
        "new_tok_span": [55, 57]
      },
      {
        "mention": "react",
        "char_span": [261, 266],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [71, 72],
        "new_tok_span": [76, 77]
      }
    ],
    "new_text": "Most halogenated cysteine S - conjugates are metabolized by cysteine S - conjugate beta - <START=Amino Acid, Peptide, or Protein> lyases <END=Amino Acid, Peptide, or Protein> to pyruvate, ammonia, and an alpha - chloroenethiolate ( with DCVC ) or an alpha - difluoroalkylthiolate ( with <START=Gene or Genome> TFEC <END=Gene or Genome> ) that may eliminate halide to give a thioacyl halide, which <START=Pharmacologic Substance> react <END=Pharmacologic Substance>s with epsilon - amino groups of lysine residues in proteins."
  },
  {
    "PMID": 23418674,
    "id": 7,
    "text": "The results suggested that both the EtOAc extract and berberine were able to activate PPARα/β/γ, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [36, 41],
        "name": "EtOAc",
        "tok_span": [6, 8],
        "new_tok_span": [6, 8]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [54, 63],
        "name": "berberine",
        "tok_span": [10, 13],
        "new_tok_span": [10, 13]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [169, 178],
        "name": "berberine",
        "tok_span": [38, 41],
        "new_tok_span": [40, 43]
      },
      {
        "ent_type": "GENE",
        "char_span": [86, 95],
        "name": "PPARα/β/γ",
        "tok_span": [17, 23],
        "new_tok_span": [17, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [155, 160],
        "name": "PPARs",
        "tok_span": [35, 37],
        "new_tok_span": [37, 39]
      }
    ],
    "relation_list": [
      {
        "subject": "EtOAc",
        "sbj_char_span": [36, 41],
        "object": "PPARα/β/γ",
        "obj_char_span": [86, 95],
        "rel_type": "activator",
        "sbj_tok_span": [6, 8],
        "obj_tok_span": [17, 23],
        "new_sbj_tok_span": [6, 8],
        "new_obj_tok_span": [17, 23]
      },
      {
        "subject": "berberine",
        "sbj_char_span": [54, 63],
        "object": "PPARα/β/γ",
        "obj_char_span": [86, 95],
        "rel_type": "activator",
        "sbj_tok_span": [10, 13],
        "obj_tok_span": [17, 23],
        "new_sbj_tok_span": [10, 13],
        "new_obj_tok_span": [17, 23]
      },
      {
        "subject": "berberine",
        "sbj_char_span": [169, 178],
        "object": "PPARα/β/γ",
        "obj_char_span": [86, 95],
        "rel_type": "activator",
        "sbj_tok_span": [38, 41],
        "obj_tok_span": [17, 23],
        "new_sbj_tok_span": [40, 43],
        "new_obj_tok_span": [17, 23]
      },
      {
        "subject": "berberine",
        "sbj_char_span": [169, 178],
        "object": "PPARs",
        "obj_char_span": [155, 160],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [38, 41],
        "obj_tok_span": [35, 37],
        "new_sbj_tok_span": [40, 43],
        "new_obj_tok_span": [37, 39]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Coptis",
        "char_span": [109, 115],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [28, 30],
        "new_tok_span": [29, 31]
      }
    ],
    "new_text": "The results suggested that both the EtOAc extract and berberine were able to activate PPARα / β / γ, and Rhizoma <START=Pharmacologic Substance> Coptis <END=Pharmacologic Substance> contains potential natural agonists of PPARs besides berberine."
  },
  {
    "PMID": 23562365,
    "id": 7,
    "text": "Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [15, 21],
        "name": "EVn-50",
        "tok_span": [2, 6],
        "new_tok_span": [3, 7]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [25, 28],
        "name": "VB1",
        "tok_span": [7, 9],
        "new_tok_span": [9, 11]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [190, 193],
        "name": "Ser",
        "tok_span": [48, 49],
        "new_tok_span": [50, 51]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [224, 227],
        "name": "Tyr",
        "tok_span": [57, 58],
        "new_tok_span": [63, 64]
      },
      {
        "ent_type": "GENE",
        "char_span": [177, 186],
        "name": "Histone 3",
        "tok_span": [44, 47],
        "new_tok_span": [46, 49]
      },
      {
        "ent_type": "GENE",
        "char_span": [216, 220],
        "name": "Cdk1",
        "tok_span": [53, 56],
        "new_tok_span": [57, 60]
      },
      {
        "ent_type": "GENE",
        "char_span": [245, 254],
        "name": "cyclin B1",
        "tok_span": [62, 65],
        "new_tok_span": [71, 74]
      },
      {
        "ent_type": "GENE",
        "char_span": [284, 290],
        "name": "Cdc25c",
        "tok_span": [70, 73],
        "new_tok_span": [82, 85]
      }
    ],
    "relation_list": [
      {
        "subject": "Ser",
        "sbj_char_span": [190, 193],
        "object": "Histone 3",
        "obj_char_span": [177, 186],
        "rel_type": "part of",
        "sbj_tok_span": [48, 49],
        "obj_tok_span": [44, 47],
        "new_sbj_tok_span": [50, 51],
        "new_obj_tok_span": [46, 49]
      },
      {
        "subject": "Tyr",
        "sbj_char_span": [224, 227],
        "object": "Cdk1",
        "obj_char_span": [216, 220],
        "rel_type": "part of",
        "sbj_tok_span": [57, 58],
        "obj_tok_span": [53, 56],
        "new_sbj_tok_span": [63, 64],
        "new_obj_tok_span": [57, 60]
      },
      {
        "subject": "EVn-50",
        "sbj_char_span": [15, 21],
        "object": "Histone 3",
        "obj_char_span": [177, 186],
        "rel_type": "activator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [44, 47],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [46, 49]
      },
      {
        "subject": "VB1",
        "sbj_char_span": [25, 28],
        "object": "Histone 3",
        "obj_char_span": [177, 186],
        "rel_type": "activator",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [44, 47],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [46, 49]
      },
      {
        "subject": "EVn-50",
        "sbj_char_span": [15, 21],
        "object": "Cdk1",
        "obj_char_span": [216, 220],
        "rel_type": "activator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [53, 56],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [57, 60]
      },
      {
        "subject": "VB1",
        "sbj_char_span": [25, 28],
        "object": "Cdk1",
        "obj_char_span": [216, 220],
        "rel_type": "activator",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [53, 56],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [57, 60]
      },
      {
        "subject": "EVn-50",
        "sbj_char_span": [15, 21],
        "object": "cyclin B1",
        "obj_char_span": [245, 254],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [62, 65],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [71, 74]
      },
      {
        "subject": "VB1",
        "sbj_char_span": [25, 28],
        "object": "cyclin B1",
        "obj_char_span": [245, 254],
        "rel_type": "regulator",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [62, 65],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [71, 74]
      },
      {
        "subject": "EVn-50",
        "sbj_char_span": [15, 21],
        "object": "Cdc25c",
        "obj_char_span": [284, 290],
        "rel_type": "regulator",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [70, 73],
        "new_sbj_tok_span": [3, 7],
        "new_obj_tok_span": [82, 85]
      },
      {
        "subject": "VB1",
        "sbj_char_span": [25, 28],
        "object": "Cdc25c",
        "obj_char_span": [284, 290],
        "rel_type": "regulator",
        "sbj_tok_span": [7, 9],
        "obj_tok_span": [70, 73],
        "new_sbj_tok_span": [9, 11],
        "new_obj_tok_span": [82, 85]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "EVn",
        "char_span": [15, 18],
        "sem_type": "Gene or Genome",
        "tok_span": [2, 4],
        "new_tok_span": [3, 5]
      },
      {
        "mention": "Cdk1",
        "char_span": [216, 220],
        "sem_type": "Gene or Genome",
        "tok_span": [53, 56],
        "new_tok_span": [57, 60]
      },
      {
        "mention": "Cdk1",
        "char_span": [216, 220],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [53, 56],
        "new_tok_span": [57, 60]
      },
      {
        "mention": "cyclin",
        "char_span": [245, 251],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [62, 63],
        "new_tok_span": [71, 72]
      },
      {
        "mention": "cyclin B1",
        "char_span": [245, 254],
        "sem_type": "Gene or Genome",
        "tok_span": [62, 65],
        "new_tok_span": [71, 74]
      },
      {
        "mention": "cyclin B1",
        "char_span": [245, 254],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [62, 65],
        "new_tok_span": [71, 74]
      }
    ],
    "new_text": "Treatment with <START=Gene or Genome> EVn <END=Gene or Genome> - 50 or VB1 resulted in arresting the MDA - MB - 435 and SMMC - 7721 cells at G2 / M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Cdk1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> at Tyr15, expression of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> cyclin <END=Amino Acid, Peptide, or Protein> B1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, and decreased expression of Cdc25c."
  },
  {
    "PMID": 7825862,
    "id": 4,
    "text": "We have cloned cDNAs for murine PGHS-1 and PGHS-2, expressed these enzymes in cos-1 cells, and compared the relative sensitivities of the two isozymes to some common NSAIDs. Indomethacin, piroxicam, and sulindac sulfide were found to preferentially inhibit PGHS-1.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [174, 186],
        "name": "Indomethacin",
        "tok_span": [42, 45],
        "new_tok_span": [46, 49]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [188, 197],
        "name": "piroxicam",
        "tok_span": [46, 50],
        "new_tok_span": [50, 54]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [203, 219],
        "name": "sulindac sulfide",
        "tok_span": [52, 57],
        "new_tok_span": [56, 61]
      },
      {
        "ent_type": "GENE",
        "char_span": [257, 263],
        "name": "PGHS-1",
        "tok_span": [62, 66],
        "new_tok_span": [68, 72]
      },
      {
        "ent_type": "GENE",
        "char_span": [32, 38],
        "name": "PGHS-1",
        "tok_span": [7, 11],
        "new_tok_span": [9, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [43, 49],
        "name": "PGHS-2",
        "tok_span": [12, 16],
        "new_tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "Indomethacin",
        "sbj_char_span": [174, 186],
        "object": "PGHS-1",
        "obj_char_span": [257, 263],
        "rel_type": "inhibitor",
        "sbj_tok_span": [42, 45],
        "obj_tok_span": [62, 66],
        "new_sbj_tok_span": [46, 49],
        "new_obj_tok_span": [68, 72]
      },
      {
        "subject": "piroxicam",
        "sbj_char_span": [188, 197],
        "object": "PGHS-1",
        "obj_char_span": [257, 263],
        "rel_type": "inhibitor",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [62, 66],
        "new_sbj_tok_span": [50, 54],
        "new_obj_tok_span": [68, 72]
      },
      {
        "subject": "sulindac sulfide",
        "sbj_char_span": [203, 219],
        "object": "PGHS-1",
        "obj_char_span": [257, 263],
        "rel_type": "inhibitor",
        "sbj_tok_span": [52, 57],
        "obj_tok_span": [62, 66],
        "new_sbj_tok_span": [56, 61],
        "new_obj_tok_span": [68, 72]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "PGHS-1",
        "char_span": [32, 38],
        "sem_type": "Gene or Genome",
        "tok_span": [7, 11],
        "new_tok_span": [9, 13]
      },
      {
        "mention": "PGHS-1",
        "char_span": [257, 263],
        "sem_type": "Gene or Genome",
        "tok_span": [62, 66],
        "new_tok_span": [68, 72]
      },
      {
        "mention": "PGHS-1",
        "char_span": [32, 38],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [7, 11],
        "new_tok_span": [9, 13]
      },
      {
        "mention": "PGHS-1",
        "char_span": [257, 263],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [62, 66],
        "new_tok_span": [68, 72]
      }
    ],
    "new_text": "We have cloned cDNAs for murine <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PGHS - 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and PGHS - 2, expressed these enzymes in cos - 1 cells, and compared the relative sensitivities of the two isozymes to some common NSAIDs. Indomethacin, piroxicam, and sulindac sulfide were found to preferentially inhibit <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PGHS - 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 16434489,
    "id": 0,
    "text": "Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Dasatinib",
        "tok_span": [0, 2],
        "new_tok_span": [0, 2]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [11, 21],
        "name": "BMS-354825",
        "tok_span": [3, 9],
        "new_tok_span": [3, 9]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [45, 53],
        "name": "imatinib",
        "tok_span": [18, 20],
        "new_tok_span": [19, 21]
      },
      {
        "ent_type": "GENE",
        "char_span": [32, 35],
        "name": "KIT",
        "tok_span": [11, 13],
        "new_tok_span": [11, 13]
      },
      {
        "ent_type": "GENE",
        "char_span": [35, 40],
        "name": "D816V",
        "tok_span": [12, 16],
        "new_tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "Dasatinib",
        "sbj_char_span": [0, 9],
        "object": "KIT",
        "obj_char_span": [32, 35],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [11, 13],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [11, 13]
      },
      {
        "subject": "Dasatinib",
        "sbj_char_span": [0, 9],
        "object": "D816V",
        "obj_char_span": [35, 40],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 2],
        "obj_tok_span": [12, 16],
        "new_sbj_tok_span": [0, 2],
        "new_obj_tok_span": [12, 16]
      },
      {
        "subject": "BMS-354825",
        "sbj_char_span": [11, 21],
        "object": "D816V",
        "obj_char_span": [35, 40],
        "rel_type": "inhibitor",
        "sbj_tok_span": [3, 9],
        "obj_tok_span": [12, 16],
        "new_sbj_tok_span": [3, 9],
        "new_obj_tok_span": [12, 16]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "imatinib",
        "char_span": [45, 53],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [18, 20],
        "new_tok_span": [19, 21]
      }
    ],
    "new_text": "Dasatinib ( BMS - 354825 ) inhibits KITD816V, an <START=Pharmacologic Substance> imatinib <END=Pharmacologic Substance> - resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis."
  },
  {
    "PMID": 8384716,
    "id": 8,
    "text": "HeLa cells transfected with the MR77 gene exhibited inhibition of adenylate cyclase in response to serotonin.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [66, 75],
        "name": "adenylate",
        "tok_span": [11, 13],
        "new_tok_span": [13, 15]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [99, 108],
        "name": "serotonin",
        "tok_span": [17, 18],
        "new_tok_span": [19, 20]
      },
      {
        "ent_type": "GENE",
        "char_span": [32, 36],
        "name": "MR77",
        "tok_span": [5, 7],
        "new_tok_span": [6, 8]
      },
      {
        "ent_type": "GENE",
        "char_span": [66, 83],
        "name": "adenylate cyclase",
        "tok_span": [11, 14],
        "new_tok_span": [13, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "serotonin",
        "sbj_char_span": [99, 108],
        "object": "adenylate cyclase",
        "obj_char_span": [66, 83],
        "rel_type": "inhibitor",
        "sbj_tok_span": [17, 18],
        "obj_tok_span": [11, 14],
        "new_sbj_tok_span": [19, 20],
        "new_obj_tok_span": [13, 16]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "MR77",
        "char_span": [32, 36],
        "sem_type": "Gene or Genome",
        "tok_span": [5, 7],
        "new_tok_span": [6, 8]
      }
    ],
    "new_text": "HeLa cells transfected with the <START=Gene or Genome> MR77 <END=Gene or Genome> gene exhibited inhibition of adenylate cyclase in response to serotonin."
  },
  {
    "PMID": 18081314,
    "id": 1,
    "text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (U46619) to the engineered prostacyclin (PGI2) synthase (PGIS) in solution.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [108, 114],
        "name": "U46619",
        "tok_span": [21, 25],
        "new_tok_span": [22, 26]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [134, 146],
        "name": "prostacyclin",
        "tok_span": [29, 32],
        "new_tok_span": [32, 35]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [148, 152],
        "name": "PGI2",
        "tok_span": [33, 36],
        "new_tok_span": [37, 40]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [83, 99],
        "name": "prostaglandin H2",
        "tok_span": [15, 18],
        "new_tok_span": [15, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [134, 162],
        "name": "prostacyclin (PGI2) synthase",
        "tok_span": [29, 38],
        "new_tok_span": [32, 41]
      },
      {
        "ent_type": "GENE",
        "char_span": [164, 168],
        "name": "PGIS",
        "tok_span": [39, 41],
        "new_tok_span": [44, 46]
      }
    ],
    "relation_list": [
      {
        "subject": "prostaglandin H2",
        "sbj_char_span": [83, 99],
        "object": "prostacyclin (PGI2) synthase",
        "obj_char_span": [134, 162],
        "rel_type": "regulator",
        "sbj_tok_span": [15, 18],
        "obj_tok_span": [29, 38],
        "new_sbj_tok_span": [15, 18],
        "new_obj_tok_span": [32, 41]
      },
      {
        "subject": "U46619",
        "sbj_char_span": [108, 114],
        "object": "prostacyclin (PGI2) synthase",
        "obj_char_span": [134, 162],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [29, 38],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [32, 41]
      },
      {
        "subject": "prostaglandin H2",
        "sbj_char_span": [83, 99],
        "object": "PGIS",
        "obj_char_span": [164, 168],
        "rel_type": "regulator",
        "sbj_tok_span": [15, 18],
        "obj_tok_span": [39, 41],
        "new_sbj_tok_span": [15, 18],
        "new_obj_tok_span": [44, 46]
      },
      {
        "subject": "U46619",
        "sbj_char_span": [108, 114],
        "object": "PGIS",
        "obj_char_span": [164, 168],
        "rel_type": "regulator",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [39, 41],
        "new_sbj_tok_span": [22, 26],
        "new_obj_tok_span": [44, 46]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "U46619",
        "char_span": [108, 114],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [21, 25],
        "new_tok_span": [22, 26]
      },
      {
        "mention": "prostacyclin",
        "char_span": [134, 146],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [29, 32],
        "new_tok_span": [32, 35]
      },
      {
        "mention": "PGIS",
        "char_span": [164, 168],
        "sem_type": "Gene or Genome",
        "tok_span": [39, 41],
        "new_tok_span": [44, 46]
      }
    ],
    "new_text": "High - resolution NMR spectroscopy was used to determine the docking of a substrate ( prostaglandin H2 ) mimic ( <START=Pharmacologic Substance> U46619 <END=Pharmacologic Substance> ) to the engineered <START=Pharmacologic Substance> prostacyclin <END=Pharmacologic Substance> ( PGI2 ) synthase ( <START=Gene or Genome> PGIS <END=Gene or Genome> ) in solution."
  },
  {
    "PMID": 17479245,
    "id": 11,
    "text": "Isolated islets displayed improved glucose-stimulated insulin secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [35, 42],
        "name": "glucose",
        "tok_span": [5, 6],
        "new_tok_span": [6, 7]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [164, 171],
        "name": "glucose",
        "tok_span": [56, 57],
        "new_tok_span": [59, 60]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [209, 216],
        "name": "glucose",
        "tok_span": [69, 70],
        "new_tok_span": [74, 75]
      },
      {
        "ent_type": "GENE",
        "char_span": [54, 61],
        "name": "insulin",
        "tok_span": [8, 9],
        "new_tok_span": [10, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "glucose",
        "sbj_char_span": [35, 42],
        "object": "insulin",
        "obj_char_span": [54, 61],
        "rel_type": "regulator",
        "sbj_tok_span": [5, 6],
        "obj_tok_span": [8, 9],
        "new_sbj_tok_span": [6, 7],
        "new_obj_tok_span": [10, 11]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "glucose",
        "char_span": [35, 42],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [5, 6],
        "new_tok_span": [6, 7]
      },
      {
        "mention": "glucose",
        "char_span": [164, 171],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [56, 57],
        "new_tok_span": [59, 60]
      },
      {
        "mention": "glucose",
        "char_span": [209, 216],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [69, 70],
        "new_tok_span": [74, 75]
      }
    ],
    "new_text": "Isolated islets displayed improved <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> - stimulated insulin secretion after GRA treatment ( 0. 061 + / - 0. 007 vs 0. 030 + / - 0. 004 pmol islet ( - 1 ) h ( - 1 ) at 16. 7 mmol / l <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> ; p < 0. 001 ), without affecting islet <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> oxidation."
  },
  {
    "PMID": 17138644,
    "id": 4,
    "text": "Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [249, 261],
        "name": "progesterone",
        "tok_span": [49, 50],
        "new_tok_span": [71, 72]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 9],
        "name": "Progestin",
        "tok_span": [0, 3],
        "new_tok_span": [3, 6]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [57, 69],
        "name": "progesterone",
        "tok_span": [14, 15],
        "new_tok_span": [24, 25]
      },
      {
        "ent_type": "GENE",
        "char_span": [249, 278],
        "name": "progesterone response element",
        "tok_span": [49, 52],
        "new_tok_span": [71, 74]
      },
      {
        "ent_type": "GENE",
        "char_span": [327, 329],
        "name": "PR",
        "tok_span": [59, 60],
        "new_tok_span": [85, 86]
      },
      {
        "ent_type": "GENE",
        "char_span": [344, 347],
        "name": "Src",
        "tok_span": [62, 63],
        "new_tok_span": [91, 92]
      },
      {
        "ent_type": "GENE",
        "char_span": [27, 36],
        "name": "cyclin D1",
        "tok_span": [6, 9],
        "new_tok_span": [13, 16]
      },
      {
        "ent_type": "GENE",
        "char_span": [57, 86],
        "name": "progesterone response element",
        "tok_span": [14, 17],
        "new_tok_span": [24, 27]
      },
      {
        "ent_type": "GENE",
        "char_span": [105, 107],
        "name": "PR",
        "tok_span": [21, 22],
        "new_tok_span": [35, 36]
      },
      {
        "ent_type": "GENE",
        "char_span": [126, 129],
        "name": "Src",
        "tok_span": [25, 26],
        "new_tok_span": [42, 43]
      },
      {
        "ent_type": "GENE",
        "char_span": [130, 134],
        "name": "MAPK",
        "tok_span": [27, 28],
        "new_tok_span": [45, 46]
      },
      {
        "ent_type": "GENE",
        "char_span": [169, 172],
        "name": "Sgk",
        "tok_span": [34, 37],
        "new_tok_span": [53, 56]
      },
      {
        "ent_type": "GENE",
        "char_span": [174, 215],
        "name": "serum and glucocorticoid regulated kinase",
        "tok_span": [38, 43],
        "new_tok_span": [58, 63]
      }
    ],
    "relation_list": [
      {
        "subject": "Progestin",
        "sbj_char_span": [0, 9],
        "object": "PR",
        "obj_char_span": [105, 107],
        "rel_type": "activator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [21, 22],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [35, 36]
      },
      {
        "subject": "Progestin",
        "sbj_char_span": [0, 9],
        "object": "MAPK",
        "obj_char_span": [130, 134],
        "rel_type": "activator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [27, 28],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [45, 46]
      },
      {
        "subject": "Progestin",
        "sbj_char_span": [0, 9],
        "object": "Src",
        "obj_char_span": [126, 129],
        "rel_type": "activator",
        "sbj_tok_span": [0, 3],
        "obj_tok_span": [25, 26],
        "new_sbj_tok_span": [3, 6],
        "new_obj_tok_span": [42, 43]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Progestin",
        "char_span": [0, 9],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 3],
        "new_tok_span": [3, 6]
      },
      {
        "mention": "cyclin D1 gene",
        "char_span": [27, 41],
        "sem_type": "Gene or Genome",
        "tok_span": [6, 10],
        "new_tok_span": [13, 17]
      },
      {
        "mention": "Src",
        "char_span": [126, 129],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [25, 26],
        "new_tok_span": [42, 43]
      },
      {
        "mention": "Src",
        "char_span": [344, 347],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [62, 63],
        "new_tok_span": [91, 92]
      },
      {
        "mention": "Pr",
        "char_span": [0, 2],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [0, 1],
        "new_tok_span": [3, 4]
      },
      {
        "mention": "pr",
        "char_span": [57, 59],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [14, 15],
        "new_tok_span": [24, 25]
      },
      {
        "mention": "PR",
        "char_span": [105, 107],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [21, 22],
        "new_tok_span": [35, 36]
      },
      {
        "mention": "pr",
        "char_span": [249, 251],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [49, 50],
        "new_tok_span": [71, 72]
      },
      {
        "mention": "PR",
        "char_span": [327, 329],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [59, 60],
        "new_tok_span": [85, 86]
      },
      {
        "mention": "Pr",
        "char_span": [0, 2],
        "sem_type": "Gene or Genome",
        "tok_span": [0, 1],
        "new_tok_span": [3, 4]
      },
      {
        "mention": "pr",
        "char_span": [57, 59],
        "sem_type": "Gene or Genome",
        "tok_span": [14, 15],
        "new_tok_span": [24, 25]
      },
      {
        "mention": "PR",
        "char_span": [105, 107],
        "sem_type": "Gene or Genome",
        "tok_span": [21, 22],
        "new_tok_span": [35, 36]
      },
      {
        "mention": "pr",
        "char_span": [249, 251],
        "sem_type": "Gene or Genome",
        "tok_span": [49, 50],
        "new_tok_span": [71, 72]
      },
      {
        "mention": "PR",
        "char_span": [327, 329],
        "sem_type": "Gene or Genome",
        "tok_span": [59, 60],
        "new_tok_span": [85, 86]
      },
      {
        "mention": "Sgk",
        "char_span": [169, 172],
        "sem_type": "Gene or Genome",
        "tok_span": [34, 37],
        "new_tok_span": [53, 56]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Prog <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>estin <END=Pharmacologic Substance> induction of the <START=Gene or Genome> cyclin D1 gene <END=Gene or Genome>, which lacks a <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> progesterone <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> response element, was dependent on <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PR <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activation of the <START=Amino Acid, Peptide, or Protein> Src <END=Amino Acid, Peptide, or Protein> / MAPK pathway, whereas induction of the <START=Gene or Genome> Sgk <END=Gene or Genome> ( serum and glucocorticoid regulated kinase ) gene that contains a functional <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> progesterone <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> response element was unaffected by mutations that interfere with <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PR <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activation of <START=Amino Acid, Peptide, or Protein> Src <END=Amino Acid, Peptide, or Protein>."
  },
  {
    "PMID": 15840827,
    "id": 1,
    "text": "The two active sites of dimeric 5-aminolevulinate synthase (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [184, 195],
        "name": "amino acids",
        "tok_span": [46, 48],
        "new_tok_span": [48, 50]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [32, 49],
        "name": "5-aminolevulinate",
        "tok_span": [7, 13],
        "new_tok_span": [7, 13]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [69, 91],
        "name": "pyridoxal 5'-phosphate",
        "tok_span": [20, 28],
        "new_tok_span": [22, 30]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [93, 96],
        "name": "PLP",
        "tok_span": [29, 31],
        "new_tok_span": [31, 33]
      },
      {
        "ent_type": "GENE",
        "char_span": [32, 58],
        "name": "5-aminolevulinate synthase",
        "tok_span": [7, 14],
        "new_tok_span": [7, 14]
      },
      {
        "ent_type": "GENE",
        "char_span": [60, 64],
        "name": "ALAS",
        "tok_span": [15, 17],
        "new_tok_span": [17, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "amino acids",
        "sbj_char_span": [184, 195],
        "object": "5-aminolevulinate synthase",
        "obj_char_span": [32, 58],
        "rel_type": "part of",
        "sbj_tok_span": [46, 48],
        "obj_tok_span": [7, 14],
        "new_sbj_tok_span": [48, 50],
        "new_obj_tok_span": [7, 14]
      },
      {
        "subject": "amino acids",
        "sbj_char_span": [184, 195],
        "object": "ALAS",
        "obj_char_span": [60, 64],
        "rel_type": "part of",
        "sbj_tok_span": [46, 48],
        "obj_tok_span": [15, 17],
        "new_sbj_tok_span": [48, 50],
        "new_obj_tok_span": [17, 19]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "aminolevulinate synthase",
        "char_span": [34, 58],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [9, 14],
        "new_tok_span": [10, 15]
      }
    ],
    "new_text": "The two active sites of dimeric 5 - <START=Amino Acid, Peptide, or Protein> aminolevulinate synthase <END=Amino Acid, Peptide, or Protein> ( ALAS ), a pyridoxal 5'- phosphate ( PLP ) - dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit."
  },
  {
    "PMID": 15180525,
    "id": 7,
    "text": "STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 6],
        "name": "STI571",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [43, 56],
        "name": "phenylalanine",
        "tok_span": [13, 15],
        "new_tok_span": [16, 18]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [79, 82],
        "name": "ATP",
        "tok_span": [22, 23],
        "new_tok_span": [26, 27]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [124, 133],
        "name": "threonine",
        "tok_span": [31, 33],
        "new_tok_span": [36, 38]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [185, 191],
        "name": "STI571",
        "tok_span": [42, 46],
        "new_tok_span": [49, 53]
      },
      {
        "ent_type": "GENE",
        "char_span": [18, 22],
        "name": "Flt3",
        "tok_span": [6, 9],
        "new_tok_span": [8, 11]
      },
      {
        "ent_type": "GENE",
        "char_span": [160, 164],
        "name": "Flt3",
        "tok_span": [36, 39],
        "new_tok_span": [42, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "STI571",
        "sbj_char_span": [0, 6],
        "object": "Flt3",
        "obj_char_span": [18, 22],
        "rel_type": "regulator",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [6, 9],
        "new_sbj_tok_span": [1, 5],
        "new_obj_tok_span": [8, 11]
      },
      {
        "subject": "STI571",
        "sbj_char_span": [185, 191],
        "object": "Flt3",
        "obj_char_span": [160, 164],
        "rel_type": "inhibitor",
        "sbj_tok_span": [42, 46],
        "obj_tok_span": [36, 39],
        "new_sbj_tok_span": [49, 53],
        "new_obj_tok_span": [42, 45]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "STI571",
        "char_span": [0, 6],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [0, 4],
        "new_tok_span": [1, 5]
      },
      {
        "mention": "STI571",
        "char_span": [185, 191],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [42, 46],
        "new_tok_span": [49, 53]
      },
      {
        "mention": "phenylalanine",
        "char_span": [43, 56],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [13, 15],
        "new_tok_span": [16, 18]
      },
      {
        "mention": "threonine",
        "char_span": [124, 133],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [31, 33],
        "new_tok_span": [36, 38]
      }
    ],
    "new_text": "<START=Pharmacologic Substance> STI571 <END=Pharmacologic Substance> binding to Flt3 is prevented by the <START=Amino Acid, Peptide, or Protein> phenylalanine <END=Amino Acid, Peptide, or Protein> 691 side - chain in the ATP binding center and mutating this site to <START=Amino Acid, Peptide, or Protein> threonine <END=Amino Acid, Peptide, or Protein> renders the corresponding Flt3 mutant sensitive to <START=Pharmacologic Substance> STI571 <END=Pharmacologic Substance>."
  },
  {
    "PMID": 3994963,
    "id": 3,
    "text": "Adducts of calmodulin and phenoxybenzamine were separated by high-performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol/mol.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [26, 42],
        "name": "phenoxybenzamine",
        "tok_span": [8, 12],
        "new_tok_span": [8, 12]
      },
      {
        "ent_type": "GENE",
        "char_span": [11, 21],
        "name": "calmodulin",
        "tok_span": [4, 7],
        "new_tok_span": [4, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "phenoxybenzamine",
        "sbj_char_span": [26, 42],
        "object": "calmodulin",
        "obj_char_span": [11, 21],
        "rel_type": "regulator",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [4, 7],
        "new_sbj_tok_span": [8, 12],
        "new_obj_tok_span": [4, 7]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "mol",
        "char_span": [154, 157],
        "sem_type": "Gene or Genome",
        "tok_span": [34, 35],
        "new_tok_span": [35, 36]
      },
      {
        "mention": "mol",
        "char_span": [170, 173],
        "sem_type": "Gene or Genome",
        "tok_span": [38, 39],
        "new_tok_span": [41, 42]
      },
      {
        "mention": "mol",
        "char_span": [233, 236],
        "sem_type": "Gene or Genome",
        "tok_span": [50, 51],
        "new_tok_span": [55, 56]
      },
      {
        "mention": "mol",
        "char_span": [237, 240],
        "sem_type": "Gene or Genome",
        "tok_span": [52, 53],
        "new_tok_span": [59, 60]
      }
    ],
    "new_text": "Adducts of calmodulin and phenoxybenzamine were separated by high - performance liquid chromatography into four major fractions : two containing 0. 6 and 1. 2 <START=Gene or Genome> mol <END=Gene or Genome> of drug per <START=Gene or Genome> mol <END=Gene or Genome> of protein and two different fractions each containing 2. 0 <START=Gene or Genome> mol <END=Gene or Genome> / <START=Gene or Genome> mol <END=Gene or Genome>."
  },
  {
    "PMID": 17768678,
    "id": 0,
    "text": "Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [0, 10],
        "name": "Phenelzine",
        "tok_span": [0, 4],
        "new_tok_span": [0, 4]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [76, 85],
        "name": "monoamine",
        "tok_span": [18, 20],
        "new_tok_span": [20, 22]
      },
      {
        "ent_type": "GENE",
        "char_span": [76, 93],
        "name": "monoamine oxidase",
        "tok_span": [18, 21],
        "new_tok_span": [20, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "Phenelzine",
        "sbj_char_span": [0, 10],
        "object": "monoamine oxidase",
        "obj_char_span": [76, 93],
        "rel_type": "inhibitor",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [18, 21],
        "new_sbj_tok_span": [0, 4],
        "new_obj_tok_span": [20, 23]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "ornithine",
        "char_span": [39, 48],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [9, 13],
        "new_tok_span": [10, 14]
      }
    ],
    "new_text": "Phenelzine causes an increase in brain <START=Amino Acid, Peptide, or Protein> ornithine <END=Amino Acid, Peptide, or Protein> that is prevented by prior monoamine oxidase inhibition."
  },
  {
    "PMID": 23477419,
    "id": 0,
    "text": "Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues as Extremely Potent μ-Opioid Agonists.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [65, 78],
        "name": "Endomorphin-1",
        "tok_span": [12, 17],
        "new_tok_span": [13, 18]
      },
      {
        "ent_type": "GENE",
        "char_span": [109, 117],
        "name": "μ-Opioid",
        "tok_span": [25, 30],
        "new_tok_span": [27, 32]
      }
    ],
    "relation_list": [
      {
        "subject": "Endomorphin-1",
        "sbj_char_span": [65, 78],
        "object": "μ-Opioid",
        "obj_char_span": [109, 117],
        "rel_type": "agonist or antagonist",
        "sbj_tok_span": [12, 17],
        "obj_tok_span": [25, 30],
        "new_sbj_tok_span": [13, 18],
        "new_obj_tok_span": [27, 32]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "Endomorphin",
        "char_span": [65, 76],
        "sem_type": "Amino Acid, Peptide, or Protein",
        "tok_span": [12, 15],
        "new_tok_span": [13, 16]
      }
    ],
    "new_text": "Design, Synthesis, and Pharmacological Characterization of Novel <START=Amino Acid, Peptide, or Protein> Endomorphin <END=Amino Acid, Peptide, or Protein> - 1 Analogues as Extremely Potent μ - Opioid Agonists."
  },
  {
    "PMID": 7560228,
    "id": 11,
    "text": "In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.",
    "entity_list": [
      {
        "ent_type": "CHEMICAL",
        "char_span": [47, 56],
        "name": "triclosan",
        "tok_span": [9, 12],
        "new_tok_span": [9, 12]
      },
      {
        "ent_type": "CHEMICAL",
        "char_span": [85, 101],
        "name": "prostaglandin E2",
        "tok_span": [18, 21],
        "new_tok_span": [20, 23]
      },
      {
        "ent_type": "GENE",
        "char_span": [67, 76],
        "name": "IL-1 beta",
        "tok_span": [13, 17],
        "new_tok_span": [13, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "triclosan",
        "sbj_char_span": [47, 56],
        "object": "IL-1 beta",
        "obj_char_span": [67, 76],
        "rel_type": "inhibitor",
        "sbj_tok_span": [9, 12],
        "obj_tok_span": [13, 17],
        "new_sbj_tok_span": [9, 12],
        "new_obj_tok_span": [13, 17]
      },
      {
        "subject": "prostaglandin E2",
        "sbj_char_span": [85, 101],
        "object": "IL-1 beta",
        "obj_char_span": [67, 76],
        "rel_type": "product or substrate",
        "sbj_tok_span": [18, 21],
        "obj_tok_span": [13, 17],
        "new_sbj_tok_span": [20, 23],
        "new_obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": [
      {
        "mention": "prostaglandin E2",
        "char_span": [85, 101],
        "sem_type": "Pharmacologic Substance",
        "tok_span": [18, 21],
        "new_tok_span": [20, 23]
      },
      {
        "mention": "prostaglandin",
        "char_span": [85, 98],
        "sem_type": "Organic Chemical",
        "tok_span": [18, 19],
        "new_tok_span": [20, 21]
      }
    ],
    "new_text": "In cell culture experiments, it was found that triclosan inhibited IL - 1 beta induced <START=Pharmacologic Substance> <START=Organic Chemical> prostaglandin <END=Organic Chemical> E2 <END=Pharmacologic Substance> production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations."
  }
]
